Kit or device for detecting lung cancer, and lung cancer detection method
A kit using nucleic acids that bind to specific miRNAs offers a high-sensitivity, minimally invasive method for lung cancer detection, addressing the limitations of current methods and improving early detection and treatment outcomes.
Patent Information
- Application Number
- KR1020267035690
- Authority / Receiving Office
- KR · KR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2014-06-18
- Filing Date
- 2015-06-18
- Publication Date
- 2026-11-09
AI Technical Summary
Existing lung cancer detection methods, such as chest X-rays and blood tumor markers, are inadequate for early detection, leading to missed diagnoses and unnecessary medical burdens, while advanced imaging techniques are costly and invasive, necessitating a high-precision, minimally invasive marker for accurate lung cancer detection.
A kit comprising nucleic acids that specifically bind to a set of microRNAs (miRNAs) including miR-6768-5p, miR-6836-3p, and others, allowing for the detection of lung cancer through blood samples with high sensitivity and specificity.
The kit provides a reliable, minimally invasive method for detecting lung cancer with high sensitivity, improving early detection rates and reducing the risk of misdiagnosis, thereby enhancing treatment opportunities and survival chances.
Smart Images

Figure PAT00065_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a kit or device for detecting lung cancer comprising a nucleic acid capable of specifically binding to a specific miRNA used to test for the presence or absence of lung cancer in a subject, and a method for detecting lung cancer comprising measuring the expression level of the miRNA using the nucleic acid. Background Technology
[0002] The lungs play an important role in taking in oxygen and expelling carbon dioxide within the body through respiration. Air taken in through the mouth or nose is divided into left and right sides through the trachea and bronchi, entering the left and right lungs, and then spreads throughout the lungs through finer tubes, where oxygen is finally taken into the blood and carbon dioxide is expelled in the alveoli (Non-patent Literature 1).
[0003] According to the 2012 statistics on cancer by body part in Japan, released by the Kokuritsu Kankenkyu Center, a national research and development corporation, the number of lung cancer patients was 107,241; that is, one in ten men and one in twenty-two women were diagnosed with lung cancer, making it the third most common cancer site. Furthermore, men are nearly twice as likely to be diagnosed than women. The number of deaths due to lung cancer reached 71,518 for both men and women combined, making it the leading cause of death. Additionally, the estimated number of lung cancer patients in the United States in 2014 reached 224,210, of whom approximately 159,260 died (Non-patent Literature 1).
[0004] Lung cancer has multiple histological types, and while small cell lung cancer accounts for about 15%, the remaining histological types are called non-small cell lung cancer. Non-small cell lung cancer is further broadly classified into three types: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Since these histological types differ significantly in terms of site of origin, pattern and speed of progression, and symptoms, the treatment methods also differ.
[0005] The progression of lung cancer is classified into stages 0 to 4 based on the extent of tumor spread (T0, is, 1–4), lymph node metastasis (N0–3), and distant metastasis (M0, M1). In particular, regarding tumor spread, T1 indicates a maximum tumor diameter of 3 cm or less, T2 indicates a diameter exceeding 3 cm or less than or equal to 7 cm, T3 indicates a diameter exceeding 7 cm or confirmed invasion into adjacent areas, and T4 indicates invasion into a wider adjacent area regardless of size.
[0006] The survival rate of lung cancer varies depending on the stage of progression. According to Non-Patent Literature 1, the 5-year relative survival rate of non-small cell lung cancer is reported to be 45–49% for stage 1, 30–31% for stage 2, 5–14% for stage 3, and 1% for stage 4. Therefore, if lung cancer can be detected and treated at an early stage, it contributes significantly to improving the survival rate.
[0007] Treatment for lung cancer is centered on resection surgery, radiation therapy, and chemotherapy. In particular, in early-stage lung cancer, surgery becomes applicable, and there is a high probability of a cure (Non-patent Literature 1). In addition, for early-stage lung cancer, there are several treatment options available, and there is a possibility of applying treatments that are less burdensome to the patient, such as thoracoscopic surgery, stereotactic trunk radiation therapy (SBRT), photodynamic therapy, laser therapy, and small-source radiation therapy that irradiates radiation into the body (Non-patent Literature 1).
[0008] As described in Non-Patent Literature 1, in addition to medical history and physical examination, the most widely used screening for lung cancer is the chest X-ray. If suspicious findings are detected during the chest X-ray, more precise imaging diagnostics such as CT scans, MRI scans, and PET scans are performed. Additionally, specimen-based tests include sputum cytology, pleural fluid examination, and pathological examinations in which cells or tissues are collected by inserting a needle into the lesion and examined under a microscope. Furthermore, CEA and CYFRA21-1 are known as tumor markers for detecting lung cancer.
[0009] Although it is in the research stage, there are reports that lung cancer is detected by the expression amount of microRNA (miRNA) in biological samples including blood, or by combining the expression amount of miRNA with the expression amount of other protein markers, as shown in Patent Documents 1 and 2.
[0010] Patent Document 1 describes a method for detecting lung cancer or other lung diseases using miR-19b (miR-19b-3p), etc. in serum.
[0011] Patent document 2 describes a method for detecting lung cancer using miR-1268 or miR-1228 in serum or plasma.
[0012] Patent document 3 describes a method for detecting lung cancer using miR-1307, etc., in blood cells. Prior art literature
[0013] Japanese Patent Publication No. 2013-502931, International Publication No. 2011 / 146937, and U.S. Patent Application No. 13 / 376281 Specification
[0014] American Cancer Society, *Lung Cancer (Non-Small Cell)*, supervised by 2013, pp. 2–7, 37–56. Sobin, L. et al., *TNM Classification of Malignant Tumours, 7th ed.*, 2010, pp. 129–134. Okamura, K. et al., *Lung Cancer*, 2013, Vol. 80(1), pp. 45–9. The problem to be solved
[0015] The objective of the present invention is to discover a novel lung cancer tumor marker and to provide a method for effectively detecting lung cancer using a nucleic acid capable of specifically binding to said marker. Although chest X-ray examinations are widely used as a screening method for lung cancer, the number of deaths caused by lung cancer is on an increasing trend every year, and given that it is the leading cause of death by cancer site, it cannot be said that X-ray examinations are suppressing lung cancer. Furthermore, while CT scans and MRI scans can detect lung cancer with high performance, they require specialized equipment and are expensive, making them unsuitable for widespread use as a primary screening method.
[0016] Although blood tumor markers for detecting lung cancer, such as CEA and CYFRA21-1, are known (Non-patent Literature 3), their utility has not been established, and thus the American Cancer Society's guidelines for lung cancer do not mention these markers (Non-patent Literature 1). According to Non-patent Literature 3, the general lung cancer detection sensitivities of these blood tumor markers are reported to be 69% for CEA and 43% for CYFRA21-1. Furthermore, it is noted that since tumor markers such as CEA and CYFRA21-1 can be elevated for reasons other than lung cancer, it is not possible to determine the presence or absence of lung cancer. If another cancer is mistakenly diagnosed as lung cancer, the opportunity for appropriate treatment is missed, or incorrect medical treatment is applied, thereby imposing an unnecessary economic and physical burden on the patient.
[0017] In addition, although it is still in the research stage, there are reports as follows regarding the identification of lung cancer using the expression levels of microRNA (miRNA) in biological samples, including blood, but it has not yet reached practical application.
[0018] Patent Document 1 describes a method for detecting lung cancer or other lung diseases using miR-19b (miR-19b-3p) in serum. However, since the number of healthy specimens used as negative subjects is small (only a dozen cases), it is difficult to say that the universality of the marker regarding differences between subjects is guaranteed, and thus the reliability as a method for detecting lung cancer is low.
[0019] Patent Document 2 describes a method for detecting lung cancer using miR-1268 or miR-1228 in serum or plasma, but only 3 cases of mesothelioma were identified as cancers other than lung cancer, so the possibility that it is a marker with a high false positive rate that detects cancers other than lung cancer cannot be ruled out.
[0020] Patent document 3 describes a method for detecting lung cancer using miR-1307 and others in blood cells, but it has low reliability as a method for verifying lung cancer because the marker obtained using one case group is not verified in an independent separate case group.
[0021] As such, existing tumor markers have low performance in detecting lung cancer, and since the performance and detection methods of markers in the research phase are not specifically defined, using them carries the risk of unnecessary additional testing due to misidentifying healthy individuals as lung cancer patients, or the loss of treatment opportunities due to overlooking lung cancer patients. Furthermore, measuring miRNAs, which consist of tens to hundreds, increases testing costs, making it difficult to use for large-scale screenings such as health checkups. Additionally, since collecting lung tissue to measure tumor markers is undesirable due to high invasiveness to the patient, there is a demand for high-precision lung cancer markers that allow for minimally invasive detection from blood and can correctly distinguish between lung cancer patients and healthy individuals. In particular, early detection of lung cancer significantly improves survival rates by increasing the likelihood of surgical intervention. In addition, since there are multiple treatment options for early-stage lung cancer and the possibility of applying treatments that are less burdensome to the patient, such as thoracoscopic surgery or stereotactic radiation therapy for the torso, there is a need for a lung cancer marker with high sensitivity that can detect lung cancer even at low stages of progression.
[0022] As a result of careful consideration to solve the above problem, the inventors discovered multiple genes that can be used as detection markers for lung cancer from blood that can be collected minimally, and discovered that lung cancer can be significantly detected by using nucleic acids that can specifically bind to these genes, thereby completing the present invention. means of solving the problem
[0023] <Summary of the Invention>
[0024] That is, the present invention has the following features.
[0025] (1) miR-6768-5p, miR-6836-3p, miR-6782-5p, miR-3663-3p, miR-1908-3p, miR-6726-5p, miR-4258, miR-1343-3p, miR-4516, miR-6875-5p, miR-4651, miR-6825-5p, miR-6840-3p, miR-6780b-5p, miR-6749-5p, miR-8063, miR-6784-5p, miR-3679-5p, miR-3184-5p, miR-663b, miR-6880-5p, miR-1908-5p, miR-92a-2-5p, miR-7975, miR-7110-5p, miR-6842-5p, miR-6857-5p, miR-5572, miR-3197, miR-6131, miR-6889-5p, miR-4454, miR-1199-5p, miR-1247-3p, miR-6800-5p, miR-6872-3p, miR-4649-5p, miR-6791-5p, miR-4433b-3p, miR-3135b, miR-128-2-5p, miR-4675, miR-4472, miR-6785-5p, miR-6741-5p miR-7977, miR-3665, miR-128-1-5p, miR-4286, miR-6765-3p, miR-4632-5p, miR-365a-5p, miR-6088, miR-6816-5p, miR-6885-5p, miR-711, miR-6765-5p, miR-3180, miR-4442, miR-4792, miR-6721-5p, miR-6798-5p, miR-3162-5p, miR-6126, miR-4758-5p, miR-2392, miR-486-3p, miR-6727-5p, miR-4728-5p, miR-6746-5p miR-4270, miR-3940-5p, miR-4725-3p, miR-7108-5p, miR-3656, miR-6879-5p, miR-6738-5p, miR-1260a, miR-4446-3p, miR-3131, miR-4463, miR-3185,miR-6870-5p,miR-6779-5p,miR-1273g-3p,miR-8059,miR-4697-5p,miR-4674,miR-4433-3p,miR-4257,miR-1915-5p,miR-4417,miR-1343-5p,miR-6781-5p, miR-4695-5p,miR-1237-5p,miR-6775-5p,miR-7845-5p,miR-4746-3p,miR-7641,miR-7847-3p,miR-6806-5p,miR-4467,miR-4726-5p,miR-4648,miR-6089, miR-1260b,miR-4532,miR-5195-3p,miR-3188,miR-6848-5p,miR-1233-5p,miR-6717-5p,miR-3195,miR-6757-5p,miR-8072,miR-4745-5p,miR-6511a-5p,miR-6776-5p, miR-371a-5p,miR-1227-5p,miR-7150,miR-1915-3p,miR-187-5p,miR-614,miR-1225-5p,miR-451a,miR-939-5p,miR-223-3p,miR-125a-3p, A kit for detecting lung cancer comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-92b-5p, miR-22-3p, miR-6073, miR-6845-5p, miR-6769b-5p, miR-4665-3p, miR-1913, miR-1228-3p, miR-940, miR-296-3p, miR-4690-5p, miR-548q, miR-663a, miR-1249, miR-1202, miR-7113-3p, miR-1225-3p, miR-4783-3p, miR-4448, and miR-4534.
[0026] (2)(1) In this case,
[0027] miR-6768-5p is hsa-miR-6768-5p, miR-6836-3p is hsa-miR-6836-3p, miR-6782-5p is hsa-miR-6782-5p, miR-3663-3p is hsa-miR-3663-3p, miR-1908-3p is hsa-miR-1908-3p, miR-6726-5p is hsa-miR-6726-5p, miR-4258 is hsa-miR-4258, miR-1343-3p is hsa-miR-1343-3p, miR-4516 is hsa-miR-4516, and miR-6875-5p is hsa-miR-6875-5p, miR-4651 is hsa-miR-4651, miR-6825-5p is hsa-miR-6825-5p, miR-6840-3p is hsa-miR-6840-3p, miR-6780b-5p is hsa-miR-6780b-5p, miR-6749-5p is hsa-miR-6749-5p, miR-8063 is hsa-miR-8063, miR-6784-5p is hsa-miR-6784-5p, miR-3679-5p is hsa-miR-3679-5p, miR-3184-5p is hsa-miR-3184-5p, and miR-663b is hsa-miR-663b, miR-6880-5p is hsa-miR-6880-5p, miR-1908-5p is hsa-miR-1908-5p, miR-92a-2-5p is hsa-miR-92a-2-5p, miR-7975 is hsa-miR-7975, miR-7110-5p is hsa-miR-7110-5p, miR-6842-5p is hsa-miR-6842-5p, miR-6857-5p is hsa-miR-6857-5p, miR-5572 is hsa-miR-5572, miR-3197 is hsa-miR-3197, and miR-6131 is hsa-miR-6131, miR-6889-5p is hsa-miR-6889-5p, miR-4454 is hsa-miR-4454, miR-1199-5p is hsa-miR-1199-5p, andmiR-1247-3p is hsa-miR-1247-3p, miR-6800-5p is hsa-miR-6800-5p, miR-6872-3p is hsa-miR-6872-3p, miR-4649-5p is hsa-miR-4649-5p, miR-6791-5p is hsa-miR-6791-5p, miR-4433b-3p is hsa-miR-4433b-3p, miR-3135b is hsa-miR-3135b, miR-128-2-5p is hsa-miR-128-2-5p, miR-4675 is hsa-miR-4675, and miR-4472 is hsa-miR-4472, miR-6785-5p is hsa-miR-6785-5p, miR-6741-5p is hsa-miR-6741-5p, miR-7977 is hsa-miR-7977, miR-3665 is hsa-miR-3665, miR-128-1-5p is hsa-miR-128-1-5p, miR-4286 is hsa-miR-4286, miR-6765-3p is hsa-miR-6765-3p, miR-4632-5p is hsa-miR-4632-5p, miR-365a-5p is hsa-miR-365a-5p, and miR-6088 is hsa-miR-6088, miR-6816-5p is hsa-miR-6816-5p, miR-6885-5p is hsa-miR-6885-5p, miR-711 is hsa-miR-711, miR-6765-5p is hsa-miR-6765-5p, miR-3180 is hsa-miR-3180, miR-4442 is hsa-miR-4442, miR-4792 is hsa-miR-4792, miR-6721-5p is hsa-miR-6721-5p, miR-6798-5p is hsa-miR-6798-5p, miR-3162-5p is hsa-miR-3162-5p, and miR-6126 is hsa-miR-6126, miR-4758-5p is hsa-miR-4758-5p, miR-2392 is hsa-miR-2392, andmiR-486-3p is hsa-miR-486-3p, miR-6727-5p is hsa-miR-6727-5p, miR-4728-5p is hsa-miR-4728-5p, miR-6746-5p is hsa-miR-6746-5p, miR-4270 is hsa-miR-4270, miR-3940-5p is hsa-miR-3940-5p, miR-4725-3p is hsa-miR-4725-3p, miR-7108-5p is hsa-miR-7108-5p, miR-3656 is hsa-miR-3656, miR-6879-5p is hsa-miR-6879-5p, and miR-6738-5p is hsa-miR-6738-5p, miR-1260a is hsa-miR-1260a, miR-4446-3p is hsa-miR-4446-3p, miR-3131 is hsa-miR-3131, miR-4463 is hsa-miR-4463, miR-3185 is hsa-miR-3185, miR-6870-5p is hsa-miR-6870-5p, miR-6779-5p is hsa-miR-6779-5p, miR-1273g-3p is hsa-miR-1273g-3p, miR-8059 is hsa-miR-8059, and miR-4697-5p is hsa-miR-4697-5p, miR-4674 is hsa-miR-4674, miR-4433-3p is hsa-miR-4433-3p, miR-4257 is hsa-miR-4257, miR-1915-5p is hsa-miR-1915-5p, miR-4417 is hsa-miR-4417, miR-1343-5p is hsa-miR-1343-5p, miR-6781-5p is hsa-miR-6781-5p, miR-4695-5p is hsa-miR-4695-5p, miR-1237-5p is hsa-miR-1237-5p, and miR-6775-5p is hsa-miR-6775-5p is, miR-7845-5p is hsa-miR-7845-5p, miR-4746-3p is hsa-miR-4746-3p, and,miR-7641 is hsa-miR-7641, miR-7847-3p is hsa-miR-7847-3p, miR-6806-5p is hsa-miR-6806-5p, miR-4467 is hsa-miR-4467, miR-4726-5p is hsa-miR-4726-5p, miR-4648 is hsa-miR-4648, miR-6089 is hsa-miR-6089, miR-1260b is hsa-miR-1260b, miR-4532 is hsa-miR-4532, miR-5195-3p is hsa-miR-5195-3p, miR-3188 is hsa-miR-3188, and miR-6848-5p is hsa-miR-6848-5p, miR-1233-5p is hsa-miR-1233-5p, miR-6717-5p is hsa-miR-6717-5p, miR-3195 is hsa-miR-3195, miR-6757-5p is hsa-miR-6757-5p, miR-8072 is hsa-miR-8072, miR-4745-5p is hsa-miR-4745-5p, miR-6511a-5p is hsa-miR-6511a-5p, miR-6776-5p is hsa-miR-6776-5p, and miR-371a-5p is hsa-miR-371a-5p, miR-1227-5p is hsa-miR-1227-5p, miR-7150 is hsa-miR-7150, miR-1915-3p is hsa-miR-1915-3p, miR-187-5p is hsa-miR-187-5p, miR-614 is hsa-miR-614, miR-1225-5p is hsa-miR-1225-5p, miR-451a is hsa-miR-451a, miR-939-5p is hsa-miR-939-5p, miR-223-3p is hsa-miR-223-3p, and miR-125a-3p is hsa-miR-125a-3p, miR-92b-5p is hsa-miR-92b-5p, miR-22-3p is hsa-miR-22-3p, miR-6073 is hsa-miR-6073, andmiR-6845-5p is hsa-miR-6845-5p, miR-6769b-5p is hsa-miR-6769b-5p, miR-4665-3p is hsa-miR-4665-3p, miR-1913 is hsa-miR-1913, miR-1228-3p is hsa-miR-1228-3p, miR-940 is hsa-miR-940, miR-296-3p is hsa-miR-296-3p, miR-4690-5p is hsa-miR-4690-5p, miR-548q is hsa-miR-548q, miR-663a is hsa-miR-663a, and miR-1249 is A kit in which hsa-miR-1249 is, miR-1202 is hsa-miR-1202, miR-7113-3p is hsa-miR-7113-3p, miR-1225-3p is hsa-miR-1225-3p, miR-4783-3p is hsa-miR-4783-3p, miR-4448 is hsa-miR-4448, and miR-4534 is hsa-miR-4534.
[0028] (3) In (1) or (2),
[0029] The above nucleic acid is a polynucleotide represented in (a) to (e) below:
[0030] (a) a polynucleotide, variant, derivative thereof, or fragment comprising 15 or more consecutive bases, comprising a base sequence represented by any one of SEQ ID NOs 1–125, 127–130, 132–134, and 561–578, or a base sequence in which u is t in said base sequence,
[0031] (b) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1–125, 127–130, 132–134, and 561–578,
[0032] (c) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1–125, 127–130, 132–134, and 561–578, or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,
[0033] (d) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1–125, 127–130, 132–134, and 561–578, or a nucleotide sequence complementary to a nucleotide sequence in which u is t, and
[0034] (e) a polynucleotide that hybridizes with any one of the polynucleotides (a) to (d) under stringent conditions,
[0035] A kit that is a polynucleotide selected from a group consisting of
[0036] (4) In any one of paragraphs (1) to (3),
[0037] A kit comprising the above kit further including a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of other lung cancer markers miR-19b-3p, miR-1228-5p, and miR-1307-3p.
[0038] (5)(4) In this case,
[0039] A kit in which miR-19b-3p is hsa-miR-19b-3p, miR-1228-5p is hsa-miR-1228-5p, and miR-1307-3p is hsa-miR-1307-3p.
[0040] (6)(4) or (5),
[0041] The above nucleic acid is a polynucleotide represented in (f) to (j) below:
[0042] (f) a polynucleotide consisting of a nucleotide sequence represented by any one of SEQ ID NOs 126, 131 and 579, or a nucleotide sequence in which u is t in said nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
[0043] (g) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 126, 131 and 579,
[0044] (h) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 126, 131 and 579, or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,
[0045] (i) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 126, 131 and 579, or a nucleotide sequence complementary to a nucleotide sequence in which u is t, and
[0046] (j) a polynucleotide that hybridizes with any one of (f) to (i) under stringent conditions,
[0047] A kit that is a polynucleotide selected from a group consisting of
[0048] (7) In any one of (1) to (6),
[0049] The kit can be used to detect other lung cancer markers, including: miR-4763-3p,miR-6729-5p,miR-3196,miR-8069,miR-1268a,miR-4739,miR-1268b,miR-5698,miR-6752-5p,miR-4507,miR-564,miR-4497,miR-6877-5p,miR-6087 A kit further comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-4731-5p, miR-615-5p, miR-760, miR-6891-5p, miR-6887-5p, miR-4525, miR-1914-3p, miR-619-5p, miR-5001-5p, miR-6722-3p, miR-3621, miR-4298, miR-675-5p, and miR-4655-5p.
[0050] (8)(7) In this case,
[0051] miR-4271 is hsa-miR-4271, miR-642b-3p is hsa-miR-642b-3p, miR-6075 is hsa-miR-6075, miR-6125 is hsa-miR-6125, miR-887-3p is hsa-miR-887-3p, miR-6851-5p is hsa-miR-6851-5p, miR-6763-5p is hsa-miR-6763-5p, miR-3928-3p is hsa-miR-3928-3p, miR-4443 is hsa-miR-4443, miR-3648 is hsa-miR-3648, and miR-149-3p is hsa-miR-149-3p, miR-4689 is hsa-miR-4689, miR-4763-3p is hsa-miR-4763-3p, miR-6729-5p is hsa-miR-6729-5p, miR-3196 is hsa-miR-3196, miR-8069 is hsa-miR-8069, miR-1268a is hsa-miR-1268a, miR-4739 is hsa-miR-4739, miR-1268b is hsa-miR-1268b, miR-5698 is hsa-miR-5698, miR-6752-5p is hsa-miR-6752-5p, and miR-4507 is hsa-miR-4507, miR-564 is hsa-miR-564, miR-4497 is hsa-miR-4497, miR-6877-5p is hsa-miR-6877-5p, miR-6087 is hsa-miR-6087, miR-4731-5p is hsa-miR-4731-5p, miR-615-5p is hsa-miR-615-5p, miR-760 is hsa-miR-760, miR-6891-5p is hsa-miR-6891-5p, miR-6887-5p is hsa-miR-6887-5p, miR-4525 is hsa-miR-4525, miR-1914-3p is hsa-miR-1914-3p, miR-619-5p is hsa-miR-619-5p, andA kit in which miR-5001-5p is hsa-miR-5001-5p, miR-6722-3p is hsa-miR-6722-3p, miR-3621 is hsa-miR-3621, miR-4298 is hsa-miR-4298, miR-675-5p is hsa-miR-675-5p, and miR-4655-5p is hsa-miR-4655-5p.
[0052] (9)(7) or (8),
[0053] The above nucleic acid is a polynucleotide represented in (k) to (o) below:
[0054] (k) A polynucleotide consisting of a nucleotide sequence represented by any one of SEQ ID NOs 135 to 174 or a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
[0055] (l) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 135 to 174,
[0056] (m) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 135 to 174 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
[0057] (n) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 135 to 174 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, and
[0058] (o) A polynucleotide that hybridizes with any one of the above (k) to (n) under stringent conditions,
[0059] A kit that is a polynucleotide selected from a group consisting of
[0060] (10)(1) to (9) any one of
[0061] A kit comprising at least two nucleic acids capable of specifically binding to each of at least two polynucleotides selected from the group consisting of all lung cancer markers described in (1) or (2).
[0062] (11) 폐암 마커인 miR-6768-5p, miR-6836-3p, miR-6782-5p, miR-3663-3p, miR-1908-3p, miR-6726-5p, miR-4258, miR-1343-3p, miR-4516, miR-6875-5p, miR-4651, miR-6825-5p, miR-6840-3p, miR-6780b-5p, miR-6749-5p, miR-8063, miR-6784-5p, miR-3679-5p, miR-3184-5p, miR-663b, miR-6880-5p, miR-1908-5p, miR-92a-2-5p, miR-7975, miR-7110-5p, miR-6842-5p, miR-6857-5p, miR-5572, miR-3197, miR-6131, miR-6889-5p, miR-4454, miR-1199-5p, miR-1247-3p, miR-6800-5p, miR-6872-3p, miR-4649-5p, miR-6791-5p, miR-4433b-3p, miR-3135b, miR-128-2-5p, miR-4675, miR-4472, miR-6785-5p, miR-6741-5p miR-7977, miR-3665, miR-128-1-5p, miR-4286, miR-6765-3p, miR-4632-5p, miR-365a-5p, miR-6088, miR-6816-5p, miR-6885-5p, miR-711, miR-6765-5p, miR-3180, miR-4442, miR-4792, miR-6721-5p, miR-6798-5p, miR-3162-5p, miR-6126, miR-4758-5p, miR-2392, miR-486-3p, miR-6727-5p, miR-4728-5p, miR-6746-5p miR-4270, miR-3940-5p, miR-4725-3p, miR-7108-5p, miR-3656, miR-6879-5p, miR-6738-5p, miR-1260a, miR-4446-3p, miR-3131, miR-4463, miR-3185,miR-6870-5p,miR-6779-5p,miR-1273g-3p,miR-8059,miR-4697-5p,miR-4674,miR-4433-3p,miR-4257,miR-1915-5p,miR-4417,miR-1343-5p,miR-6781-5p, miR-4695-5p,miR-1237-5p,miR-6775-5p,miR-7845-5p,miR-4746-3p,miR-7641,miR-7847-3p,miR-6806-5p,miR-4467,miR-4726-5p,miR-4648,miR-6089, miR-1260b,miR-4532,miR-5195-3p,miR-3188,miR-6848-5p,miR-1233-5p,miR-6717-5p,miR-3195,miR-6757-5p,miR-8072,miR-4745-5p,miR-6511a-5p,miR-6776-5p, miR-371a-5p,miR-1227-5p,miR-7150,miR-1915-3p,miR-187-5p,miR-614,miR-1225-5p,miR-451a,miR-939-5p,miR-223-3p,miR-125a-3p, A device for detecting lung cancer comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-92b-5p, miR-22-3p, miR-6073, miR-6845-5p, miR-6769b-5p, miR-4665-3p, miR-1913, miR-1228-3p, miR-940, miR-296-3p, miR-4690-5p, miR-548q, miR-663a, miR-1249, miR-1202, miR-7113-3p, miR-1225-3p, miR-4783-3p, miR-4448, and miR-4534.
[0063] (12)(11) In this case,
[0064] miR-6768-5p is hsa-miR-6768-5p, miR-6836-3p is hsa-miR-6836-3p, miR-6782-5p is hsa-miR-6782-5p, miR-3663-3p is hsa-miR-3663-3p, miR-1908-3p is hsa-miR-1908-3p, miR-6726-5p is hsa-miR-6726-5p, miR-4258 is hsa-miR-4258, miR-1343-3p is hsa-miR-1343-3p, miR-4516 is hsa-miR-4516, and miR-6875-5p is hsa-miR-6875-5p, miR-4651 is hsa-miR-4651, miR-6825-5p is hsa-miR-6825-5p, miR-6840-3p is hsa-miR-6840-3p, miR-6780b-5p is hsa-miR-6780b-5p, miR-6749-5p is hsa-miR-6749-5p, miR-8063 is hsa-miR-8063, miR-6784-5p is hsa-miR-6784-5p, miR-3679-5p is hsa-miR-3679-5p, miR-3184-5p is hsa-miR-3184-5p, and miR-663b is hsa-miR-663b, miR-6880-5p is hsa-miR-6880-5p, miR-1908-5p is hsa-miR-1908-5p, miR-92a-2-5p is hsa-miR-92a-2-5p, miR-7975 is hsa-miR-7975, miR-7110-5p is hsa-miR-7110-5p, miR-6842-5p is hsa-miR-6842-5p, miR-6857-5p is hsa-miR-6857-5p, miR-5572 is hsa-miR-5572, miR-3197 is hsa-miR-3197, and miR-6131 is hsa-miR-6131, miR-6889-5p is hsa-miR-6889-5p, miR-4454 is hsa-miR-4454, miR-1199-5p is hsa-miR-1199-5p, andmiR-1247-3p is hsa-miR-1247-3p, miR-6800-5p is hsa-miR-6800-5p, miR-6872-3p is hsa-miR-6872-3p, miR-4649-5p is hsa-miR-4649-5p, miR-6791-5p is hsa-miR-6791-5p, miR-4433b-3p is hsa-miR-4433b-3p, miR-3135b is hsa-miR-3135b, miR-128-2-5p is hsa-miR-128-2-5p, miR-4675 is hsa-miR-4675, and miR-4472 is hsa-miR-4472, miR-6785-5p is hsa-miR-6785-5p, miR-6741-5p is hsa-miR-6741-5p, miR-7977 is hsa-miR-7977, miR-3665 is hsa-miR-3665, miR-128-1-5p is hsa-miR-128-1-5p, miR-4286 is hsa-miR-4286, miR-6765-3p is hsa-miR-6765-3p, miR-4632-5p is hsa-miR-4632-5p, miR-365a-5p is hsa-miR-365a-5p, and miR-6088 is hsa-miR-6088, miR-6816-5p is hsa-miR-6816-5p, miR-6885-5p is hsa-miR-6885-5p, miR-711 is hsa-miR-711, miR-6765-5p is hsa-miR-6765-5p, miR-3180 is hsa-miR-3180, miR-4442 is hsa-miR-4442, miR-4792 is hsa-miR-4792, miR-6721-5p is hsa-miR-6721-5p, miR-6798-5p is hsa-miR-6798-5p, miR-3162-5p is hsa-miR-3162-5p, and miR-6126 is hsa-miR-6126, miR-4758-5p is hsa-miR-4758-5p, miR-2392 is hsa-miR-2392, andmiR-486-3p is hsa-miR-486-3p, miR-6727-5p is hsa-miR-6727-5p, miR-4728-5p is hsa-miR-4728-5p, miR-6746-5p is hsa-miR-6746-5p, miR-4270 is hsa-miR-4270, miR-3940-5p is hsa-miR-3940-5p, miR-4725-3p is hsa-miR-4725-3p, miR-7108-5p is hsa-miR-7108-5p, miR-3656 is hsa-miR-3656, miR-6879-5p is hsa-miR-6879-5p, and miR-6738-5p is hsa-miR-6738-5p, miR-1260a is hsa-miR-1260a, miR-4446-3p is hsa-miR-4446-3p, miR-3131 is hsa-miR-3131, miR-4463 is hsa-miR-4463, miR-3185 is hsa-miR-3185, miR-6870-5p is hsa-miR-6870-5p, miR-6779-5p is hsa-miR-6779-5p, miR-1273g-3p is hsa-miR-1273g-3p, miR-8059 is hsa-miR-8059, and miR-4697-5p is hsa-miR-4697-5p, miR-4674 is hsa-miR-4674, miR-4433-3p is hsa-miR-4433-3p, miR-4257 is hsa-miR-4257, miR-1915-5p is hsa-miR-1915-5p, miR-4417 is hsa-miR-4417, miR-1343-5p is hsa-miR-1343-5p, miR-6781-5p is hsa-miR-6781-5p, miR-4695-5p is hsa-miR-4695-5p, miR-1237-5p is hsa-miR-1237-5p, and miR-6775-5p is hsa-miR-6775-5p is, miR-7845-5p is hsa-miR-7845-5p, miR-4746-3p is hsa-miR-4746-3p, and,miR-7641 is hsa-miR-7641, miR-7847-3p is hsa-miR-7847-3p, miR-6806-5p is hsa-miR-6806-5p, miR-4467 is hsa-miR-4467, miR-4726-5p is hsa-miR-4726-5p, miR-4648 is hsa-miR-4648, miR-6089 is hsa-miR-6089, miR-1260b is hsa-miR-1260b, miR-4532 is hsa-miR-4532, miR-5195-3p is hsa-miR-5195-3p, miR-3188 is hsa-miR-3188, and miR-6848-5p is hsa-miR-6848-5p, miR-1233-5p is hsa-miR-1233-5p, miR-6717-5p is hsa-miR-6717-5p, miR-3195 is hsa-miR-3195, miR-6757-5p is hsa-miR-6757-5p, miR-8072 is hsa-miR-8072, miR-4745-5p is hsa-miR-4745-5p, miR-6511a-5p is hsa-miR-6511a-5p, miR-6776-5p is hsa-miR-6776-5p, and miR-371a-5p is hsa-miR-371a-5p, miR-1227-5p is hsa-miR-1227-5p, miR-7150 is hsa-miR-7150, miR-1915-3p is hsa-miR-1915-3p, miR-187-5p is hsa-miR-187-5p, miR-614 is hsa-miR-614, miR-1225-5p is hsa-miR-1225-5p, miR-451a is hsa-miR-451a, miR-939-5p is hsa-miR-939-5p, miR-223-3p is hsa-miR-223-3p, and miR-125a-3p is hsa-miR-125a-3p, miR-92b-5p is hsa-miR-92b-5p, miR-22-3p is hsa-miR-22-3p, miR-6073 is hsa-miR-6073, andmiR-6845-5p is hsa-miR-6845-5p, miR-6769b-5p is hsa-miR-6769b-5p, miR-4665-3p is hsa-miR-4665-3p, miR-1913 is hsa-miR-1913, miR-1228-3p is hsa-miR-1228-3p, miR-940 is hsa-miR-940, miR-296-3p is hsa-miR-296-3p, miR-4690-5p is hsa-miR-4690-5p, miR-548q is hsa-miR-548q, miR-663a is hsa-miR-663a, and miR-1249 is A device in which hsa-miR-1249, miR-1202 is hsa-miR-1202, miR-7113-3p is hsa-miR-7113-3p, miR-1225-3p is hsa-miR-1225-3p, miR-4783-3p is hsa-miR-4783-3p, miR-4448 is hsa-miR-4448, and miR-4534 is hsa-miR-4534.
[0065] (13)(11) or (12) in,
[0066] The above nucleic acid is a polynucleotide represented in (a) to (e) below:
[0067] (a) a polynucleotide, variant, derivative thereof, or fragment comprising 15 or more consecutive bases, comprising a base sequence represented by any one of SEQ ID NOs 1–125, 127–130, 132–134, and 561–578, or a base sequence in which u is t in said base sequence,
[0068] (b) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1–125, 127–130, 132–134, and 561–578,
[0069] (c) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1–125, 127–130, 132–134, and 561–578, or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,
[0070] (d) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1–125, 127–130, 132–134, and 561–578, or a nucleotide sequence complementary to a nucleotide sequence in which u is t, and
[0071] (e) a polynucleotide that hybridizes with any one of the polynucleotides (a) to (d) under stringent conditions,
[0072] A device that is a polynucleotide selected from the group consisting of
[0073] (14)(11) to (13) any one of
[0074] A device comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of other lung cancer markers miR-19b-3p, miR-1228-5p, and miR-1307-3p.
[0075] (15)(14) In this case,
[0076] A device in which miR-19b-3p is hsa-miR-19b-3p, miR-1228-5p is hsa-miR-1228-5p, and miR-1307-3p is hsa-miR-1307-3p.
[0077] (16)(14) or (15) in,
[0078] The above nucleic acid is a polynucleotide represented in (f) to (j) below:
[0079] (f) a polynucleotide consisting of a nucleotide sequence represented by any one of SEQ ID NOs 126, 131 and 579, or a nucleotide sequence in which u is t in said nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
[0080] (g) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 126, 131 and 579,
[0081] (h) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 126, 131 and 579, or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,
[0082] (i) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 126, 131 and 579, or a nucleotide sequence complementary to a nucleotide sequence in which u is t, and
[0083] (j) a polynucleotide that hybridizes with any one of (f) to (i) under stringent conditions,
[0084] A device that is a polynucleotide selected from the group consisting of
[0085] (17)(11) to (16) any one of
[0086] The device can be used to detect other lung cancer markers, including: miR-4763-3p,miR-6729-5p,miR-3196,miR-8069,miR-1268a,miR-4739,miR-1268b,miR-5698,miR-6752-5p,miR-4507,miR-564,miR-4497,miR-6877-5p,miR-6087 A device further comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-4731-5p, miR-615-5p, miR-760, miR-6891-5p, miR-6887-5p, miR-4525, miR-1914-3p, miR-619-5p, miR-5001-5p, miR-6722-3p, miR-3621, miR-4298, miR-675-5p, and miR-4655-5p.
[0087] (18)(17) In this case,
[0088] miR-4271 is hsa-miR-4271, miR-642b-3p is hsa-miR-642b-3p, miR-6075 is hsa-miR-6075, miR-6125 is hsa-miR-6125, miR-887-3p is hsa-miR-887-3p, miR-6851-5p is hsa-miR-6851-5p, miR-6763-5p is hsa-miR-6763-5p, miR-3928-3p is hsa-miR-3928-3p, miR-4443 is hsa-miR-4443, miR-3648 is hsa-miR-3648, and miR-149-3p is hsa-miR-149-3p, miR-4689 is hsa-miR-4689, miR-4763-3p is hsa-miR-4763-3p, miR-6729-5p is hsa-miR-6729-5p, miR-3196 is hsa-miR-3196, miR-8069 is hsa-miR-8069, miR-1268a is hsa-miR-1268a, miR-4739 is hsa-miR-4739, miR-1268b is hsa-miR-1268b, miR-5698 is hsa-miR-5698, miR-6752-5p is hsa-miR-6752-5p, and miR-4507 is hsa-miR-4507, miR-564 is hsa-miR-564, miR-4497 is hsa-miR-4497, miR-6877-5p is hsa-miR-6877-5p, miR-6087 is hsa-miR-6087, miR-4731-5p is hsa-miR-4731-5p, miR-615-5p is hsa-miR-615-5p, miR-760 is hsa-miR-760, miR-6891-5p is hsa-miR-6891-5p, miR-6887-5p is hsa-miR-6887-5p, miR-4525 is hsa-miR-4525, miR-1914-3p is hsa-miR-1914-3p, miR-619-5p is hsa-miR-619-5p, andA device in which miR-5001-5p is hsa-miR-5001-5p, miR-6722-3p is hsa-miR-6722-3p, miR-3621 is hsa-miR-3621, miR-4298 is hsa-miR-4298, miR-675-5p is hsa-miR-675-5p, and miR-4655-5p is hsa-miR-4655-5p.
[0089] (19)(17) or (18) in,
[0090] The above nucleic acid is a polynucleotide represented in (k) to (o) below:
[0091] (k) A polynucleotide consisting of a nucleotide sequence represented by any one of SEQ ID NOs 135 to 174 or a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
[0092] (l) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 135 to 174,
[0093] (m) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 135 to 174 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
[0094] (n) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 135 to 174 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, and
[0095] (o) A polynucleotide that hybridizes with any one of the above (k) to (n) under stringent conditions,
[0096] A device that is a polynucleotide selected from the group consisting of
[0097] (20)(11) to (19) any one of
[0098] The above device is a device for measurement using hybridization technology.
[0099] (21)(20) In this case,
[0100] A device in which the above hybridization technology is nucleic acid array technology.
[0101] (22)(11) to (21) any one of them,
[0102] A device comprising at least two nucleic acids capable of specifically binding to each of at least two polynucleotides selected from all lung cancer markers described in (11) or (12).
[0103] A method for detecting lung cancer comprising measuring the expression level of a target nucleic acid in a sample of a subject using a kit described in any one of (1) to (10) or a device described in any one of (11) to (22), and evaluating in vitro whether the subject has lung cancer or not using a control expression level of a healthy person measured in the same way as the measured expression level.
[0104] (24)(23) In this case,
[0105] A method in which the above subject is a human.
[0106] (25)(23) or (24) in,
[0107] A method in which the above specimen is blood, serum, or plasma.
[0108] Definition of Terms
[0109] Terms used in this specification have the following definitions.
[0110] Indications by abbreviations such as nucleotides, polynucleotides, DNA, RNA, etc. shall be in accordance with the “Guidelines for the Preparation of Specifications, etc. Including Base Sequences or Amino Acid Sequences” (compiled by the Japan Patent Office) and convention in the art.
[0111] In this specification, the term "polynucleotide" is used for nucleic acids comprising any of RNA, DNA, and RNA / DNA (chimera). Furthermore, the DNA comprises any of cDNA, genomic DNA, and synthetic DNA. Furthermore, the RNA comprises any of total RNA, mRNA, rRNA, miRNA, siRNA, snoRNA, snRNA, non-coding RNA, and synthetic RNA. In this specification, "synthetic DNA" and "synthetic RNA" refer to DNA and RNA artificially produced, for example, using an automated nucleic acid synthesizer, based on a predetermined base sequence (which may be either a natural sequence or a non-natural sequence). In this specification, the term "non-natural sequence" is intended to be used in a broad sense and includes sequences that differ from the natural sequence, such as sequences containing one or more nucleotide substitutions, deletions, insertions, and / or additions (i.e., variant sequences), sequences containing one or more modifying nucleotides (i.e., modification sequences), etc. In addition, polynucleotides are used interchangeably with nucleic acids in this specification.
[0112] In this specification, "fragment" refers to a polynucleotide having a base sequence of a continuous portion of a polynucleotide, and preferably has a length of 15 bases or more, preferably 17 bases or more, more preferably 19 bases or more.
[0113] In this specification, the term “gene” is used to mean not only RNA and double-stranded DNA, but also each single strand of DNA, such as a regular strand (or sense strand) or a complementary strand (or antisense strand), that constitutes it. Furthermore, it is not particularly limited according to its length.
[0114] Accordingly, in this specification, "gene" includes any of two-stranded DNA including human genomic DNA, one-stranded DNA (main strand), one-stranded DNA having a sequence complementary to the main strand including cDNA (complementary strand), microRNA (miRNA) and fragments thereof, and transcription products, unless specifically mentioned. In addition, "gene" includes not only "gene" represented by a specific nucleotide sequence (or sequence number), but also "nucleic acid" encoding RNA that has the same biological function as the RNA encoded by these, for example, homologues (i.e., homologs or oslogs), variants such as genetic polymorphisms, and derivatives. As for the “nucleic acid” encoding such homologues, variants, or derivatives, specifically, examples may include a “nucleic acid” having a nucleotide sequence represented by any one of SEQ ID NOs 1 to 618 under stringent conditions described later, or a nucleotide sequence that hybridizes with a nucleotide sequence in which u is t. Furthermore, the “gene” may include, for example, an expression control region, a coding region, an exon, or an intron, without distinguishing between functional regions. Additionally, the “gene” may be contained within a cell, may be released outside the cell and exist alone, or may be contained within a vesicle called an exosome.
[0115] In this specification, "exosome" refers to a vesicle contained within a lipid bilayer secreted from a cell. Exosomes originate from polypore endosomes and, when released into the extracellular environment, may contain biological materials such as proteins or "genes" such as RNA and DNA. Exosomes are known to be contained in body fluids such as blood, serum, plasma, and lymph. Additionally, "exosomes" are sometimes referred to simply as "exosomes."
[0116] In this specification, "transcription product" refers to RNA synthesized using the DNA sequence of a gene as a template. RNA polymerase binds to a region called a promoter located upstream of the gene, and RNA is synthesized by attaching ribonucleotides to the 3' end to become complementary to the DNA base sequence. This RNA includes not only the gene itself but also the entire sequence from the transcription initiation point to the end of the poly-A sequence, including the expression control region, code region, exon, or intron.
[0117] In addition, unless specifically stated otherwise in this specification, "microRNA (miRNA)" is intended to be a non-coding RNA of 15 to 25 nucleotides that is transcribed as a hairpin-shaped RNA precursor, cleaved by a dsRNA cleavage enzyme having RNase III cleavage activity, included in a protein complex called RISC, and involved in the repression of mRNA translation. In addition, "miRNA" as used in this specification includes not only "miRNA" represented by a specific nucleotide sequence (or sequence number), but also precursors of the "miRNA" (pre-miRNA, pri-miRNA), miRNAs with biological functions equivalent to these, such as homologues (i.e., homologs or osologs), variants such as genetic polymorphisms, and derivatives. Examples of such precursors, homologues, variants, or derivatives include “miRNAs” that can be specifically identified by miRBase release 20 (http: / / www.mirbase.org / ) and have a nucleotide sequence that hybridizes with the complementary sequence of a specific nucleotide sequence represented by any one of SEQ ID NOs 1 to 618 under stringent conditions described below. Additionally, “miRNAs” used herein may be gene products of miR genes, and such gene products include mature miRNAs (e.g., non-coding RNA of 15 to 25 nucleotides or 19 to 25 nucleotides involved in the repression of translation of mRNA as described above), or miRNA precursors (e.g., pre-miRNA or pri-miRNA as described above).
[0118] In this specification, the term “probe” includes a polynucleotide and / or a polynucleotide complementary thereto used to specifically detect RNA generated by gene expression or a polynucleotide derived therefrom.
[0119] In this specification, the term "primer" includes a polynucleotide and / or a polynucleotide complementary thereto that specifically recognizes and amplifies RNA generated by gene expression or a polynucleotide derived therefrom.
[0120] Here, a complementary polynucleotide (complementary chain, inverted chain) refers to a polynucleotide that is in a base-complementary relationship with respect to a base sequence defined by any one of SEQ ID NOs 1 to 618, or a polynucleotide consisting of a sequence in which u is t in the said sequence, or a partial sequence thereof (here, for convenience, this is referred to as the main chain), based on base pair relationships such as A:T(U) and G:C. However, such a complementary chain is not limited to cases where it forms a completely complementary sequence with the base sequence of the main chain to be targeted, but may also have a complementary relationship to the extent that it can hybridize under stringent conditions with the main chain to be targeted.
[0121] In this specification, "stringent conditions" refers to conditions in which a nucleic acid probe hybridizes to a target sequence to a greater degree than another sequence (e.g., the mean of background measurements + the standard error of background measurements × 2 or greater). Stringent conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. Specific examples of "stringent conditions" are described below.
[0122] In this specification, "Tm value" means the temperature at which the two-chain portion of the polynucleotide is denatured into a one-chain and the two-chain and one-chain exist in a 1:1 ratio.
[0123] In this specification, the term "variant" refers, in the case of nucleic acids, to a natural variant resulting from polymorphism, mutation, etc., or a variant comprising a deletion, substitution, addition, or insertion of 1, 2, 3, or more bases in any one of SEQ ID NOs 1 to 618, or a sequence in which u is t in said sequence, or a partial sequence, or a variant comprising a sequence of a premature miRNA of any one of SEQ ID NOs 1 to 618, or a variant comprising a deletion, substitution, addition, or insertion of 1 or 2 or more bases in said sequence, or a partial sequence, or a variant exhibiting at least 90%, at least 95%, at least 97%, at least 98%, or at least 99% identity with each of said sequences or their partial sequences, or a polynucleotide or oligonucleotide comprising said sequence or its partial sequence and the definition above It refers to nucleic acids that hybridize under strict conditions.
[0124] In this specification, “a number” means about 10, 9, 8, 7, 6, 5, 4, 3 or 2 integers.
[0125] In this specification, variants can be produced using well-known techniques, such as site-specific mutagenesis and mutation introduction using PCR.
[0126] In this specification, “identity” can be determined by using a protein or gene screening system based on BLAST or FASTA with or without introducing a gap (Zheng Zhang et al., 2000, J. Comput. Biol., Vol. 7, pp. 203-214; Altschul, SF et al., 1990, Journal of Molecular Biology, Vol. 215, pp. 403-410; Pearson, WR et al., 1988, Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 2444-2448).
[0127] In this specification, the term “derivative” means a modified nucleic acid, a derivative labeled by a fluorescent dye, etc., for example, a modified nucleotide (for example, a nucleotide containing a group such as a halogen, alkyl such as methyl, alkoxy such as methoxy, thio, carboxymethyl, etc., and a nucleotide that has undergone rearrangement of bases, saturation of double bonds, deamination, substitution of oxygen molecules with sulfur molecules, etc.), PNA (peptide nucleic acid; Nielsen, PE et al., 1991, Science, Vol. 254, pp. 1497-500), LNA (locked nucleic acid; Obika, S. et al., 1998, Tetrahedron Lett., Vol. 39, pp. 5401-5404), etc.
[0128] In the present specification, the “nucleic acid” capable of specifically binding to a polynucleotide selected from the miRNA that is the lung cancer marker is a synthesized or prepared nucleic acid, specifically comprising a “nucleic acid probe” or a “primer,” and is used directly or indirectly to detect the presence or absence of lung cancer in a subject, to diagnose the presence or absence of lung cancer, the degree of disease, the presence or degree of improvement of lung cancer, or sensitivity to lung cancer treatment, or to screen candidate substances useful for the prevention, improvement, or treatment of lung cancer. These include nucleotides, oligonucleotides, and polynucleotides capable of specifically recognizing and binding to a transcription product represented by any one of SEQ ID NOs 1 to 618 or the cDNA synthesized nucleic acid in vivo, particularly in bodily fluids such as blood and urine, in relation to lung cancer disease. These nucleotides, oligonucleotides, and polynucleotides can be effectively used as probes for detecting the said gene expressed in vivo, in tissues or cells, etc., based on the above properties, and also as primers for amplifying the said gene expressed in vivo.
[0129] The term “detection” used in this specification may be replaced with the terms inspection, measurement, detection, or judgment support. Additionally, the term “evaluation” in this specification is used to include supporting diagnosis or evaluation based on inspection results or measurement results.
[0130] As used in this specification, “subject” means humans, primates including chimpanzees, pets such as dogs and cats, livestock such as cattle, horses, sheep, and goats, and mammals such as mice and rats. Additionally, “healthy body” also means such mammals that are not infected with the cancer to be detected.
[0131] As used herein, “P” or “P-value” represents the probability that, in a statistical test, a statistic more extreme than the statistic actually calculated from the data will be observed under the null hypothesis. Therefore, the smaller the “P” or “P-value,” the more significant the difference is considered to be between the subjects of comparison.
[0132] In this specification, "sensitivity" refers to the value of (number of true positives) / (number of true positives + number of false negatives). High sensitivity enables the early detection of lung cancer, leading to the complete resection of the cancerous area and a reduction in the recurrence rate.
[0133] In this specification, "specificity" means (number of true negatives) / (number of true negatives + number of false positives). High specificity prevents unnecessary additional testing caused by misdiagnosing a healthy person as a lung cancer patient, leading to a reduction in the burden on patients and a reduction in medical costs.
[0134] In this specification, "precision" refers to the value of (number of true positives + number of true negatives) / (total number of cases). Precision represents the ratio of correct discrimination results for the total number of samples and serves as a primary indicator for evaluating detection performance.
[0135] In this specification, the term “specimen” subject to determination, detection, or diagnosis refers to tissues and biomaterials in which the expression of the gene of the present invention changes due to the occurrence of lung cancer, the progression of lung cancer, and the exertion of a therapeutic effect on lung cancer. Specifically, it refers to lung tissue and surrounding blood vessels, lymph nodes, and organs, as well as organs suspected of metastasis, skin, and body fluids such as blood, urine, saliva, sweat, and tissue exudate, serum prepared from blood, plasma, others, and hair. In addition, it refers to biological samples extracted from these, specifically genes such as RNA or miRNA.
[0136] The terms “hsa-miR-6768-5p gene” or “hsa-miR-6768-5p” as used in this specification include the hsa-miR-6768-5p gene (miRBase Accession No. MIMAT0027436) described in SEQ ID NO. 1 and other biological species homologs or osologs, etc. The hsa-miR-6768-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6768” (miRBase Accession No. MI0022613, SEQ ID NO. 175), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6768-5p”.
[0137] The terms “hsa-miR-6836-3p gene” or “hsa-miR-6836-3p” as used in this specification include the hsa-miR-6836-3p gene (miRBase Accession No. MIMAT0027575) described in SEQ ID NO. 2 and other biological species homologs or osologs, etc. The hsa-miR-6836-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6836” (miRBase Accession No. MI0022682, SEQ ID NO. 176), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6836-3p”.
[0138] The terms “hsa-miR-6782-5p gene” or “hsa-miR-6782-5p” as used herein include the hsa-miR-6782-5p gene (miRBase Accession No. MIMAT0027464) described in SEQ ID NO. 3, or other biological species homologs or oslogs. The hsa-miR-6782-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Additionally, “hsa-miR-6782” (miRBase Accession No. MI0022627, SEQ ID NO. 177), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6782-5p”.
[0139] The terms “hsa-miR-3663-3p gene” or “hsa-miR-3663-3p” as used in this specification include the hsa-miR-3663-3p gene (miRBase Accession No. MIMAT0018085) described in SEQ ID No. 4, or other biological species homologs or oslogs. The hsa-miR-3663-3p gene can be obtained by the method described in Liao JY et al., 2010, PLoS One, Vol. 5, e10563. Additionally, “hsa-miR-3663” (miRBase Accession No. MI0016064, SEQ ID No. 178), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-3663-3p”.
[0140] The terms “hsa-miR-1908-3p gene” or “hsa-miR-1908-3p” as used herein include the hsa-miR-1908-3p gene (miRBase Accession No. MIMAT0026916) described in SEQ ID No. 5, or other biological species homologs or oslogs, etc. The hsa-miR-1908-3p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. Additionally, “hsa-miR-1908” (miRBase Accession No. MI0008329, SEQ ID No. 179), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1908-3p”.
[0141] The terms “hsa-miR-6726-5p gene” or “hsa-miR-6726-5p” as used in this specification include the hsa-miR-6726-5p gene (miRBase Accession No. MIMAT0027353) described in SEQ ID No. 6, or other biological species homologs or oslogs. The hsa-miR-6726-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Additionally, “hsa-miR-6726” (miRBase Accession No. MI0022571, SEQ ID No. 180), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6726-5p”.
[0142] The terms “hsa-miR-4258 gene” or “hsa-miR-4258” as used in this specification include the hsa-miR-4258 gene (miRBase Accession No. MIMAT0016879) described in SEQ ID No. 7, as well as other biological species homologs or osologs. The hsa-miR-4258 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. Additionally, “hsa-miR-4258” (miRBase Accession No. MI0015857, SEQ ID No. 181), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4258”.
[0143] The terms “hsa-miR-1343-3p gene” or “hsa-miR-1343-3p” as used in this specification include the hsa-miR-1343-3p gene (miRBase Accession No. MIMAT0019776) described in SEQ ID NO. 8 and other biological species homologs or oslogs, etc. The hsa-miR-1343-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, “hsa-miR-1343” (miRBase Accession No. MI0017320, SEQ ID NO. 182), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1343-3p”.
[0144] The terms “hsa-miR-4516 gene” or “hsa-miR-4516” as used in this specification include the hsa-miR-4516 gene (miRBase Accession No. MIMAT0019053) described in SEQ ID No. 9, as well as other biological species homologs or oslogs. The hsa-miR-4516 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Additionally, “hsa-miR-4516” (miRBase Accession No. MI0016882, SEQ ID No. 183), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4516.”
[0145] The terms “hsa-miR-6875-5p gene” or “hsa-miR-6875-5p” as used in this specification include the hsa-miR-6875-5p gene (miRBase Accession No. MIMAT0027650) described in SEQ ID NO. 10 and other biological species homologs or osologs, etc. The hsa-miR-6875-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6875” (miRBase Accession No. MI0022722, SEQ ID NO. 184), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6875-5p”.
[0146] The terms “hsa-miR-4651 gene” or “hsa-miR-4651” as used in this specification include the hsa-miR-4651 gene (miRBase Accession No. MIMAT0019715) described in SEQ ID NO. 11 and other biological species homologs or oslogs, etc. The hsa-miR-4651 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, “hsa-miR-4651” is known as a precursor of “hsa-miR-4651” which has a hairpin-shaped structure, “hsa-mir-4651” (miRBase Accession No. MI0017279, SEQ ID NO. 185).
[0147] The terms “hsa-miR-6825-5p gene” or “hsa-miR-6825-5p” as used in this specification include the hsa-miR-6825-5p gene (miRBase Accession No. MIMAT0027550) described in SEQ ID NO. 12 and other biological species homologs or oslogs, etc. The hsa-miR-6825-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6825” (miRBase Accession No. MI0022670, SEQ ID NO. 186), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6825-5p”.
[0148] The terms “hsa-miR-6840-3p gene” or “hsa-miR-6840-3p” as used in this specification include the hsa-miR-6840-3p gene (miRBase Accession No. MIMAT0027583) described in SEQ ID NO. 13 and other biological species homologs or oslogs, etc. The hsa-miR-6840-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6840” (miRBase Accession No. MI0022686, SEQ ID NO. 187), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6840-3p”.
[0149] The terms “hsa-miR-6780b-5p gene” or “hsa-miR-6780b-5p” as used in this specification include the hsa-miR-6780b-5p gene (miRBase Accession No. MIMAT0027572) described in SEQ ID NO. 14 and other biological species homologs or oslogs, etc. The hsa-miR-6780b-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6780b” (miRBase Accession No. MI0022681, SEQ ID NO. 188), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6780b-5p”.
[0150] The terms “hsa-miR-6749-5p gene” or “hsa-miR-6749-5p” as used in this specification include the hsa-miR-6749-5p gene (miRBase Accession No. MIMAT0027398) described in SEQ ID NO. 15 and other biological species homologs or osologs, etc. The hsa-miR-6749-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6749” (miRBase Accession No. MI0022594, SEQ ID NO. 189), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6749-5p”.
[0151] The terms “hsa-miR-8063 gene” or “hsa-miR-8063” as used in this specification include the hsa-miR-8063 gene (miRBase Accession No. MIMAT0030990) described in SEQ ID NO. 16 and other biological species homologs or oslogs, etc. The hsa-miR-8063 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487. In addition, “hsa-miR-8063” is known as a precursor of “hsa-miR-8063” which has a hairpin-shaped structure, “hsa-mir-8063” (miRBase Accession No. MI0025899, SEQ ID NO. 190).
[0152] The terms “hsa-miR-6784-5p gene” or “hsa-miR-6784-5p” as used herein include the hsa-miR-6784-5p gene (miRBase Accession No. MIMAT0027468) described in SEQ ID NO. 17 and other biological species homologs or oslogs, etc. The hsa-miR-6784-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6784” (miRBase Accession No. MI0022629, SEQ ID NO. 191), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6784-5p”.
[0153] The terms “hsa-miR-3679-5p gene” or “hsa-miR-3679-5p” as used herein include the hsa-miR-3679-5p gene (miRBase Accession No. MIMAT0018104) described in SEQ ID NO. 18 and other biological species homologs or oslogs, etc. The hsa-miR-3679-5p gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. In addition, “hsa-miR-3679” (miRBase Accession No. MI0016080, SEQ ID NO. 192), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-3679-5p”.
[0154] The terms “hsa-miR-3184-5p gene” or “hsa-miR-3184-5p” as used in this specification include the hsa-miR-3184-5p gene (miRBase Accession No. MIMAT0015064) described in SEQ ID No. 19, or other biological species homologs or oslogs. The hsa-miR-3184-5p gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Additionally, “hsa-miR-3184” (miRBase Accession No. MI0014226, SEQ ID No. 193), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-3184-5p”.
[0155] The terms “hsa-miR-663b gene” or “hsa-miR-663b” as used in this specification include the hsa-miR-663b gene (miRBase Accession No. MIMAT0005867) described in SEQ ID NO. 20 and other homologs or oslogs of biological species. The hsa-miR-663b gene can be obtained by the method described in Takada S et al., 2008, Leukemia, Vol. 22, pp. 1274-1278. Additionally, “hsa-miR-663b” is known as a precursor of “hsa-miR-663b” which has a hairpin-shaped structure, “hsa-mir-663b” (miRBase Accession No. MI0006336, SEQ ID NO. 194).
[0156] The terms “hsa-miR-6880-5p gene” or “hsa-miR-6880-5p” as used in this specification include the hsa-miR-6880-5p gene (miRBase Accession No. MIMAT0027660) described in SEQ ID NO. 21 and other biological species homologs or oslogs, etc. The hsa-miR-6880-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6880” (miRBase Accession No. MI0022727, SEQ ID NO. 195), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6880-5p”.
[0157] The terms “hsa-miR-1908-5p gene” or “hsa-miR-1908-5p” as used herein include the hsa-miR-1908-5p gene (miRBase Accession No. MIMAT0007881) described in SEQ ID NO. 22, or other biological species homologs or oslogs, etc. The hsa-miR-1908-5p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. Additionally, “hsa-miR-1908” (miRBase Accession No. MI0008329, SEQ ID NO. 179), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1908-5p”.
[0158] The terms “hsa-miR-92a-2-5p gene” or “hsa-miR-92a-2-5p” as used herein include the hsa-miR-92a-2-5p gene described in SEQ ID NO. 23 (miRBase Accession No. MIMAT0004508) and other biological species homologs or oslogs. The hsa-miR-92a-2-5p gene can be obtained by the method described in Mourelatos Z et al., 2002, Genes Dev, Vol. 16, pp. 720-728. Additionally, “hsa-miR-92a-2” (miRBase Accession No. MI0000094, SEQ ID NO. 196), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-92a-2-5p”.
[0159] The terms “hsa-miR-7975 gene” or “hsa-miR-7975” as used in this specification include the hsa-miR-7975 gene (miRBase Accession No. MIMAT0031178) described in SEQ ID No. 24, or other homologs or oslogs of biological species. The hsa-miR-7975 gene can be obtained by the method described in the online edition of Velthut-Meikas A et al., 2013, Mol Endocrinol. Additionally, “hsa-miR-7975” (miRBase Accession No. MI0025751, SEQ ID No. 197), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-7975.”
[0160] The terms “hsa-miR-7110-5p gene” or “hsa-miR-7110-5p” as used in this specification include the hsa-miR-7110-5p gene (miRBase Accession No. MIMAT0028117) described in SEQ ID No. 25, or other biological species homologs or oslogs. The hsa-miR-7110-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Additionally, “hsa-miR-7110” (miRBase Accession No. MI0022961, SEQ ID No. 198), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-7110-5p”.
[0161] The terms “hsa-miR-6842-5p gene” or “hsa-miR-6842-5p” as used herein include the hsa-miR-6842-5p gene (miRBase Accession No. MIMAT0027586) described in SEQ ID No. 26, or other biological species homologs or osologs, etc. The hsa-miR-6842-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6842” (miRBase Accession No. MI0022688, SEQ ID No. 199), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6842-5p”.
[0162] The terms “hsa-miR-6857-5p gene” or “hsa-miR-6857-5p” as used in this specification include the hsa-miR-6857-5p gene (miRBase Accession No. MIMAT0027614) described in SEQ ID No. 27 and other biological species homologs or osologs, etc. The hsa-miR-6857-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6857” (miRBase Accession No. MI0022703, SEQ ID No. 200), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6857-5p”.
[0163] The terms “hsa-miR-5572 gene” or “hsa-miR-5572” as used in this specification include the hsa-miR-5572 gene (miRBase Accession No. MIMAT0022260) described in SEQ ID NO. 28 and other biological species homologs or osologs, etc. The hsa-miR-5572 gene can be obtained by the method described in Tandon M et al., 2012, Oral Dis, Vol. 18, pp. 127-131. In addition, “hsa-miR-5572” is known as a precursor of “hsa-miR-5572” which has a hairpin-shaped structure, “hsa-mir-5572” (miRBase Accession No. MI0019117, SEQ ID NO. 201).
[0164] The terms “hsa-miR-3197 gene” or “hsa-miR-3197” as used in this specification include the hsa-miR-3197 gene (miRBase Accession No. MIMAT0015082) described in SEQ ID No. 29, or other biological species homologs or oslogs, etc. The hsa-miR-3197 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, “hsa-miR-3197” is known as a precursor of “hsa-miR-3197” which has a hairpin-shaped structure, “hsa-mir-3197” (miRBase Accession No. MI0014245, SEQ ID No. 202).
[0165] The terms “hsa-miR-6131 gene” or “hsa-miR-6131” as used in this specification include the hsa-miR-6131 gene (miRBase Accession No. MIMAT0024615) described in SEQ ID NO. 30, as well as other biological species homologs or osologs. The hsa-miR-6131 gene can be obtained by the method described in Dannemann M et al., 2012, Genome Biol Evol, Vol. 4, pp. 552-564. Additionally, “hsa-miR-6131” is known as a precursor of “hsa-miR-6131” which has a hairpin-shaped structure, “hsa-mir-6131” (miRBase Accession No. MI0021276, SEQ ID NO. 203).
[0166] The terms “hsa-miR-6889-5p gene” or “hsa-miR-6889-5p” as used herein include the hsa-miR-6889-5p gene (miRBase Accession No. MIMAT0027678) described in SEQ ID NO. 31, or other biological species homologs or oslogs, etc. The hsa-miR-6889-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Additionally, “hsa-miR-6889” (miRBase Accession No. MI0022736, SEQ ID NO. 204), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6889-5p”.
[0167] The terms “hsa-miR-4454 gene” or “hsa-miR-4454” as used in this specification include the hsa-miR-4454 gene (miRBase Accession No. MIMAT0018976) described in SEQ ID NO. 32, or other biological species homologs or oslogs, etc. The hsa-miR-4454 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, “hsa-miR-4454” is known as a precursor of “hsa-miR-4454” which has a hairpin-shaped structure, “hsa-mir-4454” (miRBase Accession No. MI0016800, SEQ ID NO. 205).
[0168] The terms “hsa-miR-1199-5p gene” or “hsa-miR-1199-5p” as used in this specification include the hsa-miR-1199-5p gene (miRBase Accession No. MIMAT0031119) described in SEQ ID NO. 33, or other biological species homologs or oslogs. The hsa-miR-1199-5p gene can be obtained by the method described in Salvi A et al., 2013, Int J Oncol, Vol. 42, pp. 391-402. Additionally, “hsa-miR-1199” (miRBase Accession No. MI0020340, SEQ ID NO. 206), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1199-5p”.
[0169] The terms “hsa-miR-1247-3p gene” or “hsa-miR-1247-3p” as used in this specification include the hsa-miR-1247-3p gene (miRBase Accession No. MIMAT0022721) described in SEQ ID NO. 34 and other biological species homologs or oslogs, etc. The hsa-miR-1247-3p gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. In addition, “hsa-miR-1247” (miRBase Accession No. MI0006382, SEQ ID NO. 207), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1247-3p”.
[0170] The terms “hsa-miR-6800-5p gene” or “hsa-miR-6800-5p” as used in this specification include the hsa-miR-6800-5p gene (miRBase Accession No. MIMAT0027500) described in SEQ ID NO. 35 and other biological species homologs or oslogs, etc. The hsa-miR-6800-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6800” (miRBase Accession No. MI0022645, SEQ ID NO. 208), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6800-5p”.
[0171] The terms “hsa-miR-6872-3p gene” or “hsa-miR-6872-3p” as used herein include the hsa-miR-6872-3p gene (miRBase Accession No. MIMAT0027645) described in SEQ ID NO. 36 and other biological species homologs or oslogs, etc. The hsa-miR-6872-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6872” (miRBase Accession No. MI0022719, SEQ ID NO. 209), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6872-3p”.
[0172] The terms “hsa-miR-4649-5p gene” or “hsa-miR-4649-5p” as used in this specification include the hsa-miR-4649-5p gene (miRBase Accession No. MIMAT0019711) described in SEQ ID NO. 37 and other biological species homologs or oslogs, etc. The hsa-miR-4649-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, “hsa-miR-4649” (miRBase Accession No. MI0017276, SEQ ID NO. 210), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4649-5p”.
[0173] The terms “hsa-miR-6791-5p gene” or “hsa-miR-6791-5p” as used in this specification include the hsa-miR-6791-5p gene (miRBase Accession No. MIMAT0027482) described in SEQ ID NO. 38, or other biological species homologs or oslogs, etc. The hsa-miR-6791-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6791” (miRBase Accession No. MI0022636, SEQ ID NO. 211), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6791-5p”.
[0174] The terms “hsa-miR-4433b-3p gene” or “hsa-miR-4433b-3p” as used herein include the hsa-miR-4433b-3p gene described in SEQ ID NO. 39 (miRBase Accession No. MIMAT0030414) and other biological species homologs or oslogs. The hsa-miR-4433b-3p gene can be obtained by the method described in Ple H et al., 2012, PLoS One, Vol. 7, e50746. Additionally, “hsa-miR-4433b” (miRBase Accession No. MI0025511, SEQ ID NO. 212), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4433b-3p”.
[0175] The terms “hsa-miR-3135b gene” or “hsa-miR-3135b” as used in this specification include the hsa-miR-3135b gene (miRBase Accession No. MIMAT0018985) described in SEQ ID No. 40, or other biological species homologs or oslogs. The hsa-miR-3135b gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Additionally, “hsa-miR-3135b” is known as a precursor of the “hsa-miR-3135b” which has a hairpin-shaped structure, “hsa-mir-3135b” (miRBase Accession No. MI0016809, SEQ ID No. 213).
[0176] The terms “hsa-miR-128-2-5p gene” or “hsa-miR-128-2-5p” as used in this specification include the hsa-miR-128-2-5p gene described in SEQ ID NO. 41 (miRBase Accession No. MIMAT0031095) and other biological species homologs or oslogs. The hsa-miR-128-2-5p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, pp. 735-739. Additionally, “hsa-miR-128-2” (miRBase Accession No. MI0000727, SEQ ID NO. 214), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-128-2-5p”.
[0177] The terms “hsa-miR-4675 gene” or “hsa-miR-4675” as used in this specification include the hsa-miR-4675 gene (miRBase Accession No. MIMAT0019757) described in SEQ ID NO. 42, or other biological species homologs or oslogs. The hsa-miR-4675 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Additionally, “hsa-miR-4675” (miRBase Accession No. MI0017306, SEQ ID NO. 215), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4675.”
[0178] The terms “hsa-miR-4472 gene” or “hsa-miR-4472” as used in this specification include the hsa-miR-4472 gene described in SEQ ID NO. 43 (miRBase Accession No. MIMAT0018999) and other biological species homologs or oslogs. The hsa-miR-4472 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Additionally, “hsa-miR-4472-1, hsa-miR-4472-2” (miRBase Accession No. MI0016823, MI0016824, SEQ ID NOs 216, 217), which have a hairpin-shaped structure, are known as precursors of “hsa-miR-4472”.
[0179] The terms “hsa-miR-6785-5p gene” or “hsa-miR-6785-5p” as used herein include the hsa-miR-6785-5p gene (miRBase Accession No. MIMAT0027470) described in SEQ ID NO. 44 and other biological species homologs or oslogs, etc. The hsa-miR-6785-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6785” (miRBase Accession No. MI0022630, SEQ ID NO. 218), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6785-5p”.
[0180] The terms “hsa-miR-6741-5p gene” or “hsa-miR-6741-5p” as used in this specification include the hsa-miR-6741-5p gene (miRBase Accession No. MIMAT0027383) described in SEQ ID NO. 45 and other biological species homologs or osologs, etc. The hsa-miR-6741-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6741” (miRBase Accession No. MI0022586, SEQ ID NO. 219), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6741-5p”.
[0181] The terms “hsa-miR-7977 gene” or “hsa-miR-7977” as used in this specification include the hsa-miR-7977 gene (miRBase Accession No. MIMAT0031180) described in SEQ ID No. 46, or other biological species homologs or oslogs. The hsa-miR-7977 gene can be obtained by the method described in the online edition of Velthut-Meikas A et al., 2013, Mol Endocrinol. Additionally, “hsa-miR-7977” (miRBase Accession No. MI0025753, SEQ ID No. 220), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-7977”.
[0182] The terms “hsa-miR-3665 gene” or “hsa-miR-3665” as used in this specification include the hsa-miR-3665 gene (miRBase Accession No. MIMAT0018087) described in SEQ ID NO. 47 and other homologs or osologs of biological species. The hsa-miR-3665 gene can be obtained by the method described in Xie X et al., 2005, Nature, Vol. 434, pp. 338-345. Additionally, “hsa-miR-3665” (miRBase Accession No. MI0016066, SEQ ID NO. 221), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-3665.”
[0183] The terms “hsa-miR-128-1-5p gene” or “hsa-miR-128-1-5p” as used herein include the hsa-miR-128-1-5p gene described in SEQ ID NO. 48 (miRBase Accession No. MIMAT0026477) and other biological species homologs or oslogs. The hsa-miR-128-1-5p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, pp. 735-739. Additionally, “hsa-miR-128-1” (miRBase Accession No. MI0000447, SEQ ID NO. 222), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-128-1-5p”.
[0184] The terms “hsa-miR-4286 gene” or “hsa-miR-4286” as used in this specification include the hsa-miR-4286 gene (miRBase Accession No. MIMAT0016916) described in SEQ ID NO. 49, as well as other biological species homologs or oslogs. The hsa-miR-4286 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. Additionally, “hsa-miR-4286” (miRBase Accession No. MI0015894, SEQ ID NO. 223), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4286.”
[0185] The terms “hsa-miR-6765-3p gene” or “hsa-miR-6765-3p” as used herein include the hsa-miR-6765-3p gene (miRBase Accession No. MIMAT0027431) described in SEQ ID No. 50, or other biological species homologs or oslogs, etc. The hsa-miR-6765-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Additionally, “hsa-miR-6765” (miRBase Accession No. MI0022610, SEQ ID No. 224), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6765-3p”.
[0186] The terms “hsa-miR-4632-5p gene” or “hsa-miR-4632-5p” as used in this specification include the hsa-miR-4632-5p gene (miRBase Accession No. MIMAT0022977) described in SEQ ID NO. 51 and other biological species homologs or oslogs, etc. The hsa-miR-4632-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, “hsa-miR-4632” (miRBase Accession No. MI0017259, SEQ ID NO. 225), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4632-5p”.
[0187] The terms “hsa-miR-365a-5p gene” or “hsa-miR-365a-5p” as used in this specification include the hsa-miR-365a-5p gene (miRBase Accession No. MIMAT0009199) described in SEQ ID NO. 52, or other biological species homologs or osologs, etc. The hsa-miR-365a-5p gene can be obtained by the method described in Xie X et al., 2005, Nature, Vol. 434, pp. 338-345. In addition, “hsa-miR-365a” (miRBase Accession No. MI0000767, SEQ ID NO. 226), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-365a-5p”.
[0188] The terms “hsa-miR-6088 gene” or “hsa-miR-6088” as used in this specification include the hsa-miR-6088 gene (miRBase Accession No. MIMAT0023713) described in SEQ ID NO. 53, as well as other biological species homologs or oslogs. The hsa-miR-6088 gene can be obtained by the method described in Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, pp. 2049-2057. Additionally, “hsa-miR-6088” (miRBase Accession No. MI0020365, SEQ ID NO. 227), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6088.”
[0189] The terms “hsa-miR-6816-5p gene” or “hsa-miR-6816-5p” as used in this specification include the hsa-miR-6816-5p gene (miRBase Accession No. MIMAT0027532) described in SEQ ID NO. 54 and other biological species homologs or oslogs, etc. The hsa-miR-6816-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6816” (miRBase Accession No. MI0022661, SEQ ID NO. 228), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6816-5p”.
[0190] The terms “hsa-miR-6885-5p gene” or “hsa-miR-6885-5p” as used in this specification include the hsa-miR-6885-5p gene (miRBase Accession No. MIMAT0027670) described in SEQ ID NO. 55 and other biological species homologs or osologs, etc. The hsa-miR-6885-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6885” (miRBase Accession No. MI0022732, SEQ ID NO. 229), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6885-5p”.
[0191] The terms “hsa-miR-711 gene” or “hsa-miR-711” as used in this specification include the hsa-miR-711 gene described in SEQ ID NO. 56 (miRBase Accession No. MIMAT0012734) and other biological species homologs or oslogs. The hsa-miR-711 gene can be obtained by the method described in Artzi S et al., 2008, BMC Bioinformatics, Vol. 9, p. 39. Additionally, “hsa-miR-711” is known as a precursor of which is “hsa-mir-711” (miRBase Accession No. MI0012488, SEQ ID NO. 230), which has a hairpin-shaped structure.
[0192] The terms “hsa-miR-6765-5p gene” or “hsa-miR-6765-5p” as used herein include the hsa-miR-6765-5p gene (miRBase Accession No. MIMAT0027430) described in SEQ ID No. 57 and other biological species homologs or osologs, etc. The hsa-miR-6765-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6765” (miRBase Accession No. MI0022610, SEQ ID No. 224), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6765-5p”.
[0193] The terms “hsa-miR-3180 gene” or “hsa-miR-3180” as used in this specification include the hsa-miR-3180 gene described in SEQ ID NO. 58 (miRBase Accession No. MIMAT0018178) and other biological species homologs or oslogs. The hsa-miR-3180 gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. Additionally, “hsa-miR-3180” is known to have a hairpin-shaped structure as a precursor to “hsa-miR-3180”, which is “hsa-mir-3180-4, hsa-mir-3180-5” (miRBase Accession No. MI0016408, MI0016409, SEQ ID NOs 231, 232).
[0194] The terms “hsa-miR-4442 gene” or “hsa-miR-4442” as used in this specification include the hsa-miR-4442 gene (miRBase Accession No. MIMAT0018960) described in SEQ ID No. 59, or other biological species homologs or oslogs. The hsa-miR-4442 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Additionally, “hsa-miR-4442” (miRBase Accession No. MI0016785, SEQ ID No. 233), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4442.”
[0195] The terms “hsa-miR-4792 gene” or “hsa-miR-4792” as used in this specification include the hsa-miR-4792 gene (miRBase Accession No. MIMAT0019964) described in SEQ ID No. 60, as well as other biological species homologs or oslogs. The hsa-miR-4792 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Additionally, “hsa-miR-4792” (miRBase Accession No. MI0017439, SEQ ID No. 234), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4792.”
[0196] The terms “hsa-miR-6721-5p gene” or “hsa-miR-6721-5p” as used in this specification include the hsa-miR-6721-5p gene (miRBase Accession No. MIMAT0025852) described in SEQ ID No. 61, or other biological species homologs or oslogs, etc. The hsa-miR-6721-5p gene can be obtained by the method described in Li Y et al., 2012, Gene, Vol. 497, pp. 330-335. In addition, “hsa-miR-6721” (miRBase Accession No. MI0022556, SEQ ID No. 235), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6721-5p”.
[0197] The terms “hsa-miR-6798-5p gene” or “hsa-miR-6798-5p” as used herein include the hsa-miR-6798-5p gene (miRBase Accession No. MIMAT0027496) described in SEQ ID No. 62, or other biological species homologs or oslogs, etc. The hsa-miR-6798-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Additionally, “hsa-miR-6798” (miRBase Accession No. MI0022643, SEQ ID No. 236), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6798-5p”.
[0198] The terms “hsa-miR-3162-5p gene” or “hsa-miR-3162-5p” as used herein include the hsa-miR-3162-5p gene described in SEQ ID NO. 63 (miRBase Accession No. MIMAT0015036) and other biological species homologs or oslogs. The hsa-miR-3162-5p gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Additionally, “hsa-miR-3162” (miRBase Accession No. MI0014192, SEQ ID NO. 237), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-3162-5p”.
[0199] The terms “hsa-miR-6126 gene” or “hsa-miR-6126” as used in this specification include the hsa-miR-6126 gene (miRBase Accession No. MIMAT0024599) described in SEQ ID NO. 64, as well as other biological species homologs or oslogs. The hsa-miR-6126 gene can be obtained by the method described in Smith JL et al., 2012, J Virol, Vol. 86, pp. 5278-5287. Additionally, “hsa-miR-6126” (miRBase Accession No. MI0021260, SEQ ID NO. 238), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6126”.
[0200] The terms “hsa-miR-4758-5p gene” or “hsa-miR-4758-5p” as used in this specification include the hsa-miR-4758-5p gene (miRBase Accession No. MIMAT0019903) described in SEQ ID No. 65 and other biological species homologs or oslogs, etc. The hsa-miR-4758-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, “hsa-miR-4758” (miRBase Accession No. MI0017399, SEQ ID No. 239), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4758-5p”.
[0201] The terms “hsa-miR-2392 gene” or “hsa-miR-2392” as used in this specification include the hsa-miR-2392 gene (miRBase Accession No. MIMAT0019043) described in SEQ ID No. 66, as well as other biological species homologs or oslogs. The hsa-miR-2392 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Additionally, “hsa-miR-2392” (miRBase Accession No. MI0016870, SEQ ID No. 240), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-2392.”
[0202] The terms “hsa-miR-486-3p gene” or “hsa-miR-486-3p” as used in this specification include the hsa-miR-486-3p gene described in SEQ ID NO. 67 (miRBase Accession No. MIMAT0004762) and other biological species homologs or oslogs. The hsa-miR-486-3p gene can be obtained by the method described in Fu H et al., 2005, FEBS Lett, Vol. 579, pp. 3849-3854. Additionally, “hsa-miR-486-3p” is known to have a hairpin-shaped structure as a precursor to “hsa-miR-486-2” (miRBase Accession No. MI0002470, MI0023622, SEQ ID NOs 241, 242).
[0203] The terms “hsa-miR-6727-5p gene” or “hsa-miR-6727-5p” as used herein include the hsa-miR-6727-5p gene (miRBase Accession No. MIMAT0027355) described in SEQ ID No. 68, or other biological species homologs or oslogs, etc. The hsa-miR-6727-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Additionally, “hsa-miR-6727” (miRBase Accession No. MI0022572, SEQ ID No. 243), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6727-5p”.
[0204] The terms “hsa-miR-4728-5p gene” or “hsa-miR-4728-5p” as used in this specification include the hsa-miR-4728-5p gene (miRBase Accession No. MIMAT0019849) described in SEQ ID No. 69, as well as other biological species homologs or oslogs. The hsa-miR-4728-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Additionally, “hsa-miR-4728” (miRBase Accession No. MI0017365, SEQ ID No. 244), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4728-5p”.
[0205] The terms “hsa-miR-6746-5p gene” or “hsa-miR-6746-5p” as used in this specification include the hsa-miR-6746-5p gene (miRBase Accession No. MIMAT0027392) described in SEQ ID No. 70, or other biological species homologs or osologs, etc. The hsa-miR-6746-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6746” (miRBase Accession No. MI0022591, SEQ ID No. 245), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6746-5p”.
[0206] The terms “hsa-miR-4270 gene” or “hsa-miR-4270” as used in this specification include the hsa-miR-4270 gene (miRBase Accession No. MIMAT0016900) described in SEQ ID NO. 71 and other biological species homologs or oslogs. The hsa-miR-4270 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. Additionally, “hsa-miR-4270” is known as a precursor of “hsa-miR-4270” which has a hairpin-shaped structure, “hsa-mir-4270” (miRBase Accession No. MI0015878, SEQ ID NO. 246).
[0207] The terms “hsa-miR-3940-5p gene” or “hsa-miR-3940-5p” as used herein include the hsa-miR-3940-5p gene (miRBase Accession No. MIMAT0019229) described in SEQ ID No. 72, or other biological species homologs or osologs, etc. The hsa-miR-3940-5p gene can be obtained by the method described in Liao JY et al., 2010, PLoS One, Vol. 5, e10563. In addition, “hsa-miR-3940” (miRBase Accession No. MI0016597, SEQ ID No. 247), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-3940-5p”.
[0208] The terms “hsa-miR-4725-3p gene” or “hsa-miR-4725-3p” as used in this specification include the hsa-miR-4725-3p gene (miRBase Accession No. MIMAT0019844) described in SEQ ID No. 73, or other biological species homologs or oslogs. The hsa-miR-4725-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Additionally, “hsa-miR-4725” (miRBase Accession No. MI0017362, SEQ ID No. 248), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4725-3p”.
[0209] The terms “hsa-miR-7108-5p gene” or “hsa-miR-7108-5p” as used in this specification include the hsa-miR-7108-5p gene (miRBase Accession No. MIMAT0028113) described in SEQ ID No. 74 and other biological species homologs or oslogs, etc. The hsa-miR-7108-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-7108” (miRBase Accession No. MI0022959, SEQ ID No. 249), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-7108-5p”.
[0210] The terms “hsa-miR-3656 gene” or “hsa-miR-3656” as used in this specification include the hsa-miR-3656 gene (miRBase Accession No. MIMAT0018076) described in SEQ ID No. 75, as well as other biological species homologs or oslogs. The hsa-miR-3656 gene can be obtained by the method described in Meiri E et al., 2010, Nucleic Acids Res, Vol. 38, pp. 6234-6246. Additionally, “hsa-miR-3656” (miRBase Accession No. MI0016056, SEQ ID No. 250), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-3656.”
[0211] The terms “hsa-miR-6879-5p gene” or “hsa-miR-6879-5p” as used herein include the hsa-miR-6879-5p gene (miRBase Accession No. MIMAT0027658) described in SEQ ID No. 76, or other biological species homologs or osologs, etc. The hsa-miR-6879-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Additionally, “hsa-miR-6879” (miRBase Accession No. MI0022726, SEQ ID No. 251), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6879-5p”.
[0212] The terms “hsa-miR-6738-5p gene” or “hsa-miR-6738-5p” as used in this specification include the hsa-miR-6738-5p gene (miRBase Accession No. MIMAT0027377) described in SEQ ID No. 77, as well as other biological species homologs or oslogs. The hsa-miR-6738-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Additionally, “hsa-miR-6738” (miRBase Accession No. MI0022583, SEQ ID No. 252), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6738-5p”.
[0213] The terms “hsa-miR-1260a gene” or “hsa-miR-1260a” as used in this specification include the hsa-miR-1260a gene (miRBase Accession No. MIMAT0005911) described in SEQ ID No. 78, or other biological species homologs or oslogs. The hsa-miR-1260a gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. Additionally, “hsa-miR-1260a” is known to have a hairpin-shaped structure as its precursor, “hsa-miR-1260a” (miRBase Accession No. MI0006394, SEQ ID No. 253).
[0214] The terms “hsa-miR-4446-3p gene” or “hsa-miR-4446-3p” as used herein include the hsa-miR-4446-3p gene (miRBase Accession No. MIMAT0018965) described in SEQ ID No. 79, or other biological species homologs or oslogs, etc. The hsa-miR-4446-3p gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, “hsa-miR-4446” (miRBase Accession No. MI0016789, SEQ ID No. 254), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4446-3p”.
[0215] The terms “hsa-miR-3131 gene” or “hsa-miR-3131” as used in this specification include the hsa-miR-3131 gene (miRBase Accession No. MIMAT0014996) described in SEQ ID NO. 80, as well as other biological species homologs or oslogs. The hsa-miR-3131 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Additionally, “hsa-miR-3131” is known as a precursor of “hsa-miR-3131” which has a hairpin-shaped structure, “hsa-mir-3131” (miRBase Accession No. MI0014151, SEQ ID NO. 255).
[0216] The terms “hsa-miR-4463 gene” or “hsa-miR-4463” as used in this specification include the hsa-miR-4463 gene described in SEQ ID NO. 81 (miRBase Accession No. MIMAT0018987) and other biological species homologs or oslogs. The hsa-miR-4463 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Additionally, “hsa-miR-4463” having a hairpin-shaped structure is known as a precursor of “hsa-miR-4463” (miRBase Accession No. MI0016811, SEQ ID NO. 256).
[0217] The terms “hsa-miR-3185 gene” or “hsa-miR-3185” as used in this specification include the hsa-miR-3185 gene (miRBase Accession No. MIMAT0015065) described in SEQ ID NO. 82, as well as other biological species homologs or oslogs. The hsa-miR-3185 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Additionally, “hsa-miR-3185” (miRBase Accession No. MI0014227, SEQ ID NO. 257), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-3185.”
[0218] The terms “hsa-miR-6870-5p gene” or “hsa-miR-6870-5p” as used in this specification include the hsa-miR-6870-5p gene (miRBase Accession No. MIMAT0027640) described in SEQ ID NO. 83 and other biological species homologs or oslogs, etc. The hsa-miR-6870-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6870” (miRBase Accession No. MI0022717, SEQ ID NO. 258), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6870-5p”.
[0219] The terms “hsa-miR-6779-5p gene” or “hsa-miR-6779-5p” as used in this specification include the hsa-miR-6779-5p gene (miRBase Accession No. MIMAT0027458) described in SEQ ID No. 84, or other biological species homologs or oslogs, etc. The hsa-miR-6779-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6779” (miRBase Accession No. MI0022624, SEQ ID No. 259), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6779-5p”.
[0220] The terms “hsa-miR-1273g-3p gene” or “hsa-miR-1273g-3p” as used in this specification include the hsa-miR-1273g-3p gene (miRBase Accession No. MIMAT0022742) described in SEQ ID No. 85, or other biological species homologs or oslogs. The hsa-miR-1273g-3p gene can be obtained by the method described in Reshmi G et al., 2011, Genomics, Vol. 97, pp. 333-340. Additionally, “hsa-miR-1273g” (miRBase Accession No. MI0018003, SEQ ID No. 260), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1273g-3p”.
[0221] The terms “hsa-miR-8059 gene” or “hsa-miR-8059” as used in this specification include the hsa-miR-8059 gene (miRBase Accession No. MIMAT0030986) described in SEQ ID NO. 86, as well as other biological species homologs or osologs, etc. The hsa-miR-8059 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487. Additionally, “hsa-miR-8059” is known as a precursor of “hsa-miR-8059” which has a hairpin-shaped structure, “hsa-mir-8059” (miRBase Accession No. MI0025895, SEQ ID NO. 261).
[0222] The terms “hsa-miR-4697-5p gene” or “hsa-miR-4697-5p” as used in this specification include the hsa-miR-4697-5p gene (miRBase Accession No. MIMAT0019791) described in SEQ ID NO. 87 and other biological species homologs or oslogs, etc. The hsa-miR-4697-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, “hsa-miR-4697” (miRBase Accession No. MI0017330, SEQ ID NO. 262), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4697-5p”.
[0223] The terms “hsa-miR-4674 gene” or “hsa-miR-4674” as used in this specification include the hsa-miR-4674 gene (miRBase Accession No. MIMAT0019756) described in SEQ ID NO. 88, as well as other biological species homologs or oslogs. The hsa-miR-4674 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Additionally, “hsa-miR-4674” (miRBase Accession No. MI0017305, SEQ ID NO. 263), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4674.”
[0224] The terms “hsa-miR-4433-3p gene” or “hsa-miR-4433-3p” as used in this specification include the hsa-miR-4433-3p gene (miRBase Accession No. MIMAT0018949) described in SEQ ID No. 89, or other biological species homologs or oslogs, etc. The hsa-miR-4433-3p gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, “hsa-miR-4433” (miRBase Accession No. MI0016773, SEQ ID No. 264), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4433-3p”.
[0225] The terms “hsa-miR-4257 gene” or “hsa-miR-4257” as used in this specification include the hsa-miR-4257 gene described in SEQ ID NO. 90 (miRBase Accession No. MIMAT0016878) and other biological species homologs or oslogs. The hsa-miR-4257 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. Additionally, “hsa-miR-4257” (miRBase Accession No. MI0015856, SEQ ID NO. 265), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4257.”
[0226] The terms “hsa-miR-1915-5p gene” or “hsa-miR-1915-5p” as used herein include the hsa-miR-1915-5p gene described in SEQ ID NO. 91 (miRBase Accession No. MIMAT0007891) and other biological species homologs or oslogs. The hsa-miR-1915-5p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. Additionally, “hsa-miR-1915” (miRBase Accession No. MI0008336, SEQ ID NO. 266), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1915-5p”.
[0227] The terms “hsa-miR-4417 gene” or “hsa-miR-4417” as used in this specification include the hsa-miR-4417 gene described in SEQ ID NO. 92 (miRBase Accession No. MIMAT0018929) and other biological species homologs or oslogs. The hsa-miR-4417 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Additionally, “hsa-miR-4417” is known as a precursor of “hsa-miR-4417” which has a hairpin-shaped structure, “hsa-mir-4417” (miRBase Accession No. MI0016753, SEQ ID NO. 267).
[0228] The terms “hsa-miR-1343-5p gene” or “hsa-miR-1343-5p” as used herein include the hsa-miR-1343-5p gene (miRBase Accession No. MIMAT0027038) described in SEQ ID No. 93, as well as other biological species homologs or oslogs. The hsa-miR-1343-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Additionally, “hsa-miR-1343” (miRBase Accession No. MI0017320, SEQ ID No. 182), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1343-5p”.
[0229] The terms “hsa-miR-6781-5p gene” or “hsa-miR-6781-5p” as used in this specification include the hsa-miR-6781-5p gene (miRBase Accession No. MIMAT0027462) described in SEQ ID No. 94, or other biological species homologs or oslogs, etc. The hsa-miR-6781-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6781” (miRBase Accession No. MI0022626, SEQ ID No. 268), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6781-5p”.
[0230] The terms “hsa-miR-4695-5p gene” or “hsa-miR-4695-5p” as used in this specification include the hsa-miR-4695-5p gene (miRBase Accession No. MIMAT0019788) described in SEQ ID No. 95, as well as other biological species homologs or oslogs. The hsa-miR-4695-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Additionally, “hsa-miR-4695” (miRBase Accession No. MI0017328, SEQ ID No. 269), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4695-5p”.
[0231] The terms “hsa-miR-1237-5p gene” or “hsa-miR-1237-5p” as used herein include the hsa-miR-1237-5p gene described in SEQ ID NO. 96 (miRBase Accession No. MIMAT0022946) and other biological species homologs or oslogs. The hsa-miR-1237-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. Additionally, “hsa-miR-1237” (miRBase Accession No. MI0006327, SEQ ID NO. 270), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1237-5p”.
[0232] The terms “hsa-miR-6775-5p gene” or “hsa-miR-6775-5p” as used herein include the hsa-miR-6775-5p gene (miRBase Accession No. MIMAT0027450) described in SEQ ID No. 97 and other biological species homologs or oslogs, etc. The hsa-miR-6775-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6775” (miRBase Accession No. MI0022620, SEQ ID No. 271), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6775-5p”.
[0233] The terms “hsa-miR-7845-5p gene” or “hsa-miR-7845-5p” as used herein include the hsa-miR-7845-5p gene (miRBase Accession No. MIMAT0030420) described in SEQ ID No. 98 and other biological species homologs or oslogs, etc. The hsa-miR-7845-5p gene can be obtained by the method described in Ple H et al., 2012, PLoS One, Vol. 7, e50746. In addition, “hsa-miR-7845” (miRBase Accession No. MI0025515, SEQ ID No. 272), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-7845-5p”.
[0234] The terms “hsa-miR-4746-3p gene” or “hsa-miR-4746-3p” as used in this specification include the hsa-miR-4746-3p gene described in SEQ ID NO. 99 (miRBase Accession No. MIMAT0019881) and other biological species homologs or oslogs. The hsa-miR-4746-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Additionally, “hsa-miR-4746” (miRBase Accession No. MI0017385, SEQ ID NO. 273), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4746-3p”.
[0235] The terms “hsa-miR-7641 gene” or “hsa-miR-7641” as used in this specification include the hsa-miR-7641 gene (miRBase Accession No. MIMAT0029782) described in SEQ ID No. 100, or other biological species homologs or oslogs. The hsa-miR-7641 gene can be obtained by the method described in Yoo JK et al., 2013, Arch Pharm Res, Vol. 36, pp. 353-358. Additionally, “hsa-miR-7641” is known to have a hairpin-shaped structure as its precursor, “hsa-mir-7641-1, hsa-mir-7641-2” (miRBase Accession No. MI0024975, MI0024976, SEQ ID No. 274, 275).
[0236] The terms “hsa-miR-7847-3p gene” or “hsa-miR-7847-3p” as used herein include the hsa-miR-7847-3p gene (miRBase Accession No. MIMAT0030422) described in SEQ ID NO. 101 and other biological species homologs or oslogs, etc. The hsa-miR-7847-3p gene can be obtained by the method described in Ple H et al., 2012, PLoS One, Vol. 7, e50746. In addition, “hsa-miR-7847” (miRBase Accession No. MI0025517, SEQ ID NO. 276), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-7847-3p”.
[0237] The terms “hsa-miR-6806-5p gene” or “hsa-miR-6806-5p” as used in this specification include the hsa-miR-6806-5p gene (miRBase Accession No. MIMAT0027512) described in SEQ ID NO. 102 and other biological species homologs or oslogs, etc. The hsa-miR-6806-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6806” (miRBase Accession No. MI0022651, SEQ ID NO. 277), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6806-5p”.
[0238] The terms “hsa-miR-4467 gene” or “hsa-miR-4467” as used in this specification include the hsa-miR-4467 gene described in SEQ ID NO. 103 (miRBase Accession No. MIMAT0018994) and other biological species homologs or oslogs. The hsa-miR-4467 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Additionally, “hsa-miR-4467” having a hairpin-shaped structure is known as a precursor of “hsa-miR-4467” (miRBase Accession No. MI0016818, SEQ ID NO. 278).
[0239] The terms “hsa-miR-4726-5p gene” or “hsa-miR-4726-5p” as used in this specification include the hsa-miR-4726-5p gene (miRBase Accession No. MIMAT0019845) described in SEQ ID No. 104, or other biological species homologs or oslogs. The hsa-miR-4726-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Additionally, “hsa-miR-4726” (miRBase Accession No. MI0017363, SEQ ID No. 279), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4726-5p”.
[0240] The terms “hsa-miR-4648 gene” or “hsa-miR-4648” as used in this specification include the hsa-miR-4648 gene (miRBase Accession No. MIMAT0019710) described in SEQ ID NO. 105 and other biological species homologs or oslogs, etc. The hsa-miR-4648 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, “hsa-miR-4648” is known as a precursor of “hsa-miR-4648” which has a hairpin-shaped structure, “hsa-mir-4648” (miRBase Accession No. MI0017275, SEQ ID NO. 280).
[0241] The terms “hsa-miR-6089 gene” or “hsa-miR-6089” as used in this specification include the hsa-miR-6089 gene described in SEQ ID NO. 106 (miRBase Accession No. MIMAT0023714) and other biological species homologs or oslogs. The hsa-miR-6089 gene can be obtained by the method described in Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, pp. 2049-2057. Additionally, “hsa-miR-6089” is known to have “hsa-mir-6089-1, hsa-mir-6089-2” (miRBase Accession No. MI0020366, MI0023563, SEQ ID NOs 281, 282) which have a hairpin-shaped structure as precursors.
[0242] The terms “hsa-miR-1260b gene” or “hsa-miR-1260b” as used in this specification include the hsa-miR-1260b gene described in SEQ ID NO. 107 (miRBase Accession No. MIMAT0015041) and other biological species homologs or oslogs. The hsa-miR-1260b gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Additionally, “hsa-miR-1260b” is known as a precursor of which is “hsa-mir-1260b” (miRBase Accession No. MI0014197, SEQ ID NO. 283), which has a hairpin-shaped structure.
[0243] The terms “hsa-miR-4532 gene” or “hsa-miR-4532” as used in this specification include the hsa-miR-4532 gene (miRBase Accession No. MIMAT0019071) described in SEQ ID No. 108 and other biological species homologs or oslogs, etc. The hsa-miR-4532 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, “hsa-miR-4532” is known as a precursor of “hsa-miR-4532” which has a hairpin-shaped structure, “hsa-mir-4532” (miRBase Accession No. MI0016899, SEQ ID No. 284).
[0244] The terms “hsa-miR-5195-3p gene” or “hsa-miR-5195-3p” as used herein include the hsa-miR-5195-3p gene (miRBase Accession No. MIMAT0021127) described in SEQ ID NO. 109 and other biological species homologs or oslogs, etc. The hsa-miR-5195-3p gene can be obtained by the method described in Schotte D et al., 2011, Leukemia, Vol. 25, pp. 1389-1399. In addition, “hsa-miR-5195” (miRBase Accession No. MI0018174, SEQ ID NO. 285), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-5195-3p”.
[0245] The terms “hsa-miR-3188 gene” or “hsa-miR-3188” as used in this specification include the hsa-miR-3188 gene (miRBase Accession No. MIMAT0015070) described in SEQ ID NO. 110 and other biological species homologs or oslogs. The hsa-miR-3188 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Additionally, “hsa-miR-3188” (miRBase Accession No. MI0014232, SEQ ID NO. 286), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-3188.”
[0246] The terms “hsa-miR-6848-5p gene” or “hsa-miR-6848-5p” as used in this specification include the hsa-miR-6848-5p gene (miRBase Accession No. MIMAT0027596) described in SEQ ID No. 111 and other biological species homologs or oslogs, etc. The hsa-miR-6848-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6848” (miRBase Accession No. MI0022694, SEQ ID No. 287), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6848-5p”.
[0247] The terms “hsa-miR-1233-5p gene” or “hsa-miR-1233-5p” as used in this specification include the hsa-miR-1233-5p gene described in SEQ ID NO. 112 (miRBase Accession No. MIMAT0022943) and other biological species homologs or oslogs. The hsa-miR-1233-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. Additionally, “hsa-miR-1233-1, hsa-miR-1233-2” (miRBase Accession No. MI0006323, MI0015973, SEQ ID NOs 288, 289), which have a hairpin-shaped structure, are known as precursors of “hsa-miR-1233-5p”.
[0248] The terms “hsa-miR-6717-5p gene” or “hsa-miR-6717-5p” as used herein include the hsa-miR-6717-5p gene described in SEQ ID NO. 113 (miRBase Accession No. MIMAT0025846) and other biological species homologs or osologs, etc. The hsa-miR-6717-5p gene can be obtained by the method described in Li Y et al., 2012, Gene, Vol. 497, pp. 330-335. In addition, “hsa-miR-6717” (miRBase Accession No. MI0022551, SEQ ID NO. 290), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6717-5p”.
[0249] The terms “hsa-miR-3195 gene” or “hsa-miR-3195” as used in this specification include the hsa-miR-3195 gene described in SEQ ID NO. 114 (miRBase Accession No. MIMAT0015079) and other biological species homologs or oslogs. The hsa-miR-3195 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Additionally, “hsa-miR-3195” having a hairpin-shaped structure is known as a precursor of “hsa-miR-3195” (miRBase Accession No. MI0014240, SEQ ID NO. 291).
[0250] The terms “hsa-miR-6757-5p gene” or “hsa-miR-6757-5p” as used herein include the hsa-miR-6757-5p gene (miRBase Accession No. MIMAT0027414) described in SEQ ID No. 115 and other biological species homologs or oslogs, etc. The hsa-miR-6757-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6757” (miRBase Accession No. MI0022602, SEQ ID No. 292), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6757-5p”.
[0251] The terms “hsa-miR-8072 gene” or “hsa-miR-8072” as used in this specification include the hsa-miR-8072 gene (miRBase Accession No. MIMAT0030999) described in SEQ ID No. 116 and other biological species homologs or oslogs, etc. The hsa-miR-8072 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487. In addition, “hsa-miR-8072” is known as a precursor of “hsa-miR-8072” which has a hairpin-shaped structure, “hsa-mir-8072” (miRBase Accession No. MI0025908, SEQ ID No. 293).
[0252] The terms “hsa-miR-4745-5p gene” or “hsa-miR-4745-5p” as used in this specification include the hsa-miR-4745-5p gene (miRBase Accession No. MIMAT0019878) described in SEQ ID No. 117 and other biological species homologs or oslogs, etc. The hsa-miR-4745-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, “hsa-miR-4745” (miRBase Accession No. MI0017384, SEQ ID No. 294), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4745-5p”.
[0253] The terms “hsa-miR-6511a-5p gene” or “hsa-miR-6511a-5p” as used herein include the hsa-miR-6511a-5p gene (miRBase Accession No. MIMAT0025478) described in SEQ ID NO. 118, or other biological species homologs or oslogs, etc. The hsa-miR-6511a-5p gene can be obtained by the method described in Joyce CE et al., 2011, Hum Mol Genet, Vol. 20, pp. 4025-4040. In addition, “hsa-miR-6511a-5p” is known to have “hsa-mir-6511a-1, hsa-mir-6511a-2, hsa-mir-6511a-3, hsa-mir-6511a-4” (miRBase Accession No. MI0022223, MI0023564, MI0023565, MI0023566, SEQ ID No. 295, 296, 297, 298) which have a hairpin-shaped structure as its precursors.
[0254] The terms “hsa-miR-6776-5p gene” or “hsa-miR-6776-5p” as used herein include the hsa-miR-6776-5p gene (miRBase Accession No. MIMAT0027452) described in SEQ ID No. 119, or other biological species homologs or osologs, etc. The hsa-miR-6776-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Additionally, “hsa-miR-6776” (miRBase Accession No. MI0022621, SEQ ID No. 299), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6776-5p”.
[0255] The terms “hsa-miR-371a-5p gene” or “hsa-miR-371a-5p” as used herein include the hsa-miR-371a-5p gene described in SEQ ID NO. 120 (miRBase Accession No. MIMAT0004687) and other biological species homologs or oslogs. The hsa-miR-371a-5p gene can be obtained by the method described in Suh MR et al., 2004, Dev Biol, Vol. 270, pp. 488-498. Additionally, “hsa-miR-371a” (miRBase Accession No. MI0000779, SEQ ID NO. 300), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-371a-5p”.
[0256] The terms “hsa-miR-1227-5p gene” or “hsa-miR-1227-5p” as used in this specification include the hsa-miR-1227-5p gene described in SEQ ID NO. 121 (miRBase Accession No. MIMAT0022941) and other biological species homologs or osologs, etc. The hsa-miR-1227-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. In addition, “hsa-miR-1227” (miRBase Accession No. MI0006316, SEQ ID NO. 301), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1227-5p”.
[0257] The terms “hsa-miR-7150 gene” or “hsa-miR-7150” as used in this specification include the hsa-miR-7150 gene (miRBase Accession No. MIMAT0028211) described in SEQ ID No. 122, or other biological species homologs or oslogs, etc. The hsa-miR-7150 gene can be obtained by the method described in Oulas A et al., 2009, Nucleic Acids Res, Vol. 37, pp. 3276-3287. Additionally, “hsa-miR-7150” is known as a precursor of “hsa-miR-7150” which has a hairpin-shaped structure, “hsa-mir-7150” (miRBase Accession No. MI0023610, SEQ ID No. 302).
[0258] The terms “hsa-miR-1915-3p gene” or “hsa-miR-1915-3p” as used herein include the hsa-miR-1915-3p gene (miRBase Accession No. MIMAT0007892) described in SEQ ID NO. 123 and other biological species homologs or oslogs, etc. The hsa-miR-1915-3p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. In addition, “hsa-miR-1915” (miRBase Accession No. MI0008336, SEQ ID NO. 266), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1915-3p”.
[0259] The terms “hsa-miR-187-5p gene” or “hsa-miR-187-5p” as used in this specification include the hsa-miR-187-5p gene (miRBase Accession No. MIMAT0004561) described in SEQ ID No. 124 and other biological species homologs or oslogs, etc. The hsa-miR-187-5p gene can be obtained by the method described in Lim LP et al., 2003, Science, Vol. 299, p. 1540. In addition, “hsa-miR-187” (miRBase Accession No. MI0000274, SEQ ID No. 303), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-187-5p”.
[0260] The terms “hsa-miR-614 gene” or “hsa-miR-614” as used in this specification include the hsa-miR-614 gene (miRBase Accession No. MIMAT0003282) described in SEQ ID NO. 125 and other biological species homologs or oslogs, etc. The hsa-miR-614 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. Additionally, “hsa-miR-614” is known as a precursor of “hsa-miR-614” which has a hairpin-shaped structure, “hsa-mir-614” (miRBase Accession No. MI0003627, SEQ ID NO. 304).
[0261] The terms “hsa-miR-19b-3p gene” or “hsa-miR-19b-3p” as used in this specification include the hsa-miR-19b-3p gene described in SEQ ID NO. 126 (miRBase Accession No. MIMAT0000074) and other biological species homologs or oslogs. The hsa-miR-19b-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2001, Science, Vol. 294, pp. 853-858. Additionally, “hsa-miR-19b-1, hsa-miR-19b-2” (miRBase Accession No. MI0000074, MI0000075, SEQ ID NOs 305, 306), which have a hairpin-shaped structure, are known as precursors of “hsa-miR-19b-3p”.
[0262] The terms “hsa-miR-1225-5p gene” or “hsa-miR-1225-5p” as used herein include the hsa-miR-1225-5p gene (miRBase Accession No. MIMAT0005572) described in SEQ ID NO. 127 and other biological species homologs or oslogs, etc. The hsa-miR-1225-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. In addition, “hsa-miR-1225” (miRBase Accession No. MI0006311, SEQ ID NO. 307), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1225-5p”.
[0263] The terms “hsa-miR-451a gene” or “hsa-miR-451a” as used in this specification include the hsa-miR-451a gene (miRBase Accession No. MIMAT0001631) described in SEQ ID No. 128, or other biological species homologs or oslogs. The hsa-miR-451a gene can be obtained by the method described in Altuvia Y et al., 2005, Nucleic Acids Res, Vol. 33, pp. 2697-2706. Additionally, “hsa-miR-451a” is known as a precursor of which is “hsa-mir-451a” (miRBase Accession No. MI0001729, SEQ ID No. 308), which has a hairpin-shaped structure.
[0264] The terms “hsa-miR-939-5p gene” or “hsa-miR-939-5p” as used in this specification include the hsa-miR-939-5p gene (miRBase Accession No. MIMAT0004982) described in SEQ ID No. 129, or other biological species homologs or oslogs. The hsa-miR-939-5p gene can be obtained by the method described in Lui WO et al., 2007, Cancer Res, Vol. 67, pp. 6031-6043. Additionally, “hsa-miR-939” (miRBase Accession No. MI0005761, SEQ ID No. 309), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-939-5p”.
[0265] The terms “hsa-miR-223-3p gene” or “hsa-miR-223-3p” as used in this specification include the hsa-miR-223-3p gene (miRBase Accession No. MIMAT0000280) described in SEQ ID No. 130, or other biological species homologs or oslogs. The hsa-miR-223-3p gene can be obtained by the method described in Lim LP et al., 2003, Science, Vol. 299, p. 1540. Additionally, “hsa-miR-223” (miRBase Accession No. MI0000300, SEQ ID No. 310), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-223-3p”.
[0266] The terms “hsa-miR-1228-5p gene” or “hsa-miR-1228-5p” as used herein include the hsa-miR-1228-5p gene (miRBase Accession No. MIMAT0005582) described in SEQ ID NO. 131 and other biological species homologs or oslogs, etc. The hsa-miR-1228-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. In addition, “hsa-miR-1228” (miRBase Accession No. MI0006318, SEQ ID NO. 311), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1228-5p”.
[0267] The terms “hsa-miR-125a-3p gene” or “hsa-miR-125a-3p” as used in this specification include the hsa-miR-125a-3p gene (miRBase Accession No. MIMAT0004602) described in SEQ ID No. 132, or other biological species homologs or oslogs, etc. The hsa-miR-125a-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, pp. 735-739. In addition, “hsa-miR-125a” (miRBase Accession No. MI0000469, SEQ ID No. 312), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-125a-3p”.
[0268] The terms “hsa-miR-92b-5p gene” or “hsa-miR-92b-5p” as used in this specification include the hsa-miR-92b-5p gene (miRBase Accession No. MIMAT0004792) described in SEQ ID NO. 133, as well as other biological species homologs or oslogs. The hsa-miR-92b-5p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. Additionally, “hsa-miR-92b” (miRBase Accession No. MI0003560, SEQ ID NO. 313), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-92b-5p”.
[0269] The terms “hsa-miR-22-3p gene” or “hsa-miR-22-3p” as used herein include the hsa-miR-22-3p gene (miRBase Accession No. MIMAT0000077) described in SEQ ID NO. 134 and other biological species homologs or oslogs, etc. The hsa-miR-22-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2001, Science, Vol. 294, pp. 853-858. In addition, “hsa-miR-22” (miRBase Accession No. MI0000078, SEQ ID NO. 314), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-22-3p”.
[0270] The terms “hsa-miR-4271 gene” or “hsa-miR-4271” as used in this specification include the hsa-miR-4271 gene (miRBase Accession No. MIMAT0016901) described in SEQ ID NO. 135 and other biological species homologs or oslogs, etc. The hsa-miR-4271 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, “hsa-miR-4271” is known as a precursor of “hsa-miR-4271” which has a hairpin-shaped structure, “hsa-mir-4271” (miRBase Accession No. MI0015879, SEQ ID NO. 315).
[0271] The terms “hsa-miR-642b-3p gene” or “hsa-miR-642b-3p” as used herein include the hsa-miR-642b-3p gene described in SEQ ID NO. 136 (miRBase Accession No. MIMAT0018444) and other biological species homologs or osologs, etc. The hsa-miR-642b-3p gene can be obtained by the method described in Witten D et al., 2010, BMC Biol, Vol. 8, p. 58. In addition, “hsa-miR-642b” (miRBase Accession No. MI0016685, SEQ ID NO. 316), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-642b-3p”.
[0272] The terms “hsa-miR-6075 gene” or “hsa-miR-6075” as used in this specification include the hsa-miR-6075 gene (miRBase Accession No. MIMAT0023700) described in SEQ ID No. 137 and other biological species homologs or oslogs, etc. The hsa-miR-6075 gene can be obtained by the method described in Voellenkle C et al., 2012, RNA, Vol. 18, pp. 472-484. In addition, “hsa-miR-6075” is known as a precursor of “hsa-miR-6075” which has a hairpin-shaped structure, “hsa-mir-6075” (miRBase Accession No. MI0020352, SEQ ID No. 317).
[0273] The terms “hsa-miR-6125 gene” or “hsa-miR-6125” as used in this specification include the hsa-miR-6125 gene (miRBase Accession No. MIMAT0024598) described in SEQ ID NO. 138 and other biological species homologs or oslogs, etc. The hsa-miR-6125 gene can be obtained by the method described in Smith JL et al., 2012, J Virol, Vol. 86, pp. 5278-5287. In addition, “hsa-miR-6125” is known as a precursor of “hsa-miR-6125” which has a hairpin-shaped structure, “hsa-mir-6125” (miRBase Accession No. MI0021259, SEQ ID NO. 318).
[0274] The terms “hsa-miR-887-3p gene” or “hsa-miR-887-3p” as used in this specification include the hsa-miR-887-3p gene (miRBase Accession No. MIMAT0004951) described in SEQ ID No. 139, or other biological species homologs or oslogs, etc. The hsa-miR-887-3p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. In addition, “hsa-miR-887” (miRBase Accession No. MI0005562, SEQ ID No. 319), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-887-3p”.
[0275] The terms “hsa-miR-6851-5p gene” or “hsa-miR-6851-5p” as used herein include the hsa-miR-6851-5p gene (miRBase Accession No. MIMAT0027602) described in SEQ ID NO. 140, or other biological species homologs or osologs, etc. The hsa-miR-6851-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6851” (miRBase Accession No. MI0022697, SEQ ID NO. 320), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6851-5p”.
[0276] The terms “hsa-miR-6763-5p gene” or “hsa-miR-6763-5p” as used herein include the hsa-miR-6763-5p gene described in SEQ ID NO. 141 (miRBase Accession No. MIMAT0027426) and other biological species homologs or osologs, etc. The hsa-miR-6763-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6763” (miRBase Accession No. MI0022608, SEQ ID NO. 321), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6763-5p”.
[0277] The terms “hsa-miR-3928-3p gene” or “hsa-miR-3928-3p” as used herein include the hsa-miR-3928-3p gene (miRBase Accession No. MIMAT0018205) described in SEQ ID No. 142 and other biological species homologs or oslogs, etc. The hsa-miR-3928-3p gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. In addition, “hsa-miR-3928” (miRBase Accession No. MI0016438, SEQ ID No. 322), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-3928-3p”.
[0278] The terms “hsa-miR-4443 gene” or “hsa-miR-4443” as used in this specification include the hsa-miR-4443 gene (miRBase Accession No. MIMAT0018961) described in SEQ ID No. 143, or other biological species homologs or oslogs, etc. The hsa-miR-4443 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, “hsa-miR-4443” is known as a precursor of “hsa-miR-4443” which has a hairpin-shaped structure, “hsa-mir-4443” (miRBase Accession No. MI0016786, SEQ ID No. 323).
[0279] The terms “hsa-miR-3648 gene” or “hsa-miR-3648” as used in this specification include the hsa-miR-3648 gene (miRBase Accession No. MIMAT0018068) described in SEQ ID No. 144, as well as other biological species homologs or oslogs. The hsa-miR-3648 gene can be obtained by the method described in Meiri E et al., 2010, Nucleic Acids Res, Vol. 38, pp. 6234-6246. Additionally, “hsa-miR-3648” (miRBase Accession No. MI0016048, SEQ ID No. 324), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-3648.”
[0280] The terms “hsa-miR-149-3p gene” or “hsa-miR-149-3p” as used in this specification include the hsa-miR-149-3p gene (miRBase Accession No. MIMAT0004609) described in SEQ ID No. 145, or other biological species homologs or oslogs. The hsa-miR-149-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, pp. 735-739. Additionally, “hsa-miR-149” (miRBase Accession No. MI0000478, SEQ ID No. 325), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-149-3p”.
[0281] The terms “hsa-miR-4689 gene” or “hsa-miR-4689” as used in this specification include the hsa-miR-4689 gene (miRBase Accession No. MIMAT0019778) described in SEQ ID NO. 146 and other biological species homologs or oslogs, etc. The hsa-miR-4689 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, “hsa-miR-4689” is known as a precursor of “hsa-miR-4689” which has a hairpin-shaped structure, “hsa-mir-4689” (miRBase Accession No. MI0017322, SEQ ID NO. 326).
[0282] The terms “hsa-miR-4763-3p gene” or “hsa-miR-4763-3p” as used herein include the hsa-miR-4763-3p gene (miRBase Accession No. MIMAT0019913) described in SEQ ID No. 147 and other biological species homologs or oslogs, etc. The hsa-miR-4763-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, “hsa-miR-4763” (miRBase Accession No. MI0017404, SEQ ID No. 327), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4763-3p”.
[0283] The terms “hsa-miR-6729-5p gene” or “hsa-miR-6729-5p” as used herein include the hsa-miR-6729-5p gene (miRBase Accession No. MIMAT0027359) described in SEQ ID No. 148, or other biological species homologs or osologs, etc. The hsa-miR-6729-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6729” (miRBase Accession No. MI0022574, SEQ ID No. 328), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6729-5p”.
[0284] The terms “hsa-miR-3196 gene” or “hsa-miR-3196” as used in this specification include the hsa-miR-3196 gene (miRBase Accession No. MIMAT0015080) described in SEQ ID No. 149, as well as other biological species homologs or oslogs. The hsa-miR-3196 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Additionally, “hsa-miR-3196” (miRBase Accession No. MI0014241, SEQ ID No. 329), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-3196.”
[0285] The terms “hsa-miR-8069 gene” or “hsa-miR-8069” as used in this specification include the hsa-miR-8069 gene (miRBase Accession No. MIMAT0030996) described in SEQ ID NO. 150, or other biological species homologs or osologs, etc. The hsa-miR-8069 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487. In addition, “hsa-miR-8069” is known as a precursor of “hsa-miR-8069” which has a hairpin-shaped structure, “hsa-mir-8069” (miRBase Accession No. MI0025905, SEQ ID NO. 330).
[0286] The terms “hsa-miR-1268a gene” or “hsa-miR-1268a” as used in this specification include the hsa-miR-1268a gene (miRBase Accession No. MIMAT0005922) described in SEQ ID No. 151, or other biological species homologs or oslogs. The hsa-miR-1268a gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. Additionally, “hsa-miR-1268a” is known to have a hairpin-shaped structure as a precursor to “hsa-miR-1268a”, which is “hsa-mir-1268a” (miRBase Accession No. MI0006405, SEQ ID No. 331).
[0287] The terms “hsa-miR-4739 gene” or “hsa-miR-4739” as used in this specification include the hsa-miR-4739 gene (miRBase Accession No. MIMAT0019868) described in SEQ ID NO. 152 and other biological species homologs or oslogs, etc. The hsa-miR-4739 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, “hsa-miR-4739” is known as a precursor of “hsa-miR-4739” which has a hairpin-shaped structure, “hsa-mir-4739” (miRBase Accession No. MI0017377, SEQ ID NO. 332).
[0288] The terms “hsa-miR-1268b gene” or “hsa-miR-1268b” as used in this specification include the hsa-miR-1268b gene described in SEQ ID NO. 153 (miRBase Accession No. MIMAT0018925) and other biological species homologs or oslogs. The hsa-miR-1268b gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Additionally, “hsa-miR-1268b” is known as a precursor of “hsa-miR-1268b” which has a hairpin-shaped structure, “hsa-mir-1268b” (miRBase Accession No. MI0016748, SEQ ID NO. 333).
[0289] The terms “hsa-miR-5698 gene” or “hsa-miR-5698” as used in this specification include the hsa-miR-5698 gene (miRBase Accession No. MIMAT0022491) described in SEQ ID NO. 154 and other biological species homologs or oslogs, etc. The hsa-miR-5698 gene can be obtained by the method described in Watahiki A et al., 2011, PLoS One, Vol. 6, e24950. In addition, “hsa-miR-5698” is known as a precursor of “hsa-miR-5698” which has a hairpin-shaped structure, “hsa-mir-5698” (miRBase Accession No. MI0019305, SEQ ID NO. 334).
[0290] The terms “hsa-miR-6752-5p gene” or “hsa-miR-6752-5p” as used herein include the hsa-miR-6752-5p gene (miRBase Accession No. MIMAT0027404) described in SEQ ID NO. 155 and other biological species homologs or osologs, etc. The hsa-miR-6752-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Additionally, “hsa-miR-6752” (miRBase Accession No. MI0022597, SEQ ID NO. 335), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6752-5p”.
[0291] The terms “hsa-miR-4507 gene” or “hsa-miR-4507” as used in this specification include the hsa-miR-4507 gene described in SEQ ID NO. 156 (miRBase Accession No. MIMAT0019044) and other biological species homologs or oslogs. The hsa-miR-4507 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Additionally, “hsa-miR-4507” is known as a precursor of “hsa-miR-4507” which has a hairpin-shaped structure, “hsa-mir-4507” (miRBase Accession No. MI0016871, SEQ ID NO. 336).
[0292] The terms “hsa-miR-564 gene” or “hsa-miR-564” as used in this specification include the hsa-miR-564 gene (miRBase Accession No. MIMAT0003228) described in SEQ ID No. 157 and other biological species homologs or oslogs, etc. The hsa-miR-564 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. Additionally, “hsa-miR-564” is known as a precursor of “hsa-miR-564” which has a hairpin-shaped structure, “hsa-mir-564” (miRBase Accession No. MI0003570, SEQ ID No. 337).
[0293] The terms “hsa-miR-4497 gene” or “hsa-miR-4497” as used in this specification include the hsa-miR-4497 gene (miRBase Accession No. MIMAT0019032) described in SEQ ID No. 158 and other biological species homologs or oslogs, etc. The hsa-miR-4497 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, “hsa-miR-4497” is known as a precursor of “hsa-miR-4497” which has a hairpin-shaped structure, “hsa-mir-4497” (miRBase Accession No. MI0016859, SEQ ID No. 338).
[0294] The terms “hsa-miR-6877-5p gene” or “hsa-miR-6877-5p” as used herein include the hsa-miR-6877-5p gene (miRBase Accession No. MIMAT0027654) described in SEQ ID No. 159, or other biological species homologs or osologs, etc. The hsa-miR-6877-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Additionally, “hsa-miR-6877” (miRBase Accession No. MI0022724, SEQ ID No. 339), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6877-5p”.
[0295] The terms “hsa-miR-6087 gene” or “hsa-miR-6087” as used in this specification include the hsa-miR-6087 gene (miRBase Accession No. MIMAT0023712) described in SEQ ID NO. 160 and other biological species homologs or oslogs, etc. The hsa-miR-6087 gene can be obtained by the method described in Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, pp. 2049-2057. Additionally, “hsa-miR-6087” (miRBase Accession No. MI0020364, SEQ ID NO. 340), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6087”.
[0296] The terms “hsa-miR-4731-5p gene” or “hsa-miR-4731-5p” as used herein include the hsa-miR-4731-5p gene described in SEQ ID NO. 161 (miRBase Accession No. MIMAT0019853) and other biological species homologs or oslogs. The hsa-miR-4731-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Additionally, “hsa-miR-4731” (miRBase Accession No. MI0017368, SEQ ID NO. 341), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4731-5p”.
[0297] The terms “hsa-miR-615-5p gene” or “hsa-miR-615-5p” as used in this specification include the hsa-miR-615-5p gene described in SEQ ID NO. 162 (miRBase Accession No. MIMAT0004804) and other biological species homologs or oslogs. The hsa-miR-615-5p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. Additionally, “hsa-miR-615” (miRBase Accession No. MI0003628, SEQ ID NO. 342), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-615-5p”.
[0298] The terms “hsa-miR-760 gene” or “hsa-miR-760” as used in this specification include the hsa-miR-760 gene (miRBase Accession No. MIMAT0004957) described in SEQ ID NO. 163 and other biological species homologs or oslogs, etc. The hsa-miR-760 gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. In addition, “hsa-miR-760” is known as a precursor of “hsa-miR-760” which has a hairpin-shaped structure, “hsa-mir-760” (miRBase Accession No. MI0005567, SEQ ID NO. 343).
[0299] The terms “hsa-miR-6891-5p gene” or “hsa-miR-6891-5p” as used herein include the hsa-miR-6891-5p gene (miRBase Accession No. MIMAT0027682) described in SEQ ID NO. 164 and other biological species homologs or oslogs, etc. The hsa-miR-6891-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6891” (miRBase Accession No. MI0022738, SEQ ID NO. 344), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6891-5p”.
[0300] The terms “hsa-miR-6887-5p gene” or “hsa-miR-6887-5p” as used herein include the hsa-miR-6887-5p gene (miRBase Accession No. MIMAT0027674) described in SEQ ID NO. 165 and other biological species homologs or oslogs, etc. The hsa-miR-6887-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. In addition, “hsa-miR-6887” (miRBase Accession No. MI0022734, SEQ ID NO. 345), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6887-5p”.
[0301] The terms “hsa-miR-4525 gene” or “hsa-miR-4525” as used in this specification include the hsa-miR-4525 gene described in SEQ ID NO. 166 (miRBase Accession No. MIMAT0019064) and other biological species homologs or oslogs, etc. The hsa-miR-4525 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, “hsa-miR-4525” is known as a precursor of “hsa-miR-4525” which has a hairpin-shaped structure, “hsa-mir-4525” (miRBase Accession No. MI0016892, SEQ ID NO. 346).
[0302] The terms “hsa-miR-1914-3p gene” or “hsa-miR-1914-3p” as used herein include the hsa-miR-1914-3p gene (miRBase Accession No. MIMAT0007890) described in SEQ ID NO. 167 and other biological species homologs or oslogs, etc. The hsa-miR-1914-3p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. In addition, “hsa-miR-1914” (miRBase Accession No. MI0008335, SEQ ID NO. 347), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1914-3p”.
[0303] The terms “hsa-miR-619-5p gene” or “hsa-miR-619-5p” as used in this specification include the hsa-miR-619-5p gene (miRBase Accession No. MIMAT0026622) described in SEQ ID NO. 168 and other biological species homologs or oslogs, etc. The hsa-miR-619-5p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. In addition, “hsa-miR-619” (miRBase Accession No. MI0003633, SEQ ID NO. 348), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-619-5p”.
[0304] The terms “hsa-miR-5001-5p gene” or “hsa-miR-5001-5p” as used in this specification include the hsa-miR-5001-5p gene (miRBase Accession No. MIMAT0021021) described in SEQ ID NO. 169 and other biological species homologs or oslogs, etc. The hsa-miR-5001-5p gene can be obtained by the method described in Hansen TB et al., 2011, RNA Biol, Vol. 8, pp. 378-383. In addition, “hsa-miR-5001” (miRBase Accession No. MI0017867, SEQ ID NO. 349), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-5001-5p”.
[0305] The terms “hsa-miR-6722-3p gene” or “hsa-miR-6722-3p” as used herein include the hsa-miR-6722-3p gene (miRBase Accession No. MIMAT0025854) described in SEQ ID No. 170, or other biological species homologs or oslogs, etc. The hsa-miR-6722-3p gene can be obtained by the method described in Li Y et al., 2012, Gene, Vol. 497, pp. 330-335. In addition, “hsa-miR-6722” (miRBase Accession No. MI0022557, SEQ ID No. 350), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6722-3p”.
[0306] The terms “hsa-miR-3621 gene” or “hsa-miR-3621” as used in this specification include the hsa-miR-3621 gene (miRBase Accession No. MIMAT0018002) described in SEQ ID No. 171 and other biological species homologs or oslogs, etc. The hsa-miR-3621 gene can be obtained by the method described in Witten D et al., 2010, BMC Biol, Vol. 8, p. 58. In addition, “hsa-miR-3621” is known as a precursor of “hsa-miR-3621” which has a hairpin-shaped structure, “hsa-mir-3621” (miRBase Accession No. MI0016012, SEQ ID No. 351).
[0307] The terms “hsa-miR-4298 gene” or “hsa-miR-4298” as used in this specification include the hsa-miR-4298 gene (miRBase Accession No. MIMAT0016852) described in SEQ ID NO. 172 and other biological species homologs or oslogs, etc. The hsa-miR-4298 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, “hsa-miR-4298” is known as a precursor of “hsa-miR-4298” which has a hairpin-shaped structure, “hsa-mir-4298” (miRBase Accession No. MI0015830, SEQ ID NO. 352).
[0308] The terms “hsa-miR-675-5p gene” or “hsa-miR-675-5p” as used in this specification include the hsa-miR-675-5p gene described in SEQ ID NO. 173 (miRBase Accession No. MIMAT0004284) and other biological species homologs or osologs, etc. The hsa-miR-675-5p gene can be obtained by the method described in Cai X et al., 2007, RNA, Vol. 13, pp. 313-316. In addition, “hsa-miR-675” (miRBase Accession No. MI0005416, SEQ ID NO. 353), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-675-5p”.
[0309] The terms “hsa-miR-4655-5p gene” or “hsa-miR-4655-5p” as used in this specification include the hsa-miR-4655-5p gene (miRBase Accession No. MIMAT0019721) described in SEQ ID No. 174 and other biological species homologs or oslogs, etc. The hsa-miR-4655-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. In addition, “hsa-miR-4655” (miRBase Accession No. MI0017283, SEQ ID No. 354), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4655-5p”.
[0310] The terms “hsa-miR-6073 gene” or “hsa-miR-6073” as used in this specification include the hsa-miR-6073 gene described in SEQ ID NO. 561 (miRBase Accession No. MIMAT0023698) and other biological species homologs or oslogs. The hsa-miR-6073 gene can be obtained by the method described in Voellenkle C et al., 2012, RNA, Vol. 18, pp. 472-484. Additionally, “hsa-miR-6073” is known as a precursor of “hsa-miR-6073” which has a hairpin-shaped structure, “hsa-mir-6073” (miRBase Accession No. MI0020350, SEQ ID NO. 580).
[0311] The terms “hsa-miR-6845-5p gene” or “hsa-miR-6845-5p” as used in this specification include the hsa-miR-6845-5p gene (miRBase Accession No. MIMAT0027590) described in SEQ ID NO. 562, as well as other biological species homologs or osologs. The hsa-miR-6845-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Additionally, “hsa-miR-6845” (miRBase Accession No. MI0022691, SEQ ID NO. 581), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6845-5p”.
[0312] The terms “hsa-miR-6769b-5p gene” or “hsa-miR-6769b-5p” as used herein include the hsa-miR-6769b-5p gene described in SEQ ID NO. 563 (miRBase Accession No. MIMAT0027620) and other biological species homologs or osologs. The hsa-miR-6769b-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Additionally, “hsa-miR-6769b” (miRBase Accession No. MI0022706, SEQ ID NO. 582), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-6769b-5p”.
[0313] The terms “hsa-miR-4665-3p gene” or “hsa-miR-4665-3p” as used in this specification include the hsa-miR-4665-3p gene (miRBase Accession No. MIMAT0019740) described in SEQ ID No. 564, as well as other biological species homologs or oslogs. The hsa-miR-4665-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Additionally, “hsa-miR-4665” (miRBase Accession No. MI0017295, SEQ ID No. 583), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4665-3p”.
[0314] The terms “hsa-miR-1913 gene” or “hsa-miR-1913” as used in this specification include the hsa-miR-1913 gene (miRBase Accession No. MIMAT0007888) described in SEQ ID NO. 565, as well as other biological species homologs or oslogs. The hsa-miR-1913 gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. Additionally, “hsa-miR-1913” is known as a precursor of “hsa-miR-1913” which has a hairpin-shaped structure, “hsa-mir-1913” (miRBase Accession No. MI0008334, SEQ ID NO. 584).
[0315] The terms “hsa-miR-1228-3p gene” or “hsa-miR-1228-3p” as used in this specification include the hsa-miR-1228-3p gene described in SEQ ID NO. 566 (miRBase Accession No. MIMAT0005583) and other biological species homologs or osologs. The hsa-miR-1228-3p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. Additionally, “hsa-miR-1228” (miRBase Accession No. MI0006318, SEQ ID NO. 311), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1228-3p”.
[0316] The terms “hsa-miR-940 gene” or “hsa-miR-940” as used in this specification include the hsa-miR-940 gene described in SEQ ID NO. 567 (miRBase Accession No. MIMAT0004983) and other biological species homologs or osologs. The hsa-miR-940 gene can be obtained by the method described in Lui WO et al., 2007, Cancer Res, Vol. 67, pp. 6031-6043. Additionally, “hsa-miR-940” is known as a precursor of “hsa-miR-940” which has a hairpin-shaped structure, “hsa-mir-940” (miRBase Accession No. MI0005762, SEQ ID NO. 585).
[0317] The terms “hsa-miR-296-3p gene” or “hsa-miR-296-3p” as used in this specification include the hsa-miR-296-3p gene (miRBase Accession No. MIMAT0004679) described in SEQ ID No. 568, as well as other biological species homologs or oslogs. The hsa-miR-296-3p gene can be obtained by the method described in Houbaviy HB et al., 2003, Dev Cell, Vol. 5, pp. 351-358. Additionally, “hsa-miR-296” (miRBase Accession No. MI0000747, SEQ ID No. 586), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-296-3p”.
[0318] The terms “hsa-miR-4690-5p gene” or “hsa-miR-4690-5p” as used in this specification include the hsa-miR-4690-5p gene described in SEQ ID NO. 569 (miRBase Accession No. MIMAT0019779) and other biological species homologs or osologs. The hsa-miR-4690-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Additionally, “hsa-miR-4690” (miRBase Accession No. MI0017323, SEQ ID NO. 587), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4690-5p”.
[0319] The terms “hsa-miR-548q gene” or “hsa-miR-548q” as used in this specification include the hsa-miR-548q gene described in SEQ ID NO. 570 (miRBase Accession No. MIMAT0011163) and other biological species homologs or oslogs. The hsa-miR-548q gene can be obtained by the method described in Wyman SK et al., 2009, PLoS One. Vol. 4, e5311. Additionally, “hsa-miR-548q” (miRBase Accession No. MI0010637, SEQ ID NO. 588), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-548q”.
[0320] The terms “hsa-miR-663a gene” or “hsa-miR-663a” as used in this specification include the hsa-miR-663a gene described in SEQ ID NO. 571 (miRBase Accession No. MIMAT0003326) and other biological species homologs or oslogs. The hsa-miR-663a gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, pp. 3687-3692. Additionally, “hsa-miR-663a” is known as a precursor of “hsa-miR-663a” which has a hairpin-shaped structure, “hsa-mir-663a” (miRBase Accession No. MI0003672, SEQ ID NO. 589).
[0321] The terms “hsa-miR-1249 gene” or “hsa-miR-1249” as used in this specification include the hsa-miR-1249 gene (miRBase Accession No. MIMAT0005901) described in SEQ ID No. 572, as well as other biological species homologs or osologs. The hsa-miR-1249 gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. Additionally, “hsa-miR-1249” (miRBase Accession No. MI0006384, SEQ ID No. 590), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1249.”
[0322] The terms “hsa-miR-1202 gene” or “hsa-miR-1202” as used in this specification include the hsa-miR-1202 gene described in SEQ ID NO. 573 (miRBase Accession No. MIMAT0005865) and other biological species homologs or oslogs. The hsa-miR-1202 gene can be obtained by the method described in Marton S et al., 2008, Leukemia, Vol. 22, pp. 330-338. Additionally, “hsa-miR-1202” (miRBase Accession No. MI0006334, SEQ ID NO. 591), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1202.”
[0323] The terms “hsa-miR-7113-3p gene” or “hsa-miR-7113-3p” as used herein include the hsa-miR-7113-3p gene (miRBase Accession No. MIMAT0028124) described in SEQ ID No. 574, as well as other biological species homologs or oslogs. The hsa-miR-7113-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Additionally, “hsa-miR-7113” (miRBase Accession No. MI0022964, SEQ ID No. 592), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-7113-3p”.
[0324] The terms “hsa-miR-1225-3p gene” or “hsa-miR-1225-3p” as used herein include the hsa-miR-1225-3p gene described in SEQ ID NO. 575 (miRBase Accession No. MIMAT0005573) and other biological species homologs or oslogs. The hsa-miR-1225-3p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. Additionally, “hsa-miR-1225” (miRBase Accession No. MI0006311, SEQ ID NO. 307), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1225-3p”.
[0325] The terms “hsa-miR-4783-3p gene” or “hsa-miR-4783-3p” as used in this specification include the hsa-miR-4783-3p gene described in SEQ ID NO. 576 (miRBase Accession No. MIMAT0019947) and other biological species homologs or osologs. The hsa-miR-4783-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Additionally, “hsa-miR-4783” (miRBase Accession No. MI0017428, SEQ ID NO. 593), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4783-3p”.
[0326] The terms “hsa-miR-4448 gene” or “hsa-miR-4448” as used in this specification include the hsa-miR-4448 gene (miRBase Accession No. MIMAT0018967) described in SEQ ID No. 577, as well as other biological species homologs or oslogs. The hsa-miR-4448 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Additionally, “hsa-miR-4448” (miRBase Accession No. MI0016791, SEQ ID No. 594), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4448.”
[0327] The terms “hsa-miR-4534 gene” or “hsa-miR-4534” as used in this specification include the hsa-miR-4534 gene (miRBase Accession No. MIMAT0019073) described in SEQ ID No. 578, as well as other biological species homologs or oslogs. The hsa-miR-4534 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Additionally, “hsa-miR-4534” (miRBase Accession No. MI0016901, SEQ ID No. 595), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-4534.”
[0328] The terms “hsa-miR-1307-3p gene” or “hsa-miR-1307-3p” as used in this specification include the hsa-miR-1307-3p gene (miRBase Accession No. MIMAT0005951) described in SEQ ID No. 579, as well as other biological species homologs or oslogs. The hsa-miR-1307-3p gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. Additionally, “hsa-miR-1307” (miRBase Accession No. MI0006444, SEQ ID No. 596), which has a hairpin-shaped structure, is known as a precursor of “hsa-miR-1307-3p”.
[0329] In addition, when mature miRNAs are extruded as mature miRNAs from RNA precursors having a hairpin-shaped structure, there are cases where one to several bases at the beginning or end of the sequence are extruded shorter or longer, or where base substitutions occur, resulting in variants, which are called isomiRs (Morin RD. et al., 2008, Genome Res., Vol. 18, pp. 610-621). In miRBase Release 20, in addition to the base sequence represented by any one of SEQ ID NOs 1-174 and 561-579, variants and fragments of base sequences represented by any one of SEQ ID NOs 355-560 and 597-618, which are called several isomiRs, are also presented. These variants can also be obtained as miRNAs having base sequences represented by any one of SEQ ID NOs 1-174 and 561-579. That is, SEQ ID NOs 5, 8, 9, 11, 18, 20, 22, 23, 24, 28, 29, 30, 32, 34, 37, 40, 41, 47, 48, 49, 51, 52, 53, 56, 58, 59, 60, 61, 63, 64, 65, 66, 67, 69, 72, 73, 75, 78, 79, 80, 81, 82, 85, 88, 89, 91, 92, 95, 96, 103, 104, 105, 106, 107, 108, 109, 110, 112 of the present invention 113, 114, 117, 118, 120, 123, 124, 125, 126, 128, 129, 130, 131, 132, 133, 134, 135, 136, 138, 139, 142, 143, 144, 145, 146, 147, 149, 151, 152, 153, 154, 156, 157, 158, 160, 161, 162, 163, 166, 167, 168, 169, 172, 173, 174, 565, 566, 567, 568, 569, 571, 572, 573, 576, 577,Among variants of a polynucleotide consisting of the base sequence represented by 579 or a base sequence in which u is t, for example, the longest variant registered in miRBase Release 20, respectively SEQ ID NOs 355, 357, 359, 361, 363, 365, 367, 369, 371, 373, 375, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 407, 409, 411, 413, 415, 417, 419, 421, 423, 425, 427, 429, 431, 433, 435, 437, 439, 441, 443, 445, 447, 449, 451, 453, 455, 457, 459, 461, 463, 465, 467, 469, 471, 473, 475, 477, 479, 481, 483, 485, 487, 489, 491, 493, 495, 497, 499, 501, 503, 505, 507, 509, 511, 513, 515, 517, 519, 521, 523, 525, Polynucleotides represented by 527, 529, 531, 533, 535, 537, 539, 541, 543, 545, 547, 549, 551, 553, 555, 557, 559, 597, 599, 601, 603, 605, 607, 609, 611, 613, 615, and 617 are exemplified.
[0330] In addition, SEQ ID NOs 5, 8, 9, 11, 18, 20, 22, 23, 24, 28, 29, 30, 32, 34, 37, 40, 41, 47, 48, 49, 51, 52, 53, 56, 58, 59, 60, 61, 63, 64, 65, 66, 67, 69, 72, 73, 75, 78, 79, 80, 81, 82, 85, 88, 89, 91, 92, 95, 96, 103, 104, 105, 106, 107, 108, 109, 110, 112 of the present invention 113, 114, 117, 118, 120, 123, 124, 125, 126, 128, 129, 130, 131, 132, 133, 134, 135, 136, 138, 139, 142, 143, 144, 145, 146, 147, 149, 151, 152, 153, 154, 156, 157, 158, 160, 161, 162, 163, 166, 167, 168, 169, 172, 173, 174, 565, 566, 567, 568, Among variants of polynucleotides consisting of nucleotide sequences represented by 569, 571, 572, 573, 576, 577, and 579, or nucleotide sequences in which u is t, for example, the shortest variants registered in miRBase Release 20, respectively, SEQ ID NOs 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, 384, 386, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 414, and 416, 418, 420, 422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 492, 494,Polynucleotides of sequences represented by 496, 498, 500, 502, 504, 506, 508, 510, 512, 514, 516, 518, 520, 522, 524, 526, 528, 530, 532, 534, 536, 538, 540, 542, 544, 546, 548, 550, 552, 554, 556, 558, 560, 598, 600, 602, 604, 606, 608, 610, 612, 614, 616, and 618 are exemplified.
[0331] In addition, in addition to these variants and fragments, polynucleotides that are isomiR, such as sequence numbers 1 to 174 and 561 to 579 registered in miRBase, are exemplified.
[0332] In addition, examples of polynucleotides comprising a base sequence represented by any one of SEQ ID NOs 1 to 174 and 561 to 579 include polynucleotides represented by any one of SEQ ID NOs 175 to 354 and 579 to 596, which are precursors, respectively.
[0333] The names of the genes represented by sequence numbers 1 to 618 and the miRBase Accession No. (registration number) are listed in Table 1.
[0334] In this specification, "specifically bindable" means that the nucleic acid probe or primer used in the present invention binds to a specific target nucleic acid and cannot substantially bind to other nucleic acids.
[0335] (Table 1)
[0336]
[0337]
[0338]
[0339]
[0340]
[0341]
[0342]
[0343]
[0344]
[0345]
[0346]
[0347]
[0348]
[0349]
[0350]
[0351]
[0352]
[0353] This specification includes the contents described in the specification and / or drawings of Japanese Patent Application No. 2014-125561, which is the basis of the priority of this application. Effects of the invention
[0354] With the present invention, it becomes possible to detect lung cancer easily and with high precision.
[0355] For example, it is possible to easily detect whether a patient has lung cancer by using the measured expression levels of several miRNAs in the patient's blood, serum, and / or plasma, which can be collected minimally. Brief explanation of the drawing
[0356] Figure 1 shows the relationship between the nucleotide sequences of hsa-miR-1908-5p, represented by sequence number 22, and hsa-miR-1908-3p, represented by sequence number 5, which are generated from hsa-mir-1908, represented by sequence number 179, which is a precursor. Figure 2 shows, on the left, the measured expression levels of hsa-miR-6768-5p (sequence number 1) for healthy individuals (100 people) and lung cancer patients (17 people) selected as a learning sample group, respectively, with the vertical axis. The horizontal line in the figure represents the threshold (10.08) for distinguishing the two groups optimized by Fisher's discriminant analysis. The figure on the right shows the measured expression levels of hsa-miR-6768-5p (sequence number 1) for healthy individuals (50 people) and lung cancer patients (8 people) selected as a test sample group, respectively, with the vertical axis. The horizontal line in the figure represents the threshold (10.08) for distinguishing the two groups set in the learning sample group. Figure 3 shows the measured expression levels of hsa-miR-6768-5p (SEQ No. 1) on the horizontal axis and the measured expression levels of hsa-miR-6836-3p (SEQ No. 2) on the vertical axis for healthy individuals (100 people, circles) and lung cancer patients (17 people, triangles) selected as training sample groups, respectively. The line in the figure represents the discriminant function (0=-1.42x+y+4.7) that distinguishes the two groups optimized by Fisher's discriminant analysis. The figure on the right shows the measured expression levels of hsa-miR-6768-5p (SEQ No. 1) on the horizontal axis and the measured expression levels of hsa-miR-6836-3p (SEQ No. 2) on the vertical axis for healthy individuals (50 people, circles) and lung cancer patients (8 people, triangles) selected as test sample groups, respectively. The line in the graph represents the threshold (0 = -1.42x + y + 4.7) for distinguishing between the two groups set in the training sample group. Figure 4A shows the results of Fisher's discriminant analysis using the expression levels of hsa-miR-6768-5p (SEQ No. 1), hsa-miR-6717-5p (SEQ No. 113), hsa-miR-19b-3p (SEQ No. 126), and hsa-miR-6073 (SEQ No. 561) from 17 lung cancer patients, 99 healthy patients, 75 pancreatic cancer patients, 62 biliary tract cancer patients, 32 colorectal cancer patients, 35 gastric cancer patients, 32 esophageal cancer patients, 33 liver cancer patients, and 13 patients with benign pancreaticobiliary diseases selected as a training sample group. A discriminant (-1.86xhsa-miR-6768-5p-0.68xhsa-miR-19b-3p+0.43xhsa-miR-6073-0.87xhsa-miR-6717-5p+25.68) was formulated, and the discriminant score obtained from the discriminant was plotted on the vertical axis, with the sample group on the horizontal axis. The dotted line in the figure indicates the discriminant boundary that distinguishes the two groups where the discriminant score becomes 0. Figure 4B shows the results for 8 lung cancer patients, 51 healthy patients, 23 pancreatic cancer patients, 38 biliary tract cancer patients, 18 colorectal cancer patients, 15 gastric cancer patients, 18 esophageal cancer patients, 19 liver cancer patients, and 8 patients with pancreaticobiliary benign diseases selected as test sample groups, with the discrimination score obtained from the discriminant formula created in the training sample group on the vertical axis and the sample group on the horizontal axis, regarding the expression levels of hsa-miR-6768-5p (SEQ No. 1), hsa-miR-6717-5p (SEQ No. 113), hsa-miR-19b-3p (SEQ No. 126), and hsa-miR-6073 (SEQ No. 561). The dotted line in the figure indicates the discrimination boundary that distinguishes between the two groups where the discrimination score becomes 0. Specific details for implementing the invention
[0357] The present invention will be described in more detail below.
[0358] 1. Target nucleic acids of lung cancer
[0359] The major target nucleic acids as lung cancer markers for detecting the presence and / or absence of lung cancer or lung cancer cells using the nucleic acid probe or primer for detecting lung cancer of the above definition of the present invention include hsa-miR-6768-5p, hsa-miR-6836-3p, hsa-miR-6782-5p, hsa-miR-3663-3p, hsa-miR-1908-3p, hsa-miR-6726-5p, hsa-miR-4258, hsa-miR-1343-3p, hsa-miR-4516, hsa-miR-6875-5p, hsa-miR-4651, hsa-miR-6825-5p, hsa-miR-6840-3p, hsa-miR-6780b-5p, hsa-miR-6749-5p, hsa-miR-8063, hsa-miR-6784-5p, hsa-miR-3679-5p, hsa-miR-3184-5p, hsa-miR-663b, hsa-miR-6880-5p, hsa-miR-1908-5p, hsa-miR-92a-2-5p, hsa-miR-7975, hsa-miR-7110-5p, hsa-miR-6842-5p, hsa-miR-6857-5p, hsa-miR-5572, hsa-miR-3197, hsa-miR-6131, hsa-miR-6889-5p, hsa-miR-4454, hsa-miR-1199-5p, hsa-miR-1247-3p, hsa-miR-6800-5p, hsa-miR-6872-3p, hsa-miR-4649-5p, hsa-miR-6791-5p, hsa-miR-4433b-3p, hsa-miR-3135b, hsa-miR-128-2-5p, hsa-miR-4675, hsa-miR-4472, hsa-miR-6785-5p, hsa-miR-6741-5p, hsa-miR-7977, hsa-miR-3665, hsa-miR-128-1-5p, hsa-miR-4286, hsa-miR-6765-3p, hsa-miR-4632-5p, hsa-miR-365a-5p, hsa-miR-6088, hsa-miR-6816-5p, hsa-miR-6885-5p, hsa-miR-711,hsa-miR-6765-5p, hsa-miR-3180, hsa-miR-4442, hsa-miR-4792, hsa-miR-6721-5p, hsa-miR-6798-5p, hsa-miR-3162-5p, hsa-miR-6126, hsa-miR-4758-5p, hsa-miR-2392, hsa-miR-486-3p, hsa-miR-6727-5p, hsa-miR-4728-5p, hsa-miR-6746-5p, hsa-miR-4270, hsa-miR-3940-5p, hsa-miR-4725-3p, hsa-miR-7108-5p, hsa-miR-3656 hsa-miR-6879-5p, hsa-miR-6738-5p, hsa-miR-1260a, hsa-miR-4446-3p, hsa-miR-3131, hsa-miR-4463, hsa-miR-3185, hsa-miR-6870-5p, hsa-miR-6779-5p, hsa-miR-1273g-3p, hsa-miR-8059, hsa-miR-4697-5p, hsa-miR-4674, hsa-miR-4433-3p, hsa-miR-4257, hsa-miR-1915-5p, hsa-miR-4417, hsa-miR-1343-5p, hsa-miR-6781-5p hsa-miR-4695-5p, hsa-miR-1237-5p, hsa-miR-6775-5p, hsa-miR-7845-5p, hsa-miR-4746-3p, hsa-miR-7641, hsa-miR-7847-3p, hsa-miR-6806-5p, hsa-miR-4467, hsa-miR-4726-5p, hsa-miR-4648, hsa-miR-6089, hsa-miR-1260b, hsa-miR-4532, hsa-miR-5195-3p, hsa-miR-3188, hsa-miR-6848-5p, hsa-miR-1233-5p, hsa-miR-6717-5p hsa-miR-3195, hsa-miR-6757-5p, hsa-miR-8072, hsa-miR-4745-5p, hsa-miR-6511a-5p,hsa-miR-6776-5p, hsa-miR-371a-5p, hsa-miR-1227-5p, hsa-miR-7150, hsa-miR-1915-3p, hsa-miR-187-5p, hsa-miR-614, hsa-miR-1225-5p, hsa-miR-451a, hsa-miR-939-5p, hsa-miR-223-3p, hsa-miR-125a-3p, hsa-miR-92b-5p, hsa-miR-22-3p, hsa-miR-6073, hsa-miR-6845-5p, hsa-miR-6769b-5p, hsa-miR-4665-3p, hsa-miR-1913, At least one miRNA selected from the group consisting of hsa-miR-1228-3p, hsa-miR-940, hsa-miR-296-3p, hsa-miR-4690-5p, hsa-miR-548q, hsa-miR-663a, hsa-miR-1249, hsa-miR-1202, hsa-miR-7113-3p, hsa-miR-1225-3p, hsa-miR-4783-3p, hsa-miR-4448, and hsa-miR-4534 may be used. In addition, at least one miRNA selected from the group consisting of other lung cancer markers that can be combined with these miRNAs, namely hsa-miR-19b-3p, hsa-miR-1228-5p, and hsa-miR-1307-3p, can also preferably be used as a target nucleic acid. In addition, other lung cancer markers that can be combined with these miRNAs, namely hsa-miR-4271, hsa-miR-642b-3p, hsa-miR-6075, hsa-miR-6125, hsa-miR-887-3p, hsa-miR-6851-5p, hsa-miR-6763-5p, hsa-miR-3928-3p, hsa-miR-4443, hsa-miR-3648, hsa-miR-149-3p, hsa-miR-4689, hsa-miR-4763-3p, hsa-miR-6729-5p, hsa-miR-3196, hsa-miR-8069, hsa-miR-1268a, hsa-miR-4739,hsa-miR-1268b, hsa-miR-5698, hsa-miR-6752-5p, hsa-miR-4507, hsa-miR-564, hsa-miR-4497, hsa-miR-6877-5p, hsa-miR-6087, hsa-miR-4731-5p, hsa-miR-615-5p, hsa-miR-760, hsa-miR-6891-5p, hsa-miR-6887-5p, hsa-miR-4525, hsa-miR-1914-3p, hsa-miR-619-5p, hsa-miR-5001-5p, hsa-miR-6722-3p, hsa-miR-3621, At least one miRNA selected from the group consisting of hsa-miR-4298, hsa-miR-675-5p, and hsa-miR-4655-5p may also preferably be used as a target nucleic acid.
[0360] The above miRNA includes, for example, a human gene comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 174 and 561 to 579 (i.e., each hsa-miR-6768-5p, hsa-miR-6836-3p, hsa-miR-6782-5p, hsa-miR-3663-3p, hsa-miR-1908-3p, hsa-miR-6726-5p, hsa-miR-4258, hsa-miR-1343-3p, hsa-miR-4516, hsa-miR-6875-5p, hsa-miR-4651, hsa-miR-6825-5p, hsa-miR-6840-3p, hsa-miR-6780b-5p, hsa-miR-6749-5p, hsa-miR-8063, hsa-miR-6784-5p, hsa-miR-3679-5p, hsa-miR-3184-5p, hsa-miR-663b, hsa-miR-6880-5p, hsa-miR-1908-5p, hsa-miR-92a-2-5p, hsa-miR-7975, hsa-miR-7110-5p, hsa-miR-6842-5p, hsa-miR-6857-5p, hsa-miR-5572, hsa-miR-3197, hsa-miR-6131, hsa-miR-6889-5p, hsa-miR-4454, hsa-miR-1199-5p, hsa-miR-1247-3p, hsa-miR-6800-5p, hsa-miR-6872-3p, hsa-miR-4649-5p, hsa-miR-6791-5p, hsa-miR-4433b-3p, hsa-miR-3135b, hsa-miR-128-2-5p, hsa-miR-4675, hsa-miR-4472, hsa-miR-6785-5p, hsa-miR-6741-5p, hsa-miR-7977, hsa-miR-3665, hsa-miR-128-1-5p, hsa-miR-4286, hsa-miR-6765-3p, hsa-miR-4632-5p, hsa-miR-365a-5p, hsa-miR-6088, hsa-miR-6816-5p, hsa-miR-6885-5p, hsa-miR-711, hsa-miR-6765-5p,hsa-miR-3180, hsa-miR-4442, hsa-miR-4792, hsa-miR-6721-5p, hsa-miR-6798-5p, hsa-miR-3162-5p, hsa-miR-6126, hsa-miR-4758-5p, hsa-miR-2392, hsa-miR-486-3p, hsa-miR-6727-5p, hsa-miR-4728-5p, hsa-miR-6746-5p, hsa-miR-4270, hsa-miR-3940-5p, hsa-miR-4725-3p, hsa-miR-7108-5p, hsa-miR-3656, hsa-miR-6879-5p hsa-miR-6738-5p, hsa-miR-1260a, hsa-miR-4446-3p, hsa-miR-3131, hsa-miR-4463, hsa-miR-3185, hsa-miR-6870-5p, hsa-miR-6779-5p, hsa-miR-1273g-3p, hsa-miR-8059, hsa-miR-4697-5p, hsa-miR-4674, hsa-miR-4433-3p, hsa-miR-4257, hsa-miR-1915-5p, hsa-miR-4417, hsa-miR-1343-5p, hsa-miR-6781-5p, hsa-miR-4695-5p hsa-miR-1237-5p, hsa-miR-6775-5p, hsa-miR-7845-5p, hsa-miR-4746-3p, hsa-miR-7641, hsa-miR-7847-3p, hsa-miR-6806-5p, hsa-miR-4467, hsa-miR-4726-5p, hsa-miR-4648, hsa-miR-6089, hsa-miR-1260b, hsa-miR-4532, hsa-miR-5195-3p, hsa-miR-3188, hsa-miR-6848-5p, hsa-miR-1233-5p, hsa-miR-6717-5p, hsa-miR-3195 hsa-miR-6757-5p, hsa-miR-8072, hsa-miR-4745-5p, hsa-miR-6511a-5p, hsa-miR-6776-5p,hsa-miR-371a-5p, hsa-miR-1227-5p, hsa-miR-7150, hsa-miR-1915-3p, hsa-miR-187-5p, hsa-miR-614, hsa-miR-19b-3p, hsa-miR-1225-5p, hsa-miR-451a, hsa-miR-939-5p, hsa-miR-223-3p, hsa-miR-1228-5p, hsa-miR-125a-3p, hsa-miR-92b-5p, hsa-miR-22-3p, hsa-miR-6073, hsa-miR-6845-5p, hsa-miR-6769b-5p hsa-miR-4665-3p, hsa-miR-1913, hsa-miR-1228-3p, hsa-miR-940, hsa-miR-296-3p, hsa-miR-4690-5p, hsa-miR-548q, hsa-miR-663a, hsa-miR-1249, hsa-miR-1202, hsa-miR-7113-3p, hsa-miR-1225-3p, hsa-miR-4783-3p, hsa-miR-4448, hsa-miR-4534, hsa-miR-1307-3p, hsa-miR-4271, hsa-miR-642b-3p, hsa-miR-6075 hsa-miR-6125, hsa-miR-887-3p, hsa-miR-6851-5p, hsa-miR-6763-5p, hsa-miR-3928-3p, hsa-miR-4443, hsa-miR-3648, hsa-miR-149-3p, hsa-miR-4689, hsa-miR-4763-3p, hsa-miR-6729-5p, hsa-miR-3196, hsa-miR-8069, hsa-miR-1268a, hsa-miR-4739, hsa-miR-1268b, hsa-miR-5698, hsa-miR-6752-5p, hsa-miR-4507, hsa-miR-564 hsa-miR-4497, hsa-miR-6877-5p, hsa-miR-6087, hsa-miR-4731-5p, hsa-miR-615-5p, hsa-miR-760, hsa-miR-6891-5p,Includes hsa-miR-6887-5p, hsa-miR-4525, hsa-miR-1914-3p, hsa-miR-619-5p, hsa-miR-5001-5p, hsa-miR-6722-3p, hsa-miR-3621, hsa-miR-4298, hsa-miR-675-5p, and hsa-miR-4655-5p), their homologues, their transcription products, and their variants or derivatives. Herein, genes, homologues, transcription products, variants, and derivatives are as defined above.
[0361] A preferred target nucleic acid is a human gene containing a nucleotide sequence represented by any one of SEQ ID NOs 1 to 618, or a transcription product thereof, and more preferably, said transcription product, namely miRNA, its precursor RNA, pri-miRNA or pre-miRNA.
[0362] The first target gene is the hsa-miR-6768-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0363] The second target gene is the hsa-miR-6836-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0364] The third target gene is the hsa-miR-6782-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0365] The fourth target gene is the hsa-miR-3663-3p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0366] The fifth target gene is the hsa-miR-1908-3p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0367] The sixth target gene is the hsa-miR-6726-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0368] The seventh target gene is the hsa-miR-4258 gene, its homologues, its transcript products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0369] The eighth target gene is the hsa-miR-1343-3p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0370] The ninth target gene is the hsa-miR-4516 gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0371] The 10th target gene is the hsa-miR-6875-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0372] The 11th target gene is the hsa-miR-4651 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0373] The 12th target gene is the hsa-miR-6825-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0374] The 13th target gene is the hsa-miR-6840-3p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0375] The 14th target gene is the hsa-miR-6780b-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0376] The 15th target gene is the hsa-miR-6749-5p gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0377] The 16th target gene is the hsa-miR-8063 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0378] The 17th target gene is the hsa-miR-6784-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0379] The 18th target gene is the hsa-miR-3679-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0380] The 19th target gene is the hsa-miR-3184-5p gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0381] The 20th target gene is the hsa-miR-663b gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0382] The 21st target gene is the hsa-miR-6880-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0383] The 22nd target gene is the hsa-miR-1908-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0384] The 23rd target gene is the hsa-miR-92a-2-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0385] The 24th target gene is the hsa-miR-7975 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0386] The 25th target gene is the hsa-miR-7110-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0387] The 26th target gene is the hsa-miR-6842-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0388] The 27th target gene is the hsa-miR-6857-5p gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0389] The 28th target gene is the hsa-miR-5572 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0390] The 29th target gene is the hsa-miR-3197 gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0391] The 30th target gene is the hsa-miR-6131 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0392] The 31st target gene is the hsa-miR-6889-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0393] The 32nd target gene is the hsa-miR-4454 gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0394] The 33rd target gene is the hsa-miR-1199-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0395] The 34th target gene is the hsa-miR-1247-3p gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0396] The 35th target gene is the hsa-miR-6800-5p gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0397] The 36th target gene is the hsa-miR-6872-3p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0398] The 37th target gene is the hsa-miR-4649-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0399] The 38th target gene is the hsa-miR-6791-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0400] The 39th target gene is the hsa-miR-4433b-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0401] The 40th target gene is the hsa-miR-3135b gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0402] The 41st target gene is the hsa-miR-128-2-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0403] The 42nd target gene is the hsa-miR-4675 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0404] The 43rd target gene is the hsa-miR-4472 gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0405] The 44th target gene is the hsa-miR-6785-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0406] The 45th target gene is the hsa-miR-6741-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0407] The 46th target gene is the hsa-miR-7977 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0408] The 47th target gene is the hsa-miR-3665 gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0409] The 48th target gene is the hsa-miR-128-1-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0410] The 49th target gene is the hsa-miR-4286 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0411] The 50th target gene is the hsa-miR-6765-3p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0412] The 51st target gene is the hsa-miR-4632-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0413] The 52nd target gene is the hsa-miR-365a-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0414] The 53rd target gene is the hsa-miR-6088 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0415] The 54th target gene is the hsa-miR-6816-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0416] The 55th target gene is the hsa-miR-6885-5p gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0417] The 56th target gene is the hsa-miR-711 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0418] The 57th target gene is the hsa-miR-6765-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0419] The 58th target gene is the hsa-miR-3180 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0420] The 59th target gene is the hsa-miR-4442 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0421] The 60th target gene is the hsa-miR-4792 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0422] The 61st target gene is the hsa-miR-6721-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0423] The 62nd target gene is the hsa-miR-6798-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0424] The 63rd target gene is the hsa-miR-3162-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0425] The 64th target gene is the hsa-miR-6126 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0426] The 65th target gene is the hsa-miR-4758-5p gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0427] The 66th target gene is the hsa-miR-2392 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0428] The 67th target gene is the hsa-miR-486-3p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0429] The 68th target gene is the hsa-miR-6727-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0430] The 69th target gene is the hsa-miR-4728-5p gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0431] The 70th target gene is the hsa-miR-6746-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0432] The 71st target gene is the hsa-miR-4270 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0433] The 72nd target gene is the hsa-miR-3940-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0434] The 73rd target gene is the hsa-miR-4725-3p gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0435] The 74th target gene is the hsa-miR-7108-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0436] The 75th target gene is the hsa-miR-3656 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0437] The 76th target gene is the hsa-miR-6879-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0438] The 77th target gene is the hsa-miR-6738-5p gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0439] The 78th target gene is the hsa-miR-1260a gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0440] The 79th target gene is the hsa-miR-4446-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0441] The 80th target gene is the hsa-miR-3131 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0442] The 81st target gene is the hsa-miR-4463 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0443] The 82nd target gene is the hsa-miR-3185 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0444] The 83rd target gene is the hsa-miR-6870-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0445] The 84th target gene is the hsa-miR-6779-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0446] The 85th target gene is the hsa-miR-1273g-3p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0447] The 86th target gene is the hsa-miR-8059 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0448] The 87th target gene is the hsa-miR-4697-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0449] The 88th target gene is the hsa-miR-4674 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0450] The 89th target gene is the hsa-miR-4433-3p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0451] The 90th target gene is the hsa-miR-4257 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0452] The 91st target gene is the hsa-miR-1915-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0453] The 92nd target gene is the hsa-miR-4417 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0454] The 93rd target gene is the hsa-miR-1343-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0455] The 94th target gene is the hsa-miR-6781-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0456] The 95th target gene is the hsa-miR-4695-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0457] The 96th target gene is the hsa-miR-1237-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0458] The 97th target gene is the hsa-miR-6775-5p gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0459] The 98th target gene is the hsa-miR-7845-5p gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0460] The 99th target gene is the hsa-miR-4746-3p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0461] The 100th target gene is the hsa-miR-7641 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0462] The 101st target gene is the hsa-miR-7847-3p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0463] The 102nd target gene is the hsa-miR-6806-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0464] The 103rd target gene is the hsa-miR-4467 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0465] The 104th target gene is the hsa-miR-4726-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0466] The 105th target gene is the hsa-miR-4648 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0467] The 106th target gene is the hsa-miR-6089 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0468] The 107th target gene is the hsa-miR-1260b gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0469] The 108th target gene is the hsa-miR-4532 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0470] The 109th target gene is the hsa-miR-5195-3p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0471] The 110th target gene is the hsa-miR-3188 gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0472] Target gene number 111 is the hsa-miR-6848-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0473] Target gene number 112 is the hsa-miR-1233-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0474] Target gene number 113 is the hsa-miR-6717-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0475] Target gene number 114 is the hsa-miR-3195 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0476] Target gene number 115 is the hsa-miR-6757-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0477] Target gene number 116 is the hsa-miR-8072 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0478] Target gene number 117 is the hsa-miR-4745-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0479] Target gene number 118 is the hsa-miR-6511a-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0480] Target gene number 119 is the hsa-miR-6776-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0481] The 120th target gene is the hsa-miR-371a-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0482] The 121st target gene is the hsa-miR-1227-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0483] Target gene number 122 is the hsa-miR-7150 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0484] Target gene number 123 is the hsa-miR-1915-3p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0485] The 124th target gene is the hsa-miR-187-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0486] The 125th target gene is the hsa-miR-614 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0487] Target gene number 126 is the hsa-miR-19b-3p gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of this gene or its transcription products can serve as markers for lung cancer (Patent Document 1).
[0488] Target gene number 127 is the hsa-miR-1225-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0489] Target gene number 128 is the hsa-miR-451a gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0490] Target gene number 129 is the hsa-miR-939-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0491] Target gene number 130 is the hsa-miR-223-3p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0492] Target gene 131 is the hsa-miR-1228-5p gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of this gene or its transcription products can serve as markers for lung cancer (Patent Document 2).
[0493] Target gene number 132 is the hsa-miR-125a-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0494] Target gene number 133 is the hsa-miR-92b-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0495] Target gene number 134 is the hsa-miR-22-3p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0496] Target gene number 135 is the hsa-miR-4271 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0497] Target gene number 136 is the hsa-miR-642b-3p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0498] Target gene number 137 is the hsa-miR-6075 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0499] Target gene number 138 is the hsa-miR-6125 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0500] Target gene number 139 is the hsa-miR-887-3p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0501] The 140th target gene is the hsa-miR-6851-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0502] Target gene number 141 is the hsa-miR-6763-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0503] Target gene number 142 is the hsa-miR-3928-3p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0504] Target gene number 143 is the hsa-miR-4443 gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0505] The 144th target gene is the hsa-miR-3648 gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0506] The 145th target gene is the hsa-miR-149-3p gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0507] Target gene number 146 is the hsa-miR-4689 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0508] Target gene number 147 is the hsa-miR-4763-3p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0509] Target gene number 148 is the hsa-miR-6729-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0510] Target gene number 149 is the hsa-miR-3196 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0511] The 150th target gene is the hsa-miR-8069 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0512] Target gene 151 is the hsa-miR-1268a gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer (Patent Document 2).
[0513] Target gene number 152 is the hsa-miR-4739 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0514] Target gene number 153 is the hsa-miR-1268b gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0515] Target gene number 154 is the hsa-miR-5698 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0516] The 155th target gene is the hsa-miR-6752-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0517] Target gene number 156 is the hsa-miR-4507 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0518] Target gene number 157 is the hsa-miR-564 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0519] Target gene number 158 is the hsa-miR-4497 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0520] Target gene number 159 is the hsa-miR-6877-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0521] Target gene number 160 is the hsa-miR-6087 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0522] Target gene number 161 is the hsa-miR-4731-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0523] Target gene number 162 is the hsa-miR-615-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0524] Target gene number 163 is the hsa-miR-760 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0525] Target gene number 164 is the hsa-miR-6891-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0526] Target gene number 165 is the hsa-miR-6887-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0527] Target gene number 166 is the hsa-miR-4525 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0528] Target gene number 167 is the hsa-miR-1914-3p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0529] Target gene number 168 is the hsa-miR-619-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0530] Target gene number 169 is the hsa-miR-5001-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0531] Target gene number 170 is the hsa-miR-6722-3p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0532] Target gene number 171 is the hsa-miR-3621 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0533] Target gene number 172 is the hsa-miR-4298 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcription products can serve as markers for lung cancer.
[0534] Target gene number 173 is the hsa-miR-675-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0535] Target gene number 174 is the hsa-miR-4655-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of this gene or its transcript products can serve as markers for lung cancer.
[0536] Target gene number 175 is the hsa-miR-6073 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcript products can serve as markers for lung cancer.
[0537] Target gene number 176 is the hsa-miR-6845-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcript products can serve as markers for lung cancer.
[0538] Target gene number 177 is the hsa-miR-6769b-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcript products can serve as markers for lung cancer.
[0539] Target gene number 178 is the hsa-miR-4665-3p gene, its homologues, its transcript products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcript products can serve as markers for lung cancer.
[0540] Target gene number 179 is the hsa-miR-1913 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for lung cancer.
[0541] Target gene number 180 is the hsa-miR-1228-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for lung cancer.
[0542] Target genes 181 are the hsa-miR-940 genes, their homologues, their transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of genes or their transcription products can serve as markers for lung cancer.
[0543] Target gene number 182 is the hsa-miR-296-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for lung cancer.
[0544] Target gene number 183 is the hsa-miR-4690-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for lung cancer.
[0545] Target gene number 184 is the hsa-miR-548q gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for lung cancer.
[0546] Target gene number 185 is the hsa-miR-663a gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for lung cancer.
[0547] Target gene number 186 is the hsa-miR-1249 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for lung cancer.
[0548] Target gene number 187 is the hsa-miR-1202 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for lung cancer.
[0549] Target gene number 188 is the hsa-miR-7113-3p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcript products can serve as markers for lung cancer.
[0550] Target gene number 189 is the hsa-miR-1225-3p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for lung cancer.
[0551] Target gene number 190 is the hsa-miR-4783-3p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for lung cancer.
[0552] Target gene number 191 is the hsa-miR-4448 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for lung cancer.
[0553] Target gene number 192 is the hsa-miR-4534 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for lung cancer.
[0554] Target gene number 193 is the hsa-miR-1307-3p gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of a gene or its transcription products can serve as markers for lung cancer (Patent Document 3).
[0555] 2. Nucleic acid probes or primers for the detection of lung cancer
[0556] In the present invention, a nucleic acid capable of specifically binding to the target nucleic acid as a lung cancer marker can be used as a nucleic acid for detecting or diagnosing lung cancer, for example, as a nucleic acid probe or primer.
[0557] In the present invention, a nucleic acid probe or primer usable for detecting or diagnosing lung cancer is a target nucleic acid as the lung cancer marker, for example, human-derived hsa-miR-6768-5p, hsa-miR-6836-3p, hsa-miR-6782-5p, hsa-miR-3663-3p, hsa-miR-1908-3p, hsa-miR-6726-5p, hsa-miR-4258, hsa-miR-1343-3p, hsa-miR-4516, hsa-miR-6875-5p, hsa-miR-4651, hsa-miR-6825-5p, hsa-miR-6840-3p, hsa-miR-6780b-5p, hsa-miR-6749-5p, hsa-miR-8063, hsa-miR-6784-5p, hsa-miR-3679-5p, hsa-miR-3184-5p, hsa-miR-663b, hsa-miR-6880-5p, hsa-miR-1908-5p, hsa-miR-92a-2-5p, hsa-miR-7975, hsa-miR-7110-5p, hsa-miR-6842-5p, hsa-miR-6857-5p, hsa-miR-5572, hsa-miR-3197, hsa-miR-6131, hsa-miR-6889-5p, hsa-miR-4454, hsa-miR-1199-5p, hsa-miR-1247-3p, hsa-miR-6800-5p, hsa-miR-6872-3p, hsa-miR-4649-5p, hsa-miR-6791-5p, hsa-miR-4433b-3p, hsa-miR-3135b, hsa-miR-128-2-5p, hsa-miR-4675, hsa-miR-4472, hsa-miR-6785-5p, hsa-miR-6741-5p, hsa-miR-7977, hsa-miR-3665, hsa-miR-128-1-5p, hsa-miR-4286, hsa-miR-6765-3p, hsa-miR-4632-5p, hsa-miR-365a-5p, hsa-miR-6088, hsa-miR-6816-5p, hsa-miR-6885-5p, hsa-miR-711,hsa-miR-6765-5p, hsa-miR-3180, hsa-miR-4442, hsa-miR-4792, hsa-miR-6721-5p, hsa-miR-6798-5p, hsa-miR-3162-5p, hsa-miR-6126, hsa-miR-4758-5p, hsa-miR-2392, hsa-miR-486-3p, hsa-miR-6727-5p, hsa-miR-4728-5p, hsa-miR-6746-5p, hsa-miR-4270, hsa-miR-3940-5p, hsa-miR-4725-3p, hsa-miR-7108-5p, hsa-miR-3656 hsa-miR-6879-5p, hsa-miR-6738-5p, hsa-miR-1260a, hsa-miR-4446-3p, hsa-miR-3131, hsa-miR-4463, hsa-miR-3185, hsa-miR-6870-5p, hsa-miR-6779-5p, hsa-miR-1273g-3p, hsa-miR-8059, hsa-miR-4697-5p, hsa-miR-4674, hsa-miR-4433-3p, hsa-miR-4257, hsa-miR-1915-5p, hsa-miR-4417, hsa-miR-1343-5p, hsa-miR-6781-5p hsa-miR-4695-5p, hsa-miR-1237-5p, hsa-miR-6775-5p, hsa-miR-7845-5p, hsa-miR-4746-3p, hsa-miR-7641, hsa-miR-7847-3p, hsa-miR-6806-5p, hsa-miR-4467, hsa-miR-4726-5p, hsa-miR-4648, hsa-miR-6089, hsa-miR-1260b, hsa-miR-4532, hsa-miR-5195-3p, hsa-miR-3188, hsa-miR-6848-5p, hsa-miR-1233-5p, hsa-miR-6717-5p hsa-miR-3195, hsa-miR-6757-5p, hsa-miR-8072, hsa-miR-4745-5p, hsa-miR-6511a-5p,hsa-miR-6776-5p, hsa-miR-371a-5p, hsa-miR-1227-5p, hsa-miR-7150, hsa-miR-1915-3p, hsa-miR-187-5p, hsa-miR-614, hsa-miR-1225-5p, hsa-miR-451a, hsa-miR-939-5p, hsa-miR-223-3p, hsa-miR-125a-3p, hsa-miR-92b-5p, hsa-miR-22-3p, hsa-miR-6073, hsa-miR-6845-5p, hsa-miR-6769b-5p, hsa-miR-4665-3p, hsa-miR-1913, hsa-miR-1228-3p, hsa-miR-940, hsa-miR-296-3p, hsa-miR-4690-5p, hsa-miR-548q, hsa-miR-663a, hsa-miR-1249, hsa-miR-1202, hsa-miR-7113-3p, hsa-miR-1225-3p, hsa-miR-4783-3p, hsa-miR-4448, or hsa-miR-4534, or combinations thereof, or their homologues, their transcription products, their variants or derivatives, and hsa-miR-19b-3p, hsa-miR-1228-5p, or hsa-miR-1307-3p, or combinations thereof, or their Homologues, their transcription products, their variants or derivatives, and hsa-miR-4271, hsa-miR-642b-3p, hsa-miR-6075, hsa-miR-6125, hsa-miR-887-3p, hsa-miR-6851-5p, hsa-miR-6763-5p, hsa-miR-3928-3p, hsa-miR-4443, hsa-miR-3648, hsa-miR-149-3p, hsa-miR-4689, hsa-miR-4763-3p, hsa-miR-6729-5p, hsa-miR-3196, hsa-miR-8069, hsa-miR-1268a, which may be combined with them in some cases hsa-miR-4739, hsa-miR-1268b,hsa-miR-5698, hsa-miR-6752-5p, hsa-miR-4507, hsa-miR-564, hsa-miR-4497, hsa-miR-6877-5p, hsa-miR-6087, hsa-miR-4731-5p, hsa-miR-615-5p, hsa-miR-760, hsa-miR-6891-5p, hsa-miR-6887-5p, hsa-miR-4525, hsa-miR-1914-3p, hsa-miR-619-5p, hsa-miR-5001-5p, hsa-miR-6722-3p, hsa-miR-3621, hsa-miR-4298, It makes it possible to qualitatively and / or quantitatively measure the presence, expression level, or presence of hsa-miR-675-5p or hsa-miR-4655-5p, or combinations thereof, or their homologues, their transcription products, their variants, or derivatives.
[0558] In subjects with lung cancer compared to healthy individuals, the expression levels of the above-mentioned target nucleic acids may increase or decrease depending on the type of target nucleic acid (hereinafter referred to as "increase / decrease"). Accordingly, the nucleic acids of the present invention can be effectively used to detect lung cancer by measuring the expression levels of the above-mentioned target nucleic acids in body fluids derived from subjects suspected of having lung cancer (e.g., humans) and body fluids derived from healthy individuals, and comparing them.
[0559] The nucleic acid probe or primer usable in the present invention is a nucleic acid probe capable of specifically binding to a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs 1 to 125, 127 to 130, 132 to 134, and 561 to 578, or a primer for amplifying a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs 1 to 125, 127 to 130, 132 to 134, and 561 to 578.
[0560] The nucleic acid probe or primer usable in the present invention may further include a nucleic acid probe capable of specifically binding to a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs 126, 131 and 579, or a primer for amplifying a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs 126, 131 and 579.
[0561] The nucleic acid probe or primer usable in the present invention may further include a nucleic acid probe capable of specifically binding to a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs 135 to 174, or a primer for amplifying a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs 135 to 174.
[0562] Specifically, the nucleic acid probe or primer comprises a combination of one or more polynucleotides selected from a polynucleotide group comprising a base sequence represented by any one of SEQ ID NOs 1 to 618, or a base sequence in which u is t in the base sequence and a complementary polynucleotide group, a polynucleotide group that hybridizes with DNA formed by a base sequence complementary to the base sequence under stringent conditions (described later) and a complementary polynucleotide group, and a polynucleotide group comprising 15 or more, preferably 17 or more, consecutive bases in the base sequence of the polynucleotide group. These polynucleotides can be used as nucleic acid probes and primers for detecting the lung cancer marker, which is the target nucleic acid.
[0563] More specifically, examples of nucleic acid probes or primers usable in the present invention are one or more polynucleotides selected from the group consisting of the following polynucleotides (a) to (e).
[0564] (a) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1–125, 127–130, 132–134, and 561–578, or a nucleotide sequence in which u is t in the said nucleotide sequence, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,
[0565] (b) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1–125, 127–130, 132–134, and 561–578,
[0566] (c) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1–125, 127–130, 132–134, and 561–578, or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,
[0567] (d) a nucleotide sequence represented by any one of SEQ ID NOs 1–125, 127–130, 132–134, and 561–578, or a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence in which u is t in the said nucleotide sequence, and
[0568] (e) A polynucleotide that hybridizes with any one of the polynucleotides (a) to (d) under stringent conditions.
[0569] The nucleic acid probe or primer usable in the present invention may further include, in addition to at least one polynucleotide selected from polynucleotides (a) to (e), a polynucleotide selected from the group consisting of polynucleotides shown in (f) to (j) below.
[0570] (f) a polynucleotide consisting of a nucleotide sequence represented by any one of SEQ ID NOs 126, 131 and 579, or a nucleotide sequence in which u is t in said nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
[0571] (g) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 126, 131 and 579,
[0572] (h) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 126, 131 and 579, or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,
[0573] (i) a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 126, 131 and 579, or a base sequence complementary to a base sequence in which u is t, and (j) a polynucleotide hybridized under stringent conditions with any one of (f) to (i).
[0574] The nucleic acid probe or primer available in the present invention may further include a polynucleotide selected from the group consisting of polynucleotides shown in (k) to (o) below, in addition to at least one polynucleotide selected from polynucleotides (a) to (j).
[0575] (k) A polynucleotide consisting of a nucleotide sequence represented by any one of SEQ ID NOs 135 to 174 or a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
[0576] (l) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 135 to 174,
[0577] (m) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 135 to 174, or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,
[0578] (n) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 135 to 174, or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the said nucleotide sequence, and
[0579] (o) A polynucleotide that hybridizes with any one of the above (k) to (n) under stringent conditions.
[0580] In the above polynucleotide, “the fragment containing 15 or more consecutive bases” may include, for example, a number of bases in the base sequence of each polynucleotide in a range of less than the total number of bases of the sequence from 15, less than the total number of bases of the sequence from 17, less than the total number of bases of the sequence from 19, but is not limited to these.
[0581] The polynucleotides or fragments used in the present invention may all be DNA or RNA.
[0582] The polynucleotide usable in the present invention can be produced using general techniques such as DNA recombination technology, PCR method, or a method using an automated DNA / RNA synthesizer.
[0583] DNA recombination technology and PCR methods may be used, for example, those described in Ausubel et al., Current Protocols in Molecular Biology, John Willey & Sons, US (1993); Sambrook et al., Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory Press, US (1989), etc.
[0584] 서열번호 1~174 및 561~579로 나타내어지는 인간 유래의 hsa-miR-6768-5p, hsa-miR-6836-3p, hsa-miR-6782-5p, hsa-miR-3663-3p, hsa-miR-1908-3p, hsa-miR-6726-5p, hsa-miR-4258, hsa-miR-1343-3p, hsa-miR-4516, hsa-miR-6875-5p, hsa-miR-4651, hsa-miR-6825-5p, hsa-miR-6840-3p, hsa-miR-6780b-5p, hsa-miR-6749-5p, hsa-miR-8063, hsa-miR-6784-5p, hsa-miR-3679-5p, hsa-miR-3184-5p, hsa-miR-663b, hsa-miR-6880-5p, hsa-miR-1908-5p, hsa-miR-92a-2-5p, hsa-miR-7975, hsa-miR-7110-5p, hsa-miR-6842-5p, hsa-miR-6857-5p, hsa-miR-5572, hsa-miR-3197, hsa-miR-6131, hsa-miR-6889-5p hsa-miR-4454, hsa-miR-1199-5p, hsa-miR-1247-3p, hsa-miR-6800-5p, hsa-miR-6872-3p, hsa-miR-4649-5p, hsa-miR-6791-5p, hsa-miR-4433b-3p, hsa-miR-3135b, hsa-miR-128-2-5p, hsa-miR-4675, hsa-miR-4472, hsa-miR-6785-5p, hsa-miR-6741-5p, hsa-miR-7977, hsa-miR-3665, hsa-miR-128-1-5p, hsa-miR-4286 hsa-miR-6765-3p, hsa-miR-4632-5p, hsa-miR-365a-5p, hsa-miR-6088, hsa-miR-6816-5p, hsa-miR-6885-5p, hsa-miR-711, hsa-miR-6765-5p, hsa-miR-3180, hsa-miR-4442, hsa-miR-4792,hsa-miR-6721-5p, hsa-miR-6798-5p, hsa-miR-3162-5p, hsa-miR-6126, hsa-miR-4758-5p, hsa-miR-2392, hsa-miR-486-3p, hsa-miR-6727-5p, hsa-miR-4728-5p, hsa-miR-6746-5p, hsa-miR-4270, hsa-miR-3940-5p, hsa-miR-4725-3p, hsa-miR-7108-5p, hsa-miR-3656, hsa-miR-6879-5p, hsa-miR-6738-5p, hsa-miR-1260a hsa-miR-4446-3p, hsa-miR-3131, hsa-miR-4463, hsa-miR-3185, hsa-miR-6870-5p, hsa-miR-6779-5p, hsa-miR-1273g-3p, hsa-miR-8059, hsa-miR-4697-5p, hsa-miR-4674, hsa-miR-4433-3p, hsa-miR-4257, hsa-miR-1915-5p, hsa-miR-4417, hsa-miR-1343-5p, hsa-miR-6781-5p, hsa-miR-4695-5p, hsa-miR-1237-5p, hsa-miR-6775-5p hsa-miR-7845-5p, hsa-miR-4746-3p, hsa-miR-7641, hsa-miR-7847-3p, hsa-miR-6806-5p, hsa-miR-4467, hsa-miR-4726-5p, hsa-miR-4648, hsa-miR-6089, hsa-miR-1260b, hsa-miR-4532, hsa-miR-5195-3p, hsa-miR-3188, hsa-miR-6848-5p, hsa-miR-1233-5p, hsa-miR-6717-5p, hsa-miR-3195, hsa-miR-6757-5p, hsa-miR-8072 hsa-miR-4745-5p, hsa-miR-6511a-5p, hsa-miR-6776-5p, hsa-miR-371a-5p, hsa-miR-1227-5p, hsa-miR-7150,hsa-miR-1915-3p, hsa-miR-187-5p, hsa-miR-614, hsa-miR-19b-3p, hsa-miR-1225-5p, hsa-miR-451a, hsa-miR-939-5p, hsa-miR-223-3p, hsa-miR-1228-5p, hsa-miR-125a-3p, hsa-miR-92b-5p, hsa-miR-22-3p, hsa-miR-6073, hsa-miR-6845-5p, hsa-miR-6769b-5p, hsa-miR-4665-3p, hsa-miR-1913, hsa-miR-1228-3p, hsa-miR-940 hsa-miR-296-3p, hsa-miR-4690-5p, hsa-miR-548q, hsa-miR-663a, hsa-miR-1249, hsa-miR-1202, hsa-miR-7113-3p, hsa-miR-1225-3p, hsa-miR-4783-3p, hsa-miR-4448, hsa-miR-4534, hsa-miR-1307-3p, hsa-miR-4271, hsa-miR-642b-3p, hsa-miR-6075, hsa-miR-6125, hsa-miR-887-3p, hsa-miR-6851-5p, hsa-miR-6763-5p hsa-miR-3928-3p, hsa-miR-4443, hsa-miR-3648, hsa-miR-149-3p, hsa-miR-4689, hsa-miR-4763-3p, hsa-miR-6729-5p, hsa-miR-3196, hsa-miR-8069, hsa-miR-1268a, hsa-miR-4739, hsa-miR-1268b, hsa-miR-5698, hsa-miR-6752-5p, hsa-miR-4507, hsa-miR-564, hsa-miR-4497, hsa-miR-6877-5p, hsa-miR-6087, hsa-miR-4731-5p hsa-miR-615-5p, hsa-miR-760, hsa-miR-6891-5p, hsa-miR-6887-5p, hsa-miR-4525, hsa-miR-1914-3p,hsa-miR-619-5p, hsa-miR-5001-5p, hsa-miR-6722-3p, hsa-miR-3621, hsa-miR-4298, hsa-miR-675-5p, and hsa-miR-4655-5p are known, and as described above, the method of obtaining them is also known. Therefore, by cloning these genes, polynucleotides that can be used as nucleic acid probes or primers in the present invention can be produced.
[0585] Such nucleic acid probes or primers can be chemically synthesized using an automated DNA synthesis device. The phosphoramidite method is generally used for this synthesis, and this method allows for the automated synthesis of single-stranded DNA up to about 100 bases. Automated DNA synthesis devices are commercially available from, for example, Polygen, ABI, and Applied BioSystems.
[0586] Alternatively, the polynucleotide of the present invention can be produced by cDNA cloning. For example, the microRNA Cloning Kit Wako can be used as the cDNA cloning technology.
[0587] Here, the sequences of the nucleic acid probe and primer for detecting a polynucleotide consisting of any one of the base sequences represented by SEQ ID NOs 1 to 174 and 561 to 579 do not exist in vivo as miRNA or its precursors. For example, the base sequences represented by SEQ ID NOs 5 and 22 are generated from the precursor represented by SEQ ID NO. 179, but this precursor has a hairpin-shaped structure as shown in FIG. 1, and the base sequences represented by SEQ ID NOs 5 and 22 have mismatched sequences. Likewise, a base sequence that is entirely complementary to the base sequence represented by SEQ ID NO. 5 or SEQ ID NO. 22 is not naturally generated in vivo. For this reason, the nucleic acid probe and primer for detecting the base sequences represented by any one of SEQ ID NOs 1 to 174 and 561 to 579 have artificial base sequences that do not exist in vivo.
[0588] 3. Kit or device for detecting lung cancer
[0589] The present invention provides a kit or device for detecting lung cancer comprising one or more polynucleotides (which may further include variants, fragments, or derivatives; hereinafter referred to as detection polynucleotides) that can be used as nucleic acid probes or primers for measuring target nucleic acids that are lung cancer markers.
[0590] For more information, please see: hsa-miR-6768-5p, hsa-miR-6836-3p, hsa-miR-6782-5p, hsa-miR-3663-3p, hsa-miR-1908-3p, hsa-miR-6726-5p, hsa-miR-4258, hsa-miR-1343-3p, hsa-miR-4516, hsa-miR-6875-5p, hsa-miR-4651, hsa-miR-6825-5p, hsa-miR-6840-3p, hsa-miR-6780b-5p, hsa-miR-6749-5p, hsa-miR-8063, hsa-miR-6784-5p, hsa-miR-3679-5p, hsa-miR-3184-5p, hsa-miR-663b, hsa-miR-6880-5p, hsa-miR-1908-5p, hsa-miR-92a-2-5p, hsa-miR-7975, hsa-miR-7110-5p, hsa-miR-6842-5p, hsa-miR-6857-5p hsa-miR-5572, hsa-miR-3197, hsa-miR-6131, hsa-miR-6889-5p, hsa-miR-4454, hsa-miR-1199-5p, hsa-miR-1247-3p, hsa-miR-6800-5p, hsa-miR-6872-3p, hsa-miR-4649-5p, hsa-miR-6791-5p, hsa-miR-4433b-3p, hsa-miR-3135b, hsa-miR-128-2-5p, hsa-miR-4675, hsa-miR-4472, hsa-miR-6785-5p, hsa-miR-6741-5p, hsa-miR-7977 hsa-miR-3665, hsa-miR-128-1-5p, hsa-miR-4286, hsa-miR-6765-3p, hsa-miR-4632-5p, hsa-miR-365a-5p, hsa-miR-6088, hsa-miR-6816-5p, hsa-miR-6885-5p, hsa-miR-711, hsa-miR-6765-5p, hsa-miR-3180, hsa-miR-4442,hsa-miR-4792, hsa-miR-6721-5p, hsa-miR-6798-5p, hsa-miR-3162-5p, hsa-miR-6126, hsa-miR-4758-5p, hsa-miR-2392, hsa-miR-486-3p, hsa-miR-6727-5p, hsa-miR-4728-5p, hsa-miR-6746-5p, hsa-miR-4270, hsa-miR-3940-5p, hsa-miR-4725-3p, hsa-miR-7108-5p, hsa-miR-3656, hsa-miR-6879-5p, hsa-miR-6738-5p hsa-miR-1260a, hsa-miR-4446-3p, hsa-miR-3131, hsa-miR-4463, hsa-miR-3185, hsa-miR-6870-5p, hsa-miR-6779-5p, hsa-miR-1273g-3p, hsa-miR-8059, hsa-miR-4697-5p, hsa-miR-4674, hsa-miR-4433-3p, hsa-miR-4257, hsa-miR-1915-5p, hsa-miR-4417, hsa-miR-1343-5p, hsa-miR-6781-5p, hsa-miR-4695-5p, hsa-miR-1237-5p hsa-miR-6775-5p, hsa-miR-7845-5p, hsa-miR-4746-3p, hsa-miR-7641, hsa-miR-7847-3p, hsa-miR-6806-5p, hsa-miR-4467, hsa-miR-4726-5p, hsa-miR-4648, hsa-miR-6089, hsa-miR-1260b, hsa-miR-4532, hsa-miR-5195-3p, hsa-miR-3188, hsa-miR-6848-5p, hsa-miR-1233-5p, hsa-miR-6717-5p, hsa-miR-3195, hsa-miR-6757-5p hsa-miR-8072, hsa-miR-4745-5p, hsa-miR-6511a-5p, hsa-miR-6776-5p, hsa-miR-371a-5p, hsa-miR-1227-5p,hsa-miR-7150, hsa-miR-1915-3p, hsa-miR-187-5p, hsa-miR-614, hsa-miR-1225-5p, hsa-miR-451a, hsa-miR-939-5p, hsa-miR-223-3p, hsa-miR-125a-3p, hsa-miR-92b-5p, hsa-miR-22-3p, hsa-miR-6073, hsa-miR-6845-5p, hsa-miR-6769b-5p, hsa-miR-4665-3p, hsa-miR-1913, hsa-miR-1228-3p, hsa-miR-940, hsa-miR-296-3p, hsa-miR-4690-5p, hsa-miR-548q, hsa-miR-663a, hsa-miR-1249, hsa-miR-1202, hsa-miR-7113-3p, hsa-miR-1225-3p, hsa-miR-4783-3p, hsa-miR-4448, and hsa-miR-4534.,
[0591] In some cases, additional target nucleic acids available for measurement are selected from the following Group 2: hsa-miR-19b-3p, hsa-miR-1228-5p, and hsa-miR-1307-3p.
[0592] In some cases, additional target nucleic acids available for measurement are further selected from the following Group 3: hsa-miR-4271, hsa-miR-642b-3p, hsa-miR-6075, hsa-miR-6125, hsa-miR-887-3p, hsa-miR-6851-5p, hsa-miR-6763-5p, hsa-miR-3928-3p, hsa-miR-4443, hsa-miR-3648, hsa-miR-149-3p, hsa-miR-4689, hsa-miR-4763-3p, hsa-miR-6729-5p, hsa-miR-3196, hsa-miR-8069, hsa-miR-1268a, hsa-miR-4739, hsa-miR-1268b, hsa-miR-5698, hsa-miR-6752-5p, hsa-miR-4507, hsa-miR-564, hsa-miR-4497, hsa-miR-6877-5p, hsa-miR-6087, hsa-miR-4731-5p, hsa-miR-615-5p, hsa-miR-760, hsa-miR-6891-5p, hsa-miR-6887-5p, hsa-miR-4525, hsa-miR-1914-3p, hsa-miR-619-5p, hsa-miR-5001-5p, hsa-miR-6722-3p, hsa-miR-3621, hsa-miR-4298, hsa-miR-675-5p and hsa-miR-4655-5p.
[0593] The kit or device of the present invention comprises a nucleic acid capable of specifically binding to the target nucleic acid, which is the lung cancer marker, preferably a nucleic acid probe or primer described in 2, specifically one or more polynucleotides selected from the polynucleotides described in 2 or variants thereof.
[0594] Specifically, the kit or device of the present invention may include at least one variant or fragment comprising a base sequence represented by any one of SEQ ID NOs 1 to 125, 127 to 130, 132 to 134, and 561 to 578, or a polynucleotide comprising (or composed of) a base sequence in which u is t in said base sequence, a polynucleotide comprising (or composed of) a complementary sequence thereof, a polynucleotide hybridizing with said polynucleotides under stringent conditions, or a variant or fragment comprising 15 or more consecutive bases of said polynucleotide sequences.
[0595] The kit or device of the present invention may further include one or more variants or fragments comprising a base sequence represented by any one of SEQ ID NOs 126 and 131, or a base sequence in which u is t in the base sequence (or composed thereof), a polynucleotide comprising a complementary sequence (or composed thereof), a polynucleotide that hybridizes with the polynucleotides under stringent conditions, or a sequence of 15 or more consecutive bases of the polynucleotide sequences.
[0596] The kit or device of the present invention may further include one or more variants or fragments comprising a base sequence represented by any one of SEQ ID NOs 135 to 174, or a base sequence in which u is t in the base sequence (or composed thereof), a polynucleotide comprising a complementary sequence (or composed thereof), a polynucleotide that hybridizes with the polynucleotides under stringent conditions, or a sequence of 15 or more consecutive bases of the polynucleotide sequences.
[0597] The fragments that may be included in the kit or device of the present invention are, for example, one or more polynucleotides selected from the group consisting of (1) to (3) below, preferably two or more polynucleotides.
[0598] (1) A polynucleotide comprising 15 or more consecutive bases in a base sequence in which u is t in any one of sequence numbers 1 to 125, 127 to 130, 132 to 134 and 561 to 578 or in a sequence complementary thereof.
[0599] (2) A polynucleotide comprising 15 or more consecutive bases in a base sequence in which u is t in any one of sequence numbers 126, 131 and 579 or in a sequence complementary thereof.
[0600] (3) A polynucleotide comprising 15 or more consecutive bases in a base sequence in which u is t in any one of sequence numbers 135 to 174 or in a complementary sequence.
[0601] In a preferred embodiment, the polynucleotide is a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 1 to 125, 127 to 130, 132 to 134, and 561 to 578, or a polynucleotide comprising a base sequence in which u is t in the base sequence, a polynucleotide comprising a sequence complementary thereof, a polynucleotide hybridized under stringent conditions with the polynucleotides, or a variant comprising 15 or more, preferably 17 or more, more preferably 19 or more consecutive bases of the same.
[0602] In addition, in a preferred embodiment, the polynucleotide is a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 126, 134, and 579, or a polynucleotide comprising a base sequence in which u is t in the base sequence, a polynucleotide comprising a sequence complementary thereof, a polynucleotide hybridized under stringent conditions with the polynucleotides thereof, or a variant comprising 15 or more, preferably 17 or more, more preferably 19 or more consecutive bases thereof.
[0603] In addition, in a preferred embodiment, the polynucleotide is a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 135 to 174, or a polynucleotide comprising a base sequence in which u is t in the base sequence, a polynucleotide comprising a sequence complementary thereof, a polynucleotide hybridized under stringent conditions with the polynucleotides, or a variant comprising 15 or more, preferably 17 or more, more preferably 19 or more consecutive bases of the same.
[0604] In a preferred embodiment, the fragment may be a polynucleotide comprising 15 or more, preferably 17 or more, and more preferably 19 or more consecutive bases.
[0605] In the present invention, the size of the fragment of the polynucleotide is a number of bases in the base sequence of each polynucleotide, for example, less than the total number of bases in the sequence from 15 consecutive bases, less than the total number of bases in the sequence from 17 consecutive bases, less than the total number of bases in the sequence from 19 consecutive bases, etc.
[0606] As for the combination of polynucleotides constituting the kit or device of the present invention, specifically, the polynucleotides relating to the combination of sequence numbers shown in Table 1 (sequence numbers 1 to 174 and 561 to 579 corresponding to miRNA markers in Table 1) may be exemplified, but these are merely examples, and all other various possible combinations are included in the present invention.
[0607] For example, in the present invention, as the combination constituting the kit or device for distinguishing between lung cancer and a healthy body, it is preferable to combine two or more of the polynucleotides consisting of the nucleotide sequences represented by the sequence numbers shown in Table 1, and typically, sufficient performance can be obtained with two combinations.
[0608] Specifically, among the two combinations of polynucleotides consisting of base sequences or their complementary sequences for distinguishing between lung cancer and a healthy body, the combination is preferably one that includes at least one newly discovered polynucleotide consisting of base sequences represented by SEQ ID NOs 1 to 174 and 561 to 579.
[0609] In addition, as a combination of polynucleotides having carcinoma specificity capable of distinguishing lung cancer from healthy bodies as well as other cancers, SEQ ID NOs 1, 2, 3, 4, 5, 7, 9, 10, 11, 19, 21, 26, 29, 31, 52, 53, 63, 65, 69, 72, 87, 90, 113, 124, 125, 126, 128, 130, 143, 148, 160, 162, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, A combination of at least one polynucleotide selected from the group consisting of polynucleotides 577, 578, and 579 (hereinafter referred to as "Carcinoma-specific polynucleotide group 1") and a plurality of polynucleotides of other sequence numbers is preferred.
[0610] In addition, as a combination of polynucleotides with carcinoma specificity capable of distinguishing lung cancer from other cancers as well as healthy bodies, a combination of multiple polynucleotides selected from carcinoma-specific polynucleotide group 1 is more preferable.
[0611] In addition, among the combinations of multiple polynucleotides selected from the carcinoma-specific polynucleotide group 1, which can distinguish lung cancer from other cancers as well as from other cancers, a combination comprising at least one polynucleotide selected from the group consisting of polynucleotides of SEQ ID NOs 1, 2, 3, 10, 63, 113, 124, 125, 126, 128, 130, 143, 160, 561, 568, 573, and 578 included in the carcinoma-specific polynucleotide group 1 (hereinafter, this group is referred to as "carcinoma-specific polynucleotide group 2") is more preferable.
[0612] The number of combinations of the above-mentioned polynucleotides with cancer-specificity can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more, but more preferably there are 4 or more combinations, and typically, sufficient performance can be obtained with 4 combinations.
[0613] Below are examples of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 1 or its complementary sequence, which are not limited to polynucleotides, and five polynucleotides selected from carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 1 or its complementary sequence.
[0614] (1) Combination of sequence numbers 1, 53, 113, 125 (markers: hsa-miR-6768-5p, hsa-miR-6088, hsa-miR-6717-5p, hsa-miR-614)
[0615] (2) Combinations of sequence numbers 1, 10, 63, 113 (markers: hsa-miR-6768-5p, hsa-miR-6875-5p, hsa-miR-3162-5p, hsa-miR-6717-5p)
[0616] (3) Combination of sequence numbers 1, 19, 113, 143 (markers: hsa-miR-6768-5p, hsa-miR-3184-5p, hsa-miR-6717-5p, hsa-miR-4443)
[0617] (4) Combinations of sequence numbers 1, 10, 113, 126 (markers: hsa-miR-6768-5p, hsa-miR-6875-5p, hsa-miR-6717-5p, hsa-miR-19b-3p)
[0618] (5) Combination of sequence numbers 1, 2, 10, 113 (markers: hsa-miR-6768-5p, hsa-miR-6836-3p, hsa-miR-6875-5p, hsa-miR-6717-5p)
[0619] In addition, examples are provided of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 2 or its complementary sequence, and five polynucleotides selected from the carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 2 or its complementary sequence.
[0620] (1) Combination of sequence numbers 2, 19, 53, 113 (markers: hsa-miR-6836-3p, hsa-miR-3184-5p, hsa-miR-6088, hsa-miR-6717-5p)
[0621] (2) Combination of sequence numbers 2, 72, 113, 125 (markers: hsa-miR-6836-3p, hsa-miR-3940-5p, hsa-miR-6717-5p, hsa-miR-614)
[0622] (3) Combination of sequence numbers 2, 19, 72, 113 (markers: hsa-miR-6836-3p, hsa-miR-3184-5p, hsa-miR-3940-5p, hsa-miR-6717-5p)
[0623] (4) Combination of sequence numbers 2, 19, 113, 579 (markers: hsa-miR-6836-3p, hsa-miR-3184-5p, hsa-miR-6717-5p, hsa-miR-1307-3p)
[0624] (5) Combination of sequence numbers 1, 2, 19, 113 (markers: hsa-miR-6768-5p, hsa-miR-6836-3p, hsa-miR-3184-5p, hsa-miR-6717-5p)
[0625] In addition, examples are provided of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 3 or its complementary sequence, and five polynucleotides selected from the carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 5 or its complementary sequence.
[0626] (1) Combination of sequence numbers 3, 125, 128, 568 (markers: hsa-miR-6782-5p, hsa-miR-614, hsa-miR-451a, hsa-miR-296-3p)
[0627] (2) Combinations of sequence numbers 1, 3, 10, 113 (markers: hsa-miR-6768-5p, hsa-miR-6782-5p, hsa-miR-6875-5p, hsa-miR-6717-5p)
[0628] (3) Combination of sequence numbers 3, 113, 125, 126 (markers: hsa-miR-6782-5p, hsa-miR-6717-5p, hsa-miR-614, hsa-miR-19b-3p)
[0629] (4) Combination of sequence numbers 1, 3, 126, 573 (markers: hsa-miR-6768-5p, hsa-miR-6782-5p, hsa-miR-19b-3p, hsa-miR-1202)
[0630] (5) Combination of sequence numbers 3, 126, 130, 561 (markers: hsa-miR-6782-5p, hsa-miR-19b-3p, hsa-miR-223-3p, hsa-miR-6073)
[0631] In addition, examples are provided of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 10 or its complementary sequence, and five polynucleotides selected from the carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 10 or its complementary sequence.
[0632] (1) Combination of sequence numbers 1, 10, 113, 143 (markers: hsa-miR-6768-5p, hsa-miR-6875-5p, hsa-miR-6717-5p, hsa-miR-4443)
[0633] (2) Combinations of sequence numbers 1, 10, 113, 569 (markers: hsa-miR-6768-5p, hsa-miR-6875-5p, hsa-miR-6717-5p, hsa-miR-4690-5p)
[0634] (3) Combinations of sequence numbers 1, 10, 113, 562 (markers: hsa-miR-6768-5p, hsa-miR-6875-5p, hsa-miR-6717-5p, hsa-miR-6845-5p)
[0635] (4) Combination of sequence numbers 1, 10, 113, 578 (markers: hsa-miR-6768-5p, hsa-miR-6875-5p, hsa-miR-6717-5p, hsa-miR-4534)
[0636] (5) Combination of sequence numbers 1, 7, 10, 113 (markers: hsa-miR-6768-5p, hsa-miR-4258, hsa-miR-6875-5p, hsa-miR-6717-5p)
[0637] In addition, examples are provided of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 63 or its complementary sequence, and five polynucleotides selected from carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 63 or its complementary sequence.
[0638] (1) Combination of sequence numbers 1, 63, 567, 578 (markers: hsa-miR-6768-5p, hsa-miR-3162-5p, hsa-miR-940, hsa-miR-4534)
[0639] (2) Combination of sequence numbers 1, 53, 63, 578 (markers: hsa-miR-6768-5p, hsa-miR-6088, hsa-miR-3162-5p, hsa-miR-4534)
[0640] (3) Combination of sequence numbers 1, 63, 162, 573 (markers: hsa-miR-6768-5p, hsa-miR-3162-5p, hsa-miR-615-5p, hsa-miR-1202)
[0641] (4) Combination of sequence numbers 1, 63, 162, 578 (markers: hsa-miR-6768-5p, hsa-miR-3162-5p, hsa-miR-615-5p, hsa-miR-4534)
[0642] (5) Combination of sequence numbers 1, 63, 576, 578 (markers: hsa-miR-6768-5p, hsa-miR-3162-5p, hsa-miR-4783-3p, hsa-miR-4534)
[0643] In addition, examples are provided of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 113 or its complementary sequence, and five polynucleotides selected from carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 113 or its complementary sequence.
[0644] (1) Combination of sequence numbers 1, 10, 113, 567 (markers: hsa-miR-6768-5p, hsa-miR-6875-5p, hsa-miR-6717-5p, hsa-miR-940)
[0645] (2) Combinations of sequence numbers 1, 53, 63, 113 (markers: hsa-miR-6768-5p, hsa-miR-6088, hsa-miR-3162-5p, hsa-miR-6717-5p)
[0646] (3) Combination of sequence numbers 1, 53, 113, 143 (markers: hsa-miR-6768-5p, hsa-miR-6088, hsa-miR-6717-5p, hsa-miR-4443)
[0647] (4) Combination of sequence numbers 2, 19, 113, 125 (markers: hsa-miR-6836-3p, hsa-miR-3184-5p, hsa-miR-6717-5p, hsa-miR-614)
[0648] (5) Combination of sequence numbers 2, 10, 113, 130 (markers: hsa-miR-6836-3p, hsa-miR-6875-5p, hsa-miR-6717-5p, hsa-miR-223-3p)
[0649] In addition, examples are provided of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 124 or its complementary sequence, and five polynucleotides selected from carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 124 or its complementary sequence.
[0650] (1) Combination of sequence numbers 113, 124, 125, 126 (markers: hsa-miR-6717-5p, hsa-miR-187-5p, hsa-miR-614, hsa-miR-19b-3p)
[0651] (2) Combinations of sequence numbers 124, 125, 128, 568 (markers: hsa-miR-187-5p, hsa-miR-614, hsa-miR-451a, hsa-miR-296-3p)
[0652] (3) Combinations of sequence numbers 113, 124, 125, 162 (markers: hsa-miR-6717-5p, hsa-miR-187-5p, hsa-miR-614, hsa-miR-615-5p)
[0653] (4) Combination of sequence numbers 52, 124, 126, 561 (markers: hsa-miR-365a-5p, hsa-miR-187-5p, hsa-miR-19b-3p, hsa-miR-6073)
[0654] (5) Combination of sequence numbers 19, 113, 124, 126 (markers: hsa-miR-3184-5p, hsa-miR-6717-5p, hsa-miR-187-5p, hsa-miR-19b-3p)
[0655] In addition, examples are provided of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 125 or its complementary sequence, and five polynucleotides selected from the carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 125 or its complementary sequence.
[0656] (1) Combination of sequence numbers 1, 113, 125, 160 (markers: hsa-miR-6768-5p, hsa-miR-6717-5p, hsa-miR-614, hsa-miR-6087)
[0657] (2) Combination of sequence numbers 31, 113, 125, 568 (markers: hsa-miR-6889-5p, hsa-miR-6717-5p, hsa-miR-614, hsa-miR-296-3p)
[0658] (3) Combination of sequence numbers 2, 53, 113, 125 (markers: hsa-miR-6836-3p, hsa-miR-6088, hsa-miR-6717-5p, hsa-miR-614)
[0659] (4) Combinations of sequence numbers 1, 10, 113, 125 (markers: hsa-miR-6768-5p, hsa-miR-6875-5p, hsa-miR-6717-5p, hsa-miR-614)
[0660] (5) Combination of sequence numbers 1, 113, 125, 143 (markers: hsa-miR-6768-5p, hsa-miR-6717-5p, hsa-miR-614, hsa-miR-4443)
[0661] In addition, examples are provided of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 126 or its complementary sequence, and five polynucleotides selected from carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 126 or its complementary sequence.
[0662] (1) Combination of sequence numbers 1, 126, 561, 573 (markers: hsa-miR-6768-5p, hsa-miR-19b-3p, hsa-miR-6073, hsa-miR-1202)
[0663] (2) Combinations of sequence numbers 113, 125, 126, 568 (markers: hsa-miR-6717-5p, hsa-miR-614, hsa-miR-19b-3p, hsa-miR-296-3p)
[0664] (3) Combination of sequence numbers 113, 125, 126, 561 (markers: hsa-miR-6717-5p, hsa-miR-614, hsa-miR-19b-3p, hsa-miR-6073)
[0665] (4) Combination of sequence numbers 1, 113, 125, 126 (markers: hsa-miR-6768-5p, hsa-miR-6717-5p, hsa-miR-614, hsa-miR-19b-3p)
[0666] (5) Combination of sequence numbers 1, 52, 126, 561 (markers: hsa-miR-6768-5p, hsa-miR-365a-5p, hsa-miR-19b-3p, hsa-miR-6073)
[0667] In addition, examples are provided of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 128 or its complementary sequence, and five polynucleotides selected from carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 128 or its complementary sequence.
[0668] (1) Combination of sequence numbers 26, 113, 125, 128 (markers: hsa-miR-6842-5p, hsa-miR-6717-5p, hsa-miR-614, hsa-miR-451a)
[0669] (2) Combination of sequence numbers 1, 113, 125, 128 (markers: hsa-miR-6768-5p, hsa-miR-6717-5p, hsa-miR-614, hsa-miR-451a)
[0670] (3) Combinations of sequence numbers 1, 10, 113, 128 (markers: hsa-miR-6768-5p, hsa-miR-6875-5p, hsa-miR-6717-5p, hsa-miR-451a)
[0671] (4) Combination of sequence numbers 31, 113, 125, 128 (markers: hsa-miR-6889-5p, hsa-miR-6717-5p, hsa-miR-614, hsa-miR-451a)
[0672] (5) Combination of sequence numbers 2, 19, 113, 128 (markers: hsa-miR-6836-3p, hsa-miR-3184-5p, hsa-miR-6717-5p, hsa-miR-451a)
[0673] In addition, examples are provided of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 130 or its complementary sequence, and five polynucleotides selected from carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 130 or its complementary sequence.
[0674] (1) Combination of sequence numbers 1, 3, 130, 143 (markers: hsa-miR-6768-5p, hsa-miR-6782-5p, hsa-miR-223-3p, hsa-miR-4443)
[0675] (2) Combinations of sequence numbers 1, 10, 113, 130 (markers: hsa-miR-6768-5p, hsa-miR-6875-5p, hsa-miR-6717-5p, hsa-miR-223-3p)
[0676] (3) Combination of sequence numbers 1, 63, 130, 578 (markers: hsa-miR-6768-5p, hsa-miR-3162-5p, hsa-miR-223-3p, hsa-miR-4534)
[0677] (4) Combinations of sequence numbers 124, 125, 130, 568 (markers: hsa-miR-187-5p, hsa-miR-614, hsa-miR-223-3p, hsa-miR-296-3p)
[0678] (5) Combination of sequence numbers 2, 19, 113, 130 (markers: hsa-miR-6836-3p, hsa-miR-3184-5p, hsa-miR-6717-5p, hsa-miR-223-3p)
[0679] In addition, examples are provided of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 143 or its complementary sequence, and five polynucleotides selected from carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 143 or its complementary sequence.
[0680] (1) Combination of sequence numbers 1, 3, 126, 143 (markers: hsa-miR-6768-5p, hsa-miR-6782-5p, hsa-miR-19b-3p, hsa-miR-4443)
[0681] (2) Combination of sequence numbers 1, 63, 130, 143 (markers: hsa-miR-6768-5p, hsa-miR-3162-5p, hsa-miR-223-3p, hsa-miR-4443)
[0682] (3) Combinations of sequence numbers 1, 10, 52, 143 (markers: hsa-miR-6768-5p, hsa-miR-6875-5p, hsa-miR-365a-5p, hsa-miR-4443)
[0683] (4) Combination of sequence numbers 2, 19, 113, 143 (markers: hsa-miR-6836-3p, hsa-miR-3184-5p, hsa-miR-6717-5p, hsa-miR-4443)
[0684] (5) Combination of sequence numbers 63, 124, 130, 143 (markers: hsa-miR-3162-5p, hsa-miR-187-5p, hsa-miR-223-3p, hsa-miR-4443)
[0685] In addition, examples are provided of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 160 or its complementary sequence, and five polynucleotides selected from carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 160 or its complementary sequence.
[0686] (1) Combination of sequence numbers 1, 10, 113, 160 (markers: hsa-miR-6768-5p, hsa-miR-6875-5p, hsa-miR-6717-5p, hsa-miR-6087)
[0687] (2) Combination of sequence numbers 7, 113, 125, 160 (markers: hsa-miR-4258, hsa-miR-6717-5p, hsa-miR-614, hsa-miR-6087)
[0688] (3) Combination of sequence numbers 1, 113, 160, 567 (markers: hsa-miR-6768-5p, hsa-miR-6717-5p, hsa-miR-6087, hsa-miR-940)
[0689] (4) Combination of sequence numbers 1, 113, 160, 578 (markers: hsa-miR-6768-5p, hsa-miR-6717-5p, hsa-miR-6087, hsa-miR-4534)
[0690] (5) Combination of sequence numbers 2, 19, 113, 160 (markers: hsa-miR-6836-3p, hsa-miR-3184-5p, hsa-miR-6717-5p, hsa-miR-6087)
[0691] In addition, examples are provided of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 561 or its complementary sequence, and five polynucleotides selected from carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 561 or its complementary sequence.
[0692] (1) Combination of sequence numbers 113, 125, 130, 561 (markers: hsa-miR-6717-5p, hsa-miR-614, hsa-miR-223-3p, hsa-miR-6073)
[0693] (2) Combination of sequence numbers 7, 126, 143, 561 (markers: hsa-miR-4258, hsa-miR-19b-3p, hsa-miR-4443, hsa-miR-6073)
[0694] (3) Combination of sequence numbers 1, 113, 126, 561 (markers: hsa-miR-6768-5p, hsa-miR-6717-5p, hsa-miR-19b-3p, hsa-miR-6073)
[0695] (4) Combination of sequence numbers 1, 126, 561, 568 (markers: hsa-miR-6768-5p, hsa-miR-19b-3p, hsa-miR-6073, hsa-miR-296-3p)
[0696] (5) Combination of sequence numbers 7, 113, 126, 561 (markers: hsa-miR-4258, hsa-miR-6717-5p, hsa-miR-19b-3p, hsa-miR-6073)
[0697] In addition, examples are provided of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 568 or its complementary sequence, and five polynucleotides selected from carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 568 or its complementary sequence.
[0698] (1) Combination of sequence numbers 7, 125, 126, 568 (markers: hsa-miR-4258, hsa-miR-614, hsa-miR-19b-3p, hsa-miR-296-3p)
[0699] (2) Combinations of sequence numbers 124, 125, 126, 568 (markers: hsa-miR-187-5p, hsa-miR-614, hsa-miR-19b-3p, hsa-miR-296-3p)
[0700] (3) Combination of sequence numbers 7, 113, 125, 568 (markers: hsa-miR-4258, hsa-miR-6717-5p, hsa-miR-614, hsa-miR-296-3p)
[0701] (4) Combination of sequence numbers 1, 113, 125, 568 (markers: hsa-miR-6768-5p, hsa-miR-6717-5p, hsa-miR-614, hsa-miR-296-3p)
[0702] (5) Combination of sequence numbers 113, 125, 128, 568 (markers: hsa-miR-6717-5p, hsa-miR-614, hsa-miR-451a, hsa-miR-296-3p)
[0703] In addition, examples are provided of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 573 or its complementary sequence, and five polynucleotides selected from carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 573 or its complementary sequence.
[0704] (1) Combination of sequence numbers 113, 125, 126, 573 (markers: hsa-miR-6717-5p, hsa-miR-614, hsa-miR-19b-3p, hsa-miR-1202)
[0705] (2) Combination of sequence numbers 1, 113, 125, 573 (markers: hsa-miR-6768-5p, hsa-miR-6717-5p, hsa-miR-614, hsa-miR-1202)
[0706] (3) Combination of sequence numbers 1, 53, 113, 573 (markers: hsa-miR-6768-5p, hsa-miR-6088, hsa-miR-6717-5p, hsa-miR-1202)
[0707] (4) Combination of sequence numbers 1, 124, 126, 573 (markers: hsa-miR-6768-5p, hsa-miR-187-5p, hsa-miR-19b-3p, hsa-miR-1202)
[0708] (5) Combination of sequence numbers 1, 63, 130, 573 (markers: hsa-miR-6768-5p, hsa-miR-3162-5p, hsa-miR-223-3p, hsa-miR-1202)
[0709] In addition, examples are provided of combinations of a polynucleotide consisting of the base sequence represented by SEQ ID NO. 578 or its complementary sequence, and five polynucleotides selected from carcinoma-specific polynucleotide group 1, consisting of the base sequence represented by SEQ ID NO. 578 or its complementary sequence.
[0710] (1) Combination of sequence numbers 1, 126, 567, 578 (markers: hsa-miR-6768-5p, hsa-miR-19b-3p, hsa-miR-940, hsa-miR-4534)
[0711] (2) Combination of sequence numbers 1, 19, 113, 578 (markers: hsa-miR-6768-5p, hsa-miR-3184-5p, hsa-miR-6717-5p, hsa-miR-4534)
[0712] (3) Combination of sequence numbers 31, 126, 561, 578 (markers: hsa-miR-6889-5p, hsa-miR-19b-3p, hsa-miR-6073, hsa-miR-4534)
[0713] (4) Combination of sequence numbers 1, 126, 160, 578 (markers: hsa-miR-6768-5p, hsa-miR-19b-3p, hsa-miR-6087, hsa-miR-4534)
[0714] (5) Combination of sequence numbers 1, 113, 125, 578 (markers: hsa-miR-6768-5p, hsa-miR-6717-5p, hsa-miR-614, hsa-miR-4534)
[0715] The kit or device of the present invention may also include existing polynucleotides or polynucleotides that may be discovered in the future that enable lung cancer detection in addition to the polynucleotides of the present invention described above (which may include variants, fragments, or derivatives).
[0716] In addition to the polynucleotide in the present invention described above, the kit of the present invention may also include an antibody for measuring known lung cancer detection markers such as CEA or CYFRA21-1.
[0717] The polynucleotides included in the kit of the present invention may be packaged individually or in optional combinations in other containers.
[0718] The kit of the present invention may include a kit for extracting nucleic acids (e.g., total RNA) from body fluids, cells, or tissues, a fluorescent labeling substance, an enzyme and culture medium for nucleic acid amplification, instructions for use, etc.
[0719] The device of the present invention is a device for measuring cancer markers in which the nucleic acid, such as the polynucleotide described above in the present invention, is bound or attached, for example, in a solid form. Examples of solid materials include plastic, paper, glass, silicon, etc., and plastic is a preferred solid material due to its ease of processing. The shape of the solid is arbitrary, for example, square, round, strip, film, etc. The device of the present invention includes, for example, a device for measurement using hybridization technology, and specifically, examples include a blotting device, a nucleic acid array (e.g., a microarray, a DNA chip, an RNA chip, etc.).
[0720] Nucleic acid array technology is a technology that fabricates an array, such as a chip, by combining or attaching the nucleic acids one by one using methods such as a high-density dispenser called a spotter or arrayer, which are surface treatments such as L-lysine coating or the introduction of functional groups such as amino groups or carboxyl groups as needed, a method of spotting nucleic acids onto a solid surface using an inkjet that sprays minute droplets from a nozzle using a piezoelectric element, or a method of performing sequential nucleotide synthesis on a solid surface, and measures a target nucleic acid using hybridization with the array.
[0721] The kit or device of the present invention comprises a nucleic acid capable of specifically binding to each of at least one, preferably at least two, more preferably at least three, and most preferably at least five polynucleotides of miRNAs that are lung cancer markers of Group 1. The kit or device of the present invention may, in some cases, further comprise a nucleic acid capable of specifically binding to each of at least one, preferably at least two, more preferably at least three, and most preferably at least five polynucleotides of miRNAs that are lung cancer markers of Group 2. The kit or device of the present invention may, in some cases, further comprise a nucleic acid capable of specifically binding to each of at least one, preferably at least two, more preferably at least three, and most preferably at least five polynucleotides of miRNAs that are lung cancer markers of Group 3.
[0722] The kit or device of the present invention can be used for the detection of lung cancer as described in 4 below.
[0723] 4. Methods for detecting lung cancer
[0724] The present invention also utilizes the kit or device of the present invention described in 3 above (including the nucleic acids available for use in the present invention) to obtain the following group A in a sample: hsa-miR-6768-5p, hsa-miR-6836-3p, hsa-miR-6782-5p, hsa-miR-3663-3p, hsa-miR-1908-3p, hsa-miR-6726-5p, hsa-miR-4258, hsa-miR-1343-3p, hsa-miR-4516, hsa-miR-6875-5p, hsa-miR-4651, hsa-miR-6825-5p, hsa-miR-6840-3p, hsa-miR-6780b-5p, hsa-miR-6749-5p, hsa-miR-8063, hsa-miR-6784-5p, hsa-miR-3679-5p, hsa-miR-3184-5p, hsa-miR-663b, hsa-miR-6880-5p, hsa-miR-1908-5p, hsa-miR-92a-2-5p, hsa-miR-7975, hsa-miR-7110-5p, hsa-miR-6842-5p, hsa-miR-6857-5p, hsa-miR-5572, hsa-miR-3197, hsa-miR-6131, hsa-miR-6889-5p, hsa-miR-4454, hsa-miR-1199-5p, hsa-miR-1247-3p, hsa-miR-6800-5p, hsa-miR-6872-3p, hsa-miR-4649-5p, hsa-miR-6791-5p, hsa-miR-4433b-3p, hsa-miR-3135b, hsa-miR-128-2-5p, hsa-miR-4675, hsa-miR-4472, hsa-miR-6785-5p, hsa-miR-6741-5p, hsa-miR-7977, hsa-miR-3665, hsa-miR-128-1-5p, hsa-miR-4286, hsa-miR-6765-3p, hsa-miR-4632-5p, hsa-miR-365a-5p, hsa-miR-6088, hsa-miR-6816-5p, hsa-miR-6885-5p, hsa-miR-711,hsa-miR-6765-5p, hsa-miR-3180, hsa-miR-4442, hsa-miR-4792, hsa-miR-6721-5p, hsa-miR-6798-5p, hsa-miR-3162-5p, hsa-miR-6126, hsa-miR-4758-5p, hsa-miR-2392, hsa-miR-486-3p, hsa-miR-6727-5p, hsa-miR-4728-5p, hsa-miR-6746-5p, hsa-miR-4270, hsa-miR-3940-5p, hsa-miR-4725-3p, hsa-miR-7108-5p, hsa-miR-3656 hsa-miR-6879-5p, hsa-miR-6738-5p, hsa-miR-1260a, hsa-miR-4446-3p, hsa-miR-3131, hsa-miR-4463, hsa-miR-3185, hsa-miR-6870-5p, hsa-miR-6779-5p, hsa-miR-1273g-3p, hsa-miR-8059, hsa-miR-4697-5p, hsa-miR-4674, hsa-miR-4433-3p, hsa-miR-4257, hsa-miR-1915-5p, hsa-miR-4417, hsa-miR-1343-5p, hsa-miR-6781-5p hsa-miR-4695-5p, hsa-miR-1237-5p, hsa-miR-6775-5p, hsa-miR-7845-5p, hsa-miR-4746-3p, hsa-miR-7641, hsa-miR-7847-3p, hsa-miR-6806-5p, hsa-miR-4467, hsa-miR-4726-5p, hsa-miR-4648, hsa-miR-6089, hsa-miR-1260b, hsa-miR-4532, hsa-miR-5195-3p, hsa-miR-3188, hsa-miR-6848-5p, hsa-miR-1233-5p, hsa-miR-6717-5p hsa-miR-3195, hsa-miR-6757-5p, hsa-miR-8072, hsa-miR-4745-5p, hsa-miR-6511a-5p,hsa-miR-6776-5p, hsa-miR-371a-5p, hsa-miR-1227-5p, hsa-miR-7150, hsa-miR-1915-3p, hsa-miR-187-5p, hsa-miR-614, hsa-miR-1225-5p, hsa-miR-451a, hsa-miR-939-5p, hsa-miR-223-3p, hsa-miR-125a-3p, hsa-miR-92b-5p, hsa-miR-22-3p, hsa-miR-6073, hsa-miR-6845-5p, hsa-miR-6769b-5p, hsa-miR-4665-3p, hsa-miR-1913, Expression levels of lung cancer-derived genes selected from hsa-miR-1228-3p, hsa-miR-940, hsa-miR-296-3p, hsa-miR-4690-5p, hsa-miR-548q, hsa-miR-663a, hsa-miR-1249, hsa-miR-1202, hsa-miR-7113-3p, hsa-miR-1225-3p, hsa-miR-4783-3p, hsa-miR-4448, and hsa-miR-4534, and in some cases, the expression levels of lung cancer-derived genes selected from the following group B: hsa-miR-19b-3p, hsa-miR-1228-5p, and hsa-miR-1307-3p, and in some cases, the following group C: hsa-miR-4271, hsa-miR-642b-3p, hsa-miR-6075, hsa-miR-6125, hsa-miR-887-3p, hsa-miR-6851-5p, hsa-miR-6763-5p, hsa-miR-3928-3p, hsa-miR-4443, hsa-miR-3648, hsa-miR-149-3p, hsa-miR-4689, hsa-miR-4763-3p, hsa-miR-6729-5p, hsa-miR-3196, hsa-miR-8069, hsa-miR-1268a, hsa-miR-4739, hsa-miR-1268b, hsa-miR-5698, hsa-miR-6752-5p, hsa-miR-4507, hsa-miR-564, hsa-miR-4497,Measure in vitro the expression levels of one or more lung cancer-derived genes selected from hsa-miR-6877-5p, hsa-miR-6087, hsa-miR-4731-5p, hsa-miR-615-5p, hsa-miR-760, hsa-miR-6891-5p, hsa-miR-6887-5p, hsa-miR-4525, hsa-miR-1914-3p, hsa-miR-619-5p, hsa-miR-5001-5p, hsa-miR-6722-3p, hsa-miR-3621, hsa-miR-4298, hsa-miR-675-5p, and hsa-miR-4655-5p, and also [individuals] suspected of having lung cancer A method for detecting lung cancer is provided, comprising evaluating that a subject has lung cancer by comparing the expression levels of the gene in a sample and a control expression level of a healthy person (including non-lung cancer patients) with the expression levels of the gene in the sample and, for example, comparing the two expression levels, if there is a statistically significant difference in the expression level of the target nucleic acid in the sample.
[0725] The above method of the present invention enables early diagnosis of cancer with high sensitivity and specificity in a low-invasive manner, thereby leading to early treatment and improvement of prognosis, and also enables monitoring of disease progression or monitoring of the effectiveness of surgical, radiotherapeutic, and chemical treatments.
[0726] In the method for extracting lung cancer-derived genes from specimens such as blood, serum, and plasma according to the present invention, it is particularly preferable to prepare the solution by adding the RNA extraction reagent from the 3D-Gene (registered trademark) RNA extraction reagent from liquid sample kit (Toray Kabushiki Kaisha), but the general acidic phenol method (Acid Guanidinium-Phenol-Chloroform (AGPC) method) may be used, or Trizol (registered trademark) (Life Technologies Co., Ltd.) may be used, or the solution may be prepared by adding an RNA extraction reagent containing acidic phenol such as Trizol (Life Technologies Co., Ltd.) or Isogen (Nipponjin Co., Ltd.). In addition, kits such as the miRNeasy (registered trademark) Mini Kit (Qiagen Co., Ltd.) may be used, but the method is not limited to these methods.
[0727] The present invention also provides the use of the kit or device of the present invention for the in vitro detection of expression products of miRNA genes derived from lung cancer in specimens derived from subjects.
[0728] In the above method of the present invention, the kit or device is used to comprise a polynucleotide available in the present invention as described above, either as a single one or in any possible combination.
[0729] In the detection or (genetic) diagnosis of lung cancer according to the present invention, the polynucleotide included in the kit or device of the present invention may be used as a probe or primer. When used as a primer, the TaqMan (registered trademark) MicroRNA Assays of Life Technologies, the miScript PCR System of Qiagen, etc., may be used, but are not limited to these methods.
[0730] The polynucleotide included in the kit or device of the present invention can be used as a primer or probe according to a normal method in known methods for specifically detecting specific genes, such as the Northern blot method, the Southern blot method, hybridization techniques such as in situ hybridization, Northern hybridization, and Southern hybridization, and quantitative amplification techniques such as quantitative RT-PCR. As a sample to be measured, body fluids such as blood, serum, plasma, or urine of a subject are collected depending on the type of detection method used. Alternatively, total RNA prepared by the above method may be used in such body fluids, or various polynucleotides including cDNA prepared based on said RNA may be used.
[0731] The kit or device of the present invention is useful for diagnosing lung cancer or detecting the presence or absence of the disease. Specifically, the detection of lung cancer using the kit or device can be performed by using a specimen such as blood, serum, plasma, or urine from a subject suspected of having lung cancer, and by detecting in vitro the expression level of a gene detected by a nucleic acid probe or primer included in the kit or device. If the expression level of a target miRNA marker measured by a polynucleotide (including variants, fragments, or derivatives thereof) consisting of at least one of SEQ ID NOs 1 to 125, 127 to 130, 132 to 134, and 561 to 578 in specimens such as blood, serum, plasma, or urine of a subject suspected of having lung cancer, or a sequence or its complementary sequence, and in some cases, one or more of SEQ ID NOs 126 and 131 or their complementary sequence, and in some cases, one or more of SEQ ID NOs 135 to 174 or their complementary sequence, is statistically significantly different from the expression level of the marker in specimens such as blood, serum, plasma, or urine of a healthy subject, the subject may be evaluated as having lung cancer.
[0732] The method of the present invention can be combined with imaging diagnostic methods such as CT scans, MRI scans, and PET scans in addition to chest X-ray examinations. The method of the present invention makes it possible to specifically detect lung cancer and to substantially distinguish cancers other than lung cancer.
[0733] A method for detecting that a sample containing a product of expression of a gene derived from lung cancer does not contain such a product, or contains such a product, includes collecting a body fluid such as blood, serum, plasma, or urine from a subject, and measuring the expression amount of a target gene contained therein using a single or multiple polynucleotides selected from the polynucleotide group of the present invention (including variants, fragments, or derivatives) to evaluate the presence or absence of lung cancer or to detect lung cancer. Furthermore, using the lung cancer detection method of the present invention, the presence or absence of improvement of the disease or the degree of improvement can be evaluated or diagnosed, for example, in the case where a therapeutic drug is administered to a lung cancer patient to improve the disease.
[0734] The method of the present invention is, for example, steps (a), (b), and (c) below:
[0735] (a) a step of contacting a sample derived from a subject with a polynucleotide in the kit or device of the present invention in vitro,
[0736] (b) a step of measuring the expression level of a target nucleic acid in a sample using the polynucleotide as a nucleic acid probe or primer,
[0737] (c)(b) may include a step of evaluating the presence or absence of lung cancer (cells) among the subjects based on the results of (c)(b).
[0738] 구체적으로는, 본 발명은 miR-6768-5p, miR-6836-3p, miR-6782-5p, miR-3663-3p, miR-1908-3p, miR-6726-5p, miR-4258, miR-1343-3p, miR-4516, miR-6875-5p, miR-4651, miR-6825-5p, miR-6840-3p, miR-6780b-5p, miR-6749-5p, miR-8063, miR-6784-5p, miR-3679-5p, miR-3184-5p, miR-663b, miR-6880-5p, miR-1908-5p, miR-92a-2-5p, miR-7975, miR-7110-5p, miR-6842-5p, miR-6857-5p, miR-5572, miR-3197, miR-6131, miR-6889-5p, miR-4454, miR-1199-5p, miR-1247-3p, miR-6800-5p, miR-6872-3p, miR-4649-5p, miR-6791-5p, miR-4433b-3p, miR-3135b, miR-128-2-5p, miR-4675, miR-4472, miR-6785-5p miR-6741-5p, miR-7977, miR-3665, miR-128-1-5p, miR-4286, miR-6765-3p, miR-4632-5p, miR-365a-5p, miR-6088, miR-6816-5p, miR-6885-5p, miR-711, miR-6765-5p, miR-3180, miR-4442, miR-4792, miR-6721-5p, miR-6798-5p, miR-3162-5p, miR-6126, miR-4758-5p, miR-2392, miR-486-3p, miR-6727-5p, miR-4728-5p miR-6746-5p, miR-4270, miR-3940-5p, miR-4725-3p, miR-7108-5p, miR-3656, miR-6879-5p, miR-6738-5p, miR-1260a, miR-4446-3p, miR-3131, miR-4463, miR-3185,miR-6870-5p,miR-6779-5p,miR-1273g-3p,miR-8059,miR-4697-5p,miR-4674,miR-4433-3p,miR-4257,miR-1915-5p,miR-4417,miR-1343-5p,miR-6781-5p, miR-4695-5p,miR-1237-5p,miR-6775-5p,miR-7845-5p,miR-4746-3p,miR-7641,miR-7847-3p,miR-6806-5p,miR-4467,miR-4726-5p,miR-4648,miR-6089, miR-1260b,miR-4532,miR-5195-3p,miR-3188,miR-6848-5p,miR-1233-5p,miR-6717-5p,miR-3195,miR-6757-5p,miR-8072,miR-4745-5p,miR-6511a-5p,miR-6776-5p, miR-371a-5p,miR-1227-5p,miR-7150,miR-1915-3p,miR-187-5p,miR-614,miR-1225-5p,miR-451a,miR-939-5p,miR-223-3p,miR-125a-3p, Using a nucleic acid capable of specifically binding to at least one, preferably at least two, polynucleotides selected from the group consisting of miR-92b-5p, miR-22-3p, miR-6073, miR-6845-5p, miR-6769b-5p, miR-4665-3p, miR-1913, miR-1228-3p, miR-940, miR-296-3p, miR-4690-5p, miR-548q, miR-663a, miR-1249, miR-1202, miR-7113-3p, miR-1225-3p, miR-4783-3p, miR-4448, and miR-4534, the expression level of a target nucleic acid in a subject's sample is measured, and the healthy body measured in the same manner as the measured expression level Using control expression levels, whether the subject is affected by lung cancer,Alternatively, a method for detecting lung cancer is provided, which includes evaluating in vitro whether the patient is not affected by lung cancer.
[0739] In this specification, "evaluation" refers to an evaluation based on the results of an in vitro test, rather than a judgment by a doctor.
[0740] As described above, in a preferred embodiment of the method of the present invention, the target nucleic acid is specifically miR-6768-5p is hsa-miR-6768-5p, miR-6836-3p is hsa-miR-6836-3p, miR-6782-5p is hsa-miR-6782-5p, miR-3663-3p is hsa-miR-3663-3p, miR-1908-3p is hsa-miR-1908-3p, miR-6726-5p is hsa-miR-6726-5p, miR-4258 is hsa-miR-4258, miR-1343-3p is hsa-miR-1343-3p, and miR-4516 is hsa-miR-4516. miR-6875-5p is hsa-miR-6875-5p, miR-4651 is hsa-miR-4651, miR-6825-5p is hsa-miR-6825-5p, miR-6840-3p is hsa-miR-6840-3p, miR-6780b-5p is hsa-miR-6780b-5p, miR-6749-5p is hsa-miR-6749-5p, miR-8063 is hsa-miR-8063, miR-6784-5p is hsa-miR-6784-5p, miR-3679-5p is hsa-miR-3679-5p, and miR-3184-5p is hsa-miR-3184-5p, miR-663b is hsa-miR-663b, miR-6880-5p is hsa-miR-6880-5p, miR-1908-5p is hsa-miR-1908-5p, miR-92a-2-5p is hsa-miR-92a-2-5p, miR-7975 is hsa-miR-7975, miR-7110-5p is hsa-miR-7110-5p, miR-6842-5p is hsa-miR-6842-5p, miR-6857-5p is hsa-miR-6857-5p, miR-5572 is hsa-miR-5572, and miR-3197 is hsa-miR-3197 is, miR-6131 is hsa-miR-6131, miR-6889-5p is hsa-miR-6889-5p, and,miR-4454 is hsa-miR-4454, miR-1199-5p is hsa-miR-1199-5p, miR-1247-3p is hsa-miR-1247-3p, miR-6800-5p is hsa-miR-6800-5p, miR-6872-3p is hsa-miR-6872-3p, miR-4649-5p is hsa-miR-4649-5p, miR-6791-5p is hsa-miR-6791-5p, miR-4433b-3p is hsa-miR-4433b-3p, miR-3135b is hsa-miR-3135b, and miR-128-2-5p is hsa-miR-128-2-5p and miR-4675 is hsa-miR-4675, miR-4472 is hsa-miR-4472, miR-6785-5p is hsa-miR-6785-5p, miR-6741-5p is hsa-miR-6741-5p, miR-7977 is hsa-miR-7977, miR-3665 is hsa-miR-3665, miR-128-1-5p is hsa-miR-128-1-5p, miR-4286 is hsa-miR-4286, miR-6765-3p is hsa-miR-6765-3p, and miR-4632-5p is hsa-miR-4632-5p, miR-365a-5p is hsa-miR-365a-5p, miR-6088 is hsa-miR-6088, miR-6816-5p is hsa-miR-6816-5p, miR-6885-5p is hsa-miR-6885-5p, miR-711 is hsa-miR-711, miR-6765-5p is hsa-miR-6765-5p, miR-3180 is hsa-miR-3180, miR-4442 is hsa-miR-4442, miR-4792 is hsa-miR-4792, miR-6721-5p is hsa-miR-6721-5p, and miR-6798-5p is hsa-miR-6798-5p, miR-3162-5p is hsa-miR-3162-5p, miR-6126 is hsa-miR-6126, andmiR-4758-5p is hsa-miR-4758-5p, miR-2392 is hsa-miR-2392, miR-486-3p is hsa-miR-486-3p, miR-6727-5p is hsa-miR-6727-5p, miR-4728-5p is hsa-miR-4728-5p, miR-6746-5p is hsa-miR-6746-5p, miR-4270 is hsa-miR-4270, miR-3940-5p is hsa-miR-3940-5p, miR-4725-3p is hsa-miR-4725-3p, miR-7108-5p is hsa-miR-7108-5p, and miR-3656 is hsa-miR-3656, miR-6879-5p is hsa-miR-6879-5p, miR-6738-5p is hsa-miR-6738-5p, miR-1260a is hsa-miR-1260a, miR-4446-3p is hsa-miR-4446-3p, miR-3131 is hsa-miR-3131, miR-4463 is hsa-miR-4463, miR-3185 is hsa-miR-3185, miR-6870-5p is hsa-miR-6870-5p, miR-6779-5p is hsa-miR-6779-5p, and miR-1273g-3p is hsa-miR-1273g-3p, miR-8059 is hsa-miR-8059, miR-4697-5p is hsa-miR-4697-5p, miR-4674 is hsa-miR-4674, miR-4433-3p is hsa-miR-4433-3p, miR-4257 is hsa-miR-4257, miR-1915-5p is hsa-miR-1915-5p, miR-4417 is hsa-miR-4417, miR-1343-5p is hsa-miR-1343-5p, miR-6781-5p is hsa-miR-6781-5p, and miR-4695-5p is hsa-miR-4695-5p is hsa-miR-1237-5p is hsa-miR-1237-5p, miR-6775-5p is hsa-miR-6775-5p, and,miR-7845-5p is hsa-miR-7845-5p, miR-4746-3p is hsa-miR-4746-3p, miR-7641 is hsa-miR-7641, miR-7847-3p is hsa-miR-7847-3p, miR-6806-5p is hsa-miR-6806-5p, miR-4467 is hsa-miR-4467, miR-4726-5p is hsa-miR-4726-5p, miR-4648 is hsa-miR-4648, miR-6089 is hsa-miR-6089, miR-1260b is hsa-miR-1260b, and miR-4532 is hsa-miR-4532, miR-5195-3p is hsa-miR-5195-3p, miR-3188 is hsa-miR-3188, miR-6848-5p is hsa-miR-6848-5p, miR-1233-5p is hsa-miR-1233-5p, miR-6717-5p is hsa-miR-6717-5p, miR-3195 is hsa-miR-3195, miR-6757-5p is hsa-miR-6757-5p, miR-8072 is hsa-miR-8072, miR-4745-5p is hsa-miR-4745-5p, and miR-6511a-5p is hsa-miR-6511a-5p is, miR-6776-5p is hsa-miR-6776-5p, miR-371a-5p is hsa-miR-371a-5p, miR-1227-5p is hsa-miR-1227-5p, miR-7150 is hsa-miR-7150, miR-1915-3p is hsa-miR-1915-3p, miR-187-5p is hsa-miR-187-5p, miR-614 is hsa-miR-614, miR-1225-5p is hsa-miR-1225-5p, miR-451a is hsa-miR-451a, and miR-939-5p is hsa-miR-939-5p, miR-223-3p is hsa-miR-223-3p, miR-125a-3p is hsa-miR-125a-3p, andmiR-92b-5p is hsa-miR-92b-5p, miR-22-3p is hsa-miR-22-3p, miR-6073 is hsa-miR-6073, miR-6845-5p is hsa-miR-6845-5p, miR-6769b-5p is hsa-miR-6769b-5p, miR-4665-3p is hsa-miR-4665-3p, miR-1913 is hsa-miR-1913, miR-1228-3p is hsa-miR-1228-3p, miR-940 is hsa-miR-940, miR-296-3p is hsa-miR-296-3p, and miR-4690-5p is hsa-miR-4690-5p, miR-548q is hsa-miR-548q, miR-663a is hsa-miR-663a, miR-1249 is hsa-miR-1249, miR-1202 is hsa-miR-1202, miR-7113-3p is hsa-miR-7113-3p, miR-1225-3p is hsa-miR-1225-3p, miR-4783-3p is hsa-miR-4783-3p, miR-4448 is hsa-miR-4448, and miR-4534 is hsa-miR-4534.
[0741] In addition, in a preferred embodiment of the method of the present invention, specifically, a nucleic acid (specifically a probe or primer) is a polynucleotide shown in (a) to (e) below:
[0742] (a) a polynucleotide, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive bases, comprising a base sequence represented by any one of SEQ ID NOs 1 to 125, 127 to 130, 132 to 134, and 561 to 578, or a base sequence in which u is t in the said base sequence.
[0743] (b) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1–125, and 127–130, 132–134, and 561–578,
[0744] (c) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1–125, 127–130, 132–134, and 561–578, or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the said nucleotide sequence, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,
[0745] (d) a nucleotide sequence represented by any one of SEQ ID NOs 1–125, 127–130, 132–134, and 561–578, or a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence in which u is t in the said nucleotide sequence, and
[0746] (e) Selected from the group consisting of polynucleotides that hybridize under stringent conditions with any one of (a) to (d) above.
[0747] In addition, the method of the present invention may use a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-19b-3p, miR-1228-5p and miR-1307-3p.
[0748] Specifically, such nucleic acids are miR-19b-3p which is hsa-miR-19b-3p, miR-1228-5p which is hsa-miR-1228-5p, and miR-1307-3p which is hsa-miR-1307-3p.
[0749] In addition, in a preferred embodiment, specifically such nucleic acid is a polynucleotide as shown in (f) to (j) below,
[0750] (f) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 126, 131 and 579, or a nucleotide sequence in which u is t in said nucleotide sequence, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,
[0751] (g) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 126, 131 and 579,
[0752] (h) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 126, 131 and 579, or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,
[0753] (i) a nucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 126, 131 and 579, or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the said nucleotide sequence, and
[0754] (j) is selected from the group consisting of polynucleotides that hybridize under stringent conditions with any one of (f) to (i) above.
[0755] The nucleic acids in the method of the present invention are also miR-4271, miR-642b-3p, miR-6075, miR-6125, miR-887-3p, miR-6851-5p, miR-6763-5p, miR-3928-3p, miR-4443, miR-3648, miR-149-3p, miR-4689, miR-4763-3p, miR-6729-5p, miR-3196, miR-8069, miR-1268a, miR-4739, miR-1268b, miR-5698, miR-6752-5p, miR-4507, miR-564, miR-4497, miR-6877-5p, miR-6087, A nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-4731-5p, miR-615-5p, miR-760, miR-6891-5p, miR-6887-5p, miR-4525, miR-1914-3p, miR-619-5p, miR-5001-5p, miR-6722-3p, miR-3621, miR-4298, miR-675-5p and miR-4655-5p may be used.
[0756] Specifically, such nucleic acids are miR-4271 is hsa-miR-4271, miR-642b-3p is hsa-miR-642b-3p, miR-6075 is hsa-miR-6075, miR-6125 is hsa-miR-6125, miR-887-3p is hsa-miR-887-3p, miR-6851-5p is hsa-miR-6851-5p, miR-6763-5p is hsa-miR-6763-5p, miR-3928-3p is hsa-miR-3928-3p, miR-4443 is hsa-miR-4443, miR-3648 is hsa-miR-3648, and miR-149-3p hsa-miR-149-3p, miR-4689 is hsa-miR-4689, miR-4763-3p is hsa-miR-4763-3p, miR-6729-5p is hsa-miR-6729-5p, miR-3196 is hsa-miR-3196, miR-8069 is hsa-miR-8069, miR-1268a is hsa-miR-1268a, miR-4739 is hsa-miR-4739, miR-1268b is hsa-miR-1268b, miR-5698 is hsa-miR-5698, miR-6752-5p is hsa-miR-6752-5p, and miR-4507 is hsa-miR-4507, miR-564 is hsa-miR-564, miR-4497 is hsa-miR-4497, miR-6877-5p is hsa-miR-6877-5p, miR-6087 is hsa-miR-6087, miR-4731-5p is hsa-miR-4731-5p, miR-615-5p is hsa-miR-615-5p, miR-760 is hsa-miR-760, miR-6891-5p is hsa-miR-6891-5p, miR-6887-5p is hsa-miR-6887-5p, miR-4525 is hsa-miR-4525, miR-1914-3p is hsa-miR-1914-3p, miR-619-5p is hsa-miR-619-5p, andmiR-5001-5p is hsa-miR-5001-5p, miR-6722-3p is hsa-miR-6722-3p, miR-3621 is hsa-miR-3621, miR-4298 is hsa-miR-4298, miR-675-5p is hsa-miR-675-5p, and miR-4655-5p is hsa-miR-4655-5p.
[0757] In addition, in a preferred embodiment, specifically such nucleic acid is a polynucleotide as shown in (k) to (o) below:
[0758] (k) a polynucleotide consisting of a nucleotide sequence represented by any one of SEQ ID NOs 135 to 174, or a nucleotide sequence in which u is t in the said nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
[0759] (l) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 135 to 174,
[0760] (m) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 135 to 174, or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,
[0761] (n) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 135 to 174, or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the said nucleotide sequence, and
[0762] (o) A polynucleotide selected from the group consisting of polynucleotides that hybridize under stringent conditions with any one of the above (k) to (n).
[0763] Examples of specimens used in the method of the present invention include specimens prepared from the biological tissue of a subject (preferably, lung tissue), blood, serum, plasma, urine, etc. Specifically, specimens may include RNA-containing specimens prepared from the tissue, specimens containing polynucleotides also prepared therefrom, body fluids such as blood, serum, plasma, urine, etc., and biological tissues obtained by biopsy or surgically removing part or all of the biological tissue of a subject, and specimens for measurement may be prepared from these.
[0764] In this specification, the term "subject" refers to mammals, for example, but not limited to humans, monkeys, mice, rats, etc., and preferably humans.
[0765] The method of the present invention may change the steps depending on the type of sample used as the measurement target.
[0766] When RNA is used as the measurement target, the detection of lung cancer (cells) is, for example, the following steps (a), (b), and (c):
[0767] (a) a step of combining RNA prepared from a sample of a subject or a complementary polynucleotide (cDNA) transcribed therefrom with a polynucleotide in the kit or device of the present invention,
[0768] (b) a step of measuring the RNA derived from the sample bound to the polynucleotide or the cDNA synthesized from the RNA by hybridization using the polynucleotide as a nucleic acid probe, or by quantitative RT-PCR using the polynucleotide as a primer,
[0769] (c) A step of evaluating the presence or absence of lung cancer (expression of the gene derived from the lung cancer) based on the measurement results of (b) above may be included.
[0770] According to the present invention, various hybridization methods, for example, can be used to detect, test, evaluate, or diagnose lung cancer (expression of a gene derived from the present invention) in vitro.
[0771] For these hybridization methods, examples include the Northern blot method, Southern blot method, RT-PCR method, DNA chip analysis method, in situ hybridization method, Northern hybridization method, and Southern hybridization method.
[0772] When using the Northern blot method, the presence or absence of each gene expression in RNA or the amount of expression can be detected and measured by using the nucleic acid probe available in the present invention. Specifically, a method can be exemplified in which a nucleic acid probe (complementary chain) is labeled with a radioactive isotope (32P, 33P, 35S, etc.) or a fluorescent substance, and then hybridized with RNA derived from the subject's biological tissue transferred to a nylon membrane, etc. according to the normal method, and then the signal originating from the label (radioactive isotope or fluorescent substance) of the formed DNA / RNA double chain is detected and measured by a radiation detector (e.g., BAS-1800II (Fujisha Shinfilm Co., Ltd.)) or a fluorescence detector (e.g., STORM 865 (GE Healthcare))).
[0773] When using a quantitative RT-PCR method, the presence or absence of gene expression in RNA or the amount of expression can be detected and measured by using the primers available in the present invention. Specifically, a method can be exemplified in which cDNA is prepared from RNA derived from the biological tissue of a subject according to a normal method, and a pair of primers of the present invention (consisting of a normal chain and a reverse chain that bind to the cDNA) are hybridized with the cDNA using this as a template so that the region of each target gene can be amplified, and a PCR method is performed according to a normal method to detect the obtained two-stranded DNA. Furthermore, methods for detecting two-stranded DNA may include a method of performing the PCR using primers that have been previously labeled with a radioactive isotope or a fluorescent substance, a method of detecting the two-stranded DNA by electrophoresis of the PCR product on an agarose gel and staining the DNA with ethidium bromide, etc., or a method of detecting the produced two-stranded DNA by transferring it to a nylon membrane, etc., according to a normal method and hybridizing it with a labeled nucleic acid probe.
[0774] When...
Claims
Claim 1 A kit for detecting lung cancer comprising a nucleic acid capable of specifically binding to the polynucleotide of miR-22-3p, a lung cancer marker. Claim 2 In claim 1, the nucleic acid is a polynucleotide represented by (a) to (e) below: (a) a polynucleotide comprising the base sequence represented by SEQ ID NO. 134 or a base sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive bases; (b) a polynucleotide comprising the base sequence represented by SEQ ID NO. 134; (c) a polynucleotide comprising the base sequence represented by SEQ ID NO. 134 or a base sequence complementary to the base sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive bases; (d) a polynucleotide comprising the base sequence represented by SEQ ID NO. 134 or a base sequence complementary to the base sequence in which u is t, and (e) a polynucleotide that hybridizes under stringent conditions with any one of (a) to (d). A kit that is a polynucleotide selected from the group consisting of polynucleotides. Claim 3 제 1 항 또는 제 2 항에 있어서,상기 키트가, 다른 폐암 마커인, miR-19b-3p, miR-1228-5p, miR-1307-3p, miR-4271, miR-642b-3p, miR-6075, miR-6125, miR-887-3p, miR-6851-5p, miR-6763-5p, miR-3928-3p, miR-4443, miR-3648, miR-149-3p, miR-4689, miR-4763-3p, miR-6729-5p, miR-3196, miR-8069, miR-1268a, miR-4739, miR-1268b, miR-5698, miR-6752-5p, miR-4507, miR-564, miR-4497, miR-6877-5p, miR-6087, miR-4731-5p, miR-615-5p, miR-760, miR-6891-5p, miR-6887-5p, miR-4525, miR-1914-3p, miR-619-5p, miR-5001-5p, miR-6722-3p, miR-3621, miR-4298, miR-675-5p miR-4655-5p, miR-6768-5p, miR-6836-3p, miR-3663-3p, miR-1908-3p, miR-6726-5p, miR-6875-5p, miR-4651, miR-6825-5p, miR-6840-3p, miR-6780b-5p, miR-6749-5p, miR-8063, miR-6784-5p, miR-3184-5p, miR-663b, miR-6880-5p, miR-1908-5p, miR-92a-2-5p, miR-7975, miR-7110-5p, miR-6842-5p, miR-6857-5p miR-5572, miR-3197, miR-6131, miR-6889-5p, miR-4454, miR-1199-5p, miR-1247-3p, miR-6800-5p, miR-6872-3p, miR-4649-5p, miR-6791-5p, miR-4433b-3p, miR-3135b, miR-128-2-5p, miR-4675, miR-4472,miR-6785-5p, miR-6741-5p, miR-7977, miR-3665, miR-128-1-5p, miR-4286, miR-6765-3p, miR-4632-5p, miR-365a-5p, miR-6088, miR-6816-5p, miR-6885-5p, miR-711, miR-6765-5p, miR-3180, miR-4442, miR-4792, miR-6721-5p, miR-6798-5p, miR-3162-5p, miR-6126, miR-4758-5p, miR-2392, miR-486-3p, miR-6727-5p miR-4728-5p, miR-6746-5p, miR-4270, miR-3940-5p, miR-4725-3p, miR-7108-5p, miR-3656, miR-6879-5p, miR-6738-5p, miR-1260a, miR-4446-3p, miR-3131, miR-4463, miR-3185, miR-6870-5p, miR-6779-5p, miR-1273g-3p, miR-8059, miR-4697-5p, miR-4674, miR-4433-3p, miR-4257, miR-1915-5p, miR-4417 miR-1343-5p, miR-6781-5p, miR-4695-5p, miR-1237-5p, miR-6775-5p, miR-7845-5p, miR-4746-3p, miR-7641, miR-7847-3p, miR-6806-5p, miR-4467, miR-4726-5p, miR-4648, miR-6089, miR-1260b, miR-4532, miR-5195-3p, miR-3188, miR-6848-5p, miR-1233-5p, miR-6717-5p, miR-3195, miR-6757-5p, miR-8072 miR-4745-5p, miR-6511a-5p, miR-6776-5p, miR-371a-5p, miR-1227-5p, miR-7150, miR-1915-3p, miR-187-5p, miR-614, miR-1225-5p, miR-451a,A kit further comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-939-5p, miR-223-3p, miR-125a-3p, miR-92b-5p, miR-6073, miR-6845-5p, miR-6769b-5p, miR-4665-3p, miR-1913, miR-1228-3p, miR-940, miR-296-3p, miR-4690-5p, miR-548q, miR-663a, miR-1249, miR-1202, miR-7113-3p, miR-1225-3p, miR-4783-3p, miR-4448, and miR-4534. Claim 4 In claim 3, the nucleic acid is a polynucleotide as shown in (f) to (j) below: (f) a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 1 to 2, 4 to 6, 10 to 17, 19 to 133, 135 to 174, and 561 to 579, or a base sequence in which u is t in said base sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive bases; (g) a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 1 to 2, 4 to 6, 10 to 17, 19 to 133, 135 to 174, and 561 to 579; (h) a base sequence represented by any one of SEQ ID NOs 1 to 2, 4 to 6, 10 to 17, 19 to 133, 135 to 174, and 561 to 579, or said base sequence A kit comprising a polynucleotide consisting of a base sequence complementary to a base sequence where u is t, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases, (i) a base sequence represented by any one of SEQ ID NOs 1-2, 4-6, 10-17, 19-133, 135-174 and 561-579 or a polynucleotide containing a base sequence complementary to a base sequence where u is t in said base sequence, (j) a polynucleotide hybridized under stringent conditions with any one of the polynucleotides in (f) to (i). Claim 5 A device for detecting lung cancer comprising a nucleic acid capable of specifically binding to the polynucleotide of miR-22-3p, a lung cancer marker. Claim 6 In claim 5, the nucleic acid is a polynucleotide as shown in (a) to (e) below: (a) a polynucleotide comprising the base sequence represented by SEQ ID NO. 134 or a base sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive bases; (b) a polynucleotide comprising the base sequence represented by SEQ ID NO. 134; (c) a polynucleotide comprising the base sequence represented by SEQ ID NO. 134 or a base sequence complementary to the base sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive bases; (d) a polynucleotide comprising the base sequence represented by SEQ ID NO. 134 or a base sequence complementary to the base sequence in which u is t, and (e) a polynucleotide that hybridizes under stringent conditions with any one of (a) to (d). A device that is a polynucleotide selected from the group consisting of polynucleotides. Claim 7 제 5 항 또는 제 6 항에 있어서,상기 디바이스가, 다른 폐암 마커인, miR-19b-3p, miR-1228-5p, miR-1307-3p, miR-4271, miR-642b-3p, miR-6075, miR-6125, miR-887-3p, miR-6851-5p, miR-6763-5p, miR-3928-3p, miR-4443, miR-3648, miR-149-3p, miR-4689, miR-4763-3p, miR-6729-5p, miR-3196, miR-8069, miR-1268a, miR-4739, miR-1268b, miR-5698, miR-6752-5p, miR-4507, miR-564, miR-4497, miR-6877-5p, miR-6087, miR-4731-5p, miR-615-5p, miR-760, miR-6891-5p, miR-6887-5p, miR-4525, miR-1914-3p, miR-619-5p, miR-5001-5p, miR-6722-3p, miR-3621, miR-4298, miR-675-5p miR-4655-5p, miR-6768-5p, miR-6836-3p, miR-3663-3p, miR-1908-3p, miR-6726-5p, miR-6875-5p, miR-4651, miR-6825-5p, miR-6840-3p, miR-6780b-5p, miR-6749-5p, miR-8063, miR-6784-5p, miR-3184-5p, miR-663b, miR-6880-5p, miR-1908-5p, miR-92a-2-5p, miR-7975, miR-7110-5p, miR-6842-5p, miR-6857-5p miR-5572, miR-3197, miR-6131, miR-6889-5p, miR-4454, miR-1199-5p, miR-1247-3p, miR-6800-5p, miR-6872-3p, miR-4649-5p, miR-6791-5p, miR-4433b-3p, miR-3135b, miR-128-2-5p, miR-4675, miR-4472,miR-6785-5p, miR-6741-5p, miR-7977, miR-3665, miR-128-1-5p, miR-4286, miR-6765-3p, miR-4632-5p, miR-365a-5p, miR-6088, miR-6816-5p, miR-6885-5p, miR-711, miR-6765-5p, miR-3180, miR-4442, miR-4792, miR-6721-5p, miR-6798-5p, miR-3162-5p, miR-6126, miR-4758-5p, miR-2392, miR-486-3p, miR-6727-5p miR-4728-5p, miR-6746-5p, miR-4270, miR-3940-5p, miR-4725-3p, miR-7108-5p, miR-3656, miR-6879-5p, miR-6738-5p, miR-1260a, miR-4446-3p, miR-3131, miR-4463, miR-3185, miR-6870-5p, miR-6779-5p, miR-1273g-3p, miR-8059, miR-4697-5p, miR-4674, miR-4433-3p, miR-4257, miR-1915-5p, miR-4417 miR-1343-5p, miR-6781-5p, miR-4695-5p, miR-1237-5p, miR-6775-5p, miR-7845-5p, miR-4746-3p, miR-7641, miR-7847-3p, miR-6806-5p, miR-4467, miR-4726-5p, miR-4648, miR-6089, miR-1260b, miR-4532, miR-5195-3p, miR-3188, miR-6848-5p, miR-1233-5p, miR-6717-5p, miR-3195, miR-6757-5p, miR-8072 miR-4745-5p, miR-6511a-5p, miR-6776-5p, miR-371a-5p, miR-1227-5p, miR-7150, miR-1915-3p, miR-187-5p, miR-614, miR-1225-5p, miR-451a,A device further comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-939-5p, miR-223-3p, miR-125a-3p, miR-92b-5p, miR-6073, miR-6845-5p, miR-6769b-5p, miR-4665-3p, miR-1913, miR-1228-3p, miR-940, miR-296-3p, miR-4690-5p, miR-548q, miR-663a, miR-1249, miR-1202, miR-7113-3p, miR-1225-3p, miR-4783-3p, miR-4448, and miR-4534. Claim 8 In claim 7, the nucleic acid is a polynucleotide as shown in (f) to (j) below: (f) a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 1 to 2, 4 to 6, 10 to 17, 19 to 133, 135 to 174, and 561 to 579, or a base sequence in which u is t in said base sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive bases; (g) a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 1 to 2, 4 to 6, 10 to 17, 19 to 133, 135 to 174, and 561 to 579; (h) a base sequence represented by any one of SEQ ID NOs 1 to 2, 4 to 6, 10 to 17, 19 to 133, 135 to 174, and 561 to 579, or said base sequence A device comprising a polynucleotide comprising a base sequence complementary to a base sequence where u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive bases, (i) a base sequence represented by any one of SEQ ID NOs 1-2, 4-6, 10-17, 19-133, 135-174 and 561-579 or a polynucleotide comprising a base sequence complementary to a base sequence where u is t in said base sequence, (j) a polynucleotide hybridized under stringent conditions with any one of the polynucleotides (f) to (i). Claim 9 A device according to claim 5 or 6, wherein the device is a device for measurement by hybridization technology. Claim 10 In claim 9, the device wherein the hybridization technology is nucleic acid array technology. Claim 11 A method for providing information for detecting lung cancer in a subject by comparing the expression level of a target nucleic acid in a sample of a subject using the kit described in claim 1 or 2 or the device described in claim 5 or 6. Claim 12 A method for detecting lung cancer in a subject, comprising measuring the expression level of a target gene in a sample of a subject using a kit described in claim 1 or 2 or a device described in claim 5 or 6, substituting the expression level of the gene in the sample derived from the subject into a discriminant formula that is capable of distinguishing between lung cancer and health, and using the gene expression levels of a sample derived from a subject known to have lung cancer and a sample derived from a healthy person as teacher samples, and evaluating the presence or absence of lung cancer by the same. Claim 13 In claim 11, the method in which the subject is a human. Claim 14 In claim 11, the method wherein the specimen is blood, serum, or plasma. Claim 15 In claim 12, the method in which the subject is a human. Claim 16 In claim 12, the method wherein the specimen is blood, serum, or plasma. Claim 17 A method for providing information for the detection of lung cancer using a polynucleotide of miR-22-3p as a target gene, wherein the expression level of the target gene in a subject's sample is measured, and the measured expression level is compared with the control expression level of a healthy person that is likewise measured, thereby providing information for the detection of lung cancer in the subject. Claim 18 제 17 항에 있어서,상기 방법이, 다른 폐암 마커인, miR-19b-3p, miR-1228-5p, miR-1307-3p, miR-4271, miR-642b-3p, miR-6075, miR-6125, miR-887-3p, miR-6851-5p, miR-6763-5p, miR-3928-3p, miR-4443, miR-3648, miR-149-3p, miR-4689, miR-4763-3p, miR-6729-5p, miR-3196, miR-8069, miR-1268a, miR-4739, miR-1268b, miR-5698, miR-6752-5p, miR-4507, miR-564, miR-4497, miR-6877-5p, miR-6087, miR-4731-5p, miR-615-5p, miR-760, miR-6891-5p, miR-6887-5p, miR-4525, miR-1914-3p, miR-619-5p, miR-5001-5p, miR-6722-3p, miR-3621, miR-4298, miR-675-5p, miR-4655-5p, miR-6768-5p miR-6836-3p, miR-3663-3p, miR-1908-3p, miR-6726-5p, miR-6875-5p, miR-4651, miR-6825-5p, miR-6840-3p, miR-6780b-5p, miR-6749-5p, miR-8063, miR-6784-5p, miR-3184-5p, miR-663b, miR-6880-5p, miR-1908-5p, miR-92a-2-5p, miR-7975, miR-7110-5p, miR-6842-5p, miR-6857-5p, miR-5572, miR-3197, miR-6131 miR-6889-5p, miR-4454, miR-1199-5p, miR-1247-3p, miR-6800-5p, miR-6872-3p, miR-4649-5p, miR-6791-5p, miR-4433b-3p, miR-3135b, miR-128-2-5p, miR-4675, miR-4472,miR-6785-5p, miR-6741-5p, miR-7977, miR-3665, miR-128-1-5p, miR-4286, miR-6765-3p, miR-4632-5p, miR-365a-5p, miR-6088, miR-6816-5p, miR-6885-5p, miR-711, miR-6765-5p, miR-3180, miR-4442, miR-4792, miR-6721-5p, miR-6798-5p, miR-3162-5p, miR-6126, miR-4758-5p, miR-2392, miR-486-3p, miR-6727-5p miR-4728-5p, miR-6746-5p, miR-4270, miR-3940-5p, miR-4725-3p, miR-7108-5p, miR-3656, miR-6879-5p, miR-6738-5p, miR-1260a, miR-4446-3p, miR-3131, miR-4463, miR-3185, miR-6870-5p, miR-6779-5p, miR-1273g-3p, miR-8059, miR-4697-5p, miR-4674, miR-4433-3p, miR-4257, miR-1915-5p, miR-4417 miR-1343-5p, miR-6781-5p, miR-4695-5p, miR-1237-5p, miR-6775-5p, miR-7845-5p, miR-4746-3p, miR-7641, miR-7847-3p, miR-6806-5p, miR-4467, miR-4726-5p, miR-4648, miR-6089, miR-1260b, miR-4532, miR-5195-3p, miR-3188, miR-6848-5p, miR-1233-5p, miR-6717-5p, miR-3195, miR-6757-5p, miR-8072 miR-4745-5p, miR-6511a-5p, miR-6776-5p, miR-371a-5p, miR-1227-5p, miR-7150, miR-1915-3p, miR-187-5p, miR-614, miR-1225-5p, miR-451a,A method further utilizing at least one polynucleotide selected from the group consisting of miR-939-5p, miR-223-3p, miR-125a-3p, miR-92b-5p, miR-6073, miR-6845-5p, miR-6769b-5p, miR-4665-3p, miR-1913, miR-1228-3p, miR-940, miR-296-3p, miR-4690-5p, miR-548q, miR-663a, miR-1249, miR-1202, miR-7113-3p, miR-1225-3p, miR-4783-3p, miR-4448, and miR-4534.
